TrialID,Last Refreshed on,Public title,Scientific title,Acronym,Primary sponsor,Date registration,Date registration3,Export date,Source Register,web address,Recruitment Status,other records,Inclusion agemin,Inclusion agemax,Inclusion gender,Date enrollement,Target size,Study type,Study design,Phase,Countries,Inclusion Criteria,Exclusion Criteria,Condition,Intervention,Primary outcome,Secondary outcome,Secondary ID,Source Name,Secondary Sponsor,Ethics Status,Ethics Approval Date,results yes no,results date posted,results url link,results url protocol,results date completed,results date first publication,results summary,results baseline char,results adverse events,results outcome measures,results ipd plan,results ipd description,Prospective registration,Bridging flag truefalse,Bridged type,Year,age_min_years
NCT05515770,14 October 2024,The Implementation of Pre-exposure Prophylaxis of Injectable Cabotegravir,"An Implementation Study of Long-acting Injectable Cabotegravir (CAB-LA) for HIV Pre-Exposure Prophylaxis (PrEP) Among Young MSM, Non-binary and Transgender Persons (The ImPrEP CAB Study)",ImPrepCab,Evandro Chagas National Institute of Infectious Disease,2022-08-23,20220823.0,10/13/2025 15:56:09,ClinicalTrials.gov,https://clinicaltrials.gov/ct2/show/NCT05515770,Recruiting,No,18 Years,30 Years,Male,20/09/2022,1200,Interventional,Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Prevention. Masking: None (Open Label). ,Phase 3,Brazil,"Inclusion Criteria:<br><br> 1. Cisgender men, non-binary (assigned as male at birth) or transgender women and men<br><br> 2. Report having anal sex with a person assigned male at birth in the last six months<br>   (Persons born female having sex only with other persons born female are excluded)<br><br> 3. Age 18-30 years<br><br> 4. Seek a study clinic looking for PrEP<br><br> 5. CAB LA and TDF/FTC PrEP naïve<br><br> 6. Willing and able to provide written informed consent and adhere to the study<br>   requirements<br><br> 7. Non-reactive / negative HIV test results, including both HIV rapid tests and an<br>   undetectable HIV RNA at enrollment for individuals choosing injectable CAB-LA.<br><br> 8. No report of hepatic dysfunction. Candidates reporting liver disease will have their<br>   enrollment visit postponed until laboratory results of liver function are available.<br>   Individuals with ALT >=5x ULN, OR ALT>=3xULN and bilirubin >=1.5xULN will be<br>   excluded. See section 7 (Study Procedures - Enrollment visit).<br><br> 9. Willing to undergo all required study procedures.<br><br>Exclusion Criteria:<br><br> 1. One or more reactive or positive HIV test result at enrollment visit, even if HIV<br>   infection is not confirmed.<br><br> 2. Currently participating in interventional trial of PrEP agents, HIV vaccine trial or<br>   experimental medication.<br><br> 3. Positive pregnancy test, breastfeeding, or intention to become pregnant at enrolment<br>   (for transgender men).<br><br> 4. Prior participation in studies with Cabotegravir.<br><br> 5. A history or presence of allergy to the study drug components.<br><br> 6. Past participation in HIV vaccine trial. An exception will be made for participants<br>   that can provide documentation of receipt of placebo (not active arm).<br><br> 7. Plan to relocate out of the area during the study period.<br><br> 8. Surgically placed or injected buttock implants or fillers, per self-report.<br><br> 9. Has a dermatological/inflammatory skin condition overlying the buttock region which<br>   in the opinion of the study investigator, in consultation with the Clinical Study<br>   Coordination (CSC), may interfere with interpretation of injection site reactions.<br><br> 10. Active or planned use of contraindicated co-administered for which significant<br>   decreases in Cabotegravir plasma concentrations may occur due uridine diphosphate<br>   glucuronosyltransferase (UGT1A1):<br><br>    - Anticonvulsants: Carbamazepine, Oxcarbazepine, Phenobarbital, Phenytoin<br><br>    - Antimycobacterials: Rifampin, Rifapentine *Any prohibited medications that<br>     decrease CAB concentrations should be discontinued for a minimum of four weeks<br>     or a minimum of three half-lives (whichever is longer) prior to the first dose.<br><br> 11. Current or anticipated need for chronic systemic anticoagulation or a history of<br>   known or suspected bleeding disorder, including a history of prolonged bleeding.<br><br> 12. History of severe hepatic impairment (including but not limited to a history of<br>   liver failure or hospitalization for liver disease, a history of hepatocellular<br>   carcinoma or near liver transplant).<br><br> 13. Individuals with advanced Hepatitis C.<br><br> 14. Other medical conditions that, in the opinion of the study investigator, would<br>   interfere with the conduct of the study (e.g., provided by self-report, or found<br>   upon medical).",,HIV Infections,Drug: Cabotegravir Injection,Incident HIV infection,,59166522.7.1001.5262,Please refer to primary and secondary sponsors,Beatriz Grinsztejn;Thiago Torres;Valdilea Gonçalves;Brenda Hoagland,,,No,,,,,,,,,,,,Yes,False,          ,2022.0,18.0
NCT05519046,14 April 2025,Cardiac Contractility Modulation in Chagas Heart Disease,Clinical and Functional Effects of Cardiac Contractility Modulation in Chagas Heart Disease: a Randomized Study - Contractility - FIX-Chagas,FIX-Chagas,InCor Heart Institute,2022-08-10,20220810.0,10/13/2025 15:56:09,ClinicalTrials.gov,https://clinicaltrials.gov/ct2/show/NCT05519046,Recruiting,No,18 Years,75 Years,All,25/05/2022,60,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant). ,,Brazil,"Inclusion Criteria:<br><br> - Signing of an informed consent form (ICF) before randomization and any study<br>   procedure,<br><br> - Both genders, age >18 years and <75 years,<br><br> - Recent positive (last two years) and documented serology for Chagas disease, in at<br>   least two different tests (indirect hemagglutination, indirect immunofluorescence,<br>   or ELISA),<br><br> - NYHA II-III heart failure functional class,<br><br> - LVEF< 35%,<br><br> - Non left bundle branch block<br><br> - Intraventricular desynchrony (Yu index)<br><br> - Global longitudinal strain >11 %.<br><br>Exclusion Criteria:<br><br> - Participation in another study, presently or terminated <1 year ago, except for a<br>   totally unrelated observational study,<br><br> - Other concomitant cardiovascular diseases, including uncontrolled diabetes mellitus<br>   (systemic arterial hypertension without permitted target organ compromise),<br><br> - Kidney dysfunction (serum creatinine >1.5mg/dL or eGFR <30mL/min/1.73m2) or liver<br>   dysfunction, with diagnosis of cirrhosis or portal hypertension or elevated serum<br>   enzymes (AST or ALT) > 3x the upper limit of normality,<br><br> - Moderate or severe chronic obstructive pulmonary disease,<br><br> - Peripheral polyneuropathy,<br><br> - Hyperthyroidism,<br><br> - Current alcoholism or not abandoned for >2 years,<br><br> - Diagnosed with psychopathy or psychosis or addiction to illicit drugs,<br><br> - Life expectancy <1 year, due to the disease itself or comorbidities (including NYHA<br>   class IV),<br><br> - Pregnancy or breastfeeding,<br><br> - Potential to become pregnant during the study (non-menopausal patients who have not<br>   undergone a radical and safe contraceptive process),<br><br> - Previously withdrawn from this study.",,Chagas Cardiomyopathy;Heart Failure;Systolic Dysfunction;Right Bundle Branch Block and Left Anterior Fascicular Block;Right Bundle Branch Block and Left Posterior Fascicular Block,Device: Cardiac Contractility Modulation (CCM);Device: CRT,QoL Score;QoL Score;GLS;GLS,6MWT;6MWT;NYHAFC;NYHAFC;LVEF;LVEF;Heart Failure Hospitalization (HFH) checklist,57563722.3.0000.0068,Please refer to primary and secondary sponsors,Impulse Dynamics;I2medi Comercial Medica LTDA,,,No,,,,,,,,,,,,No,False,          ,2022.0,18.0
NCT04984265,29 July 2024,SBRT in Chagas Disease Ventricular Tachycardia,Noninvasive Cardiac Radiation for Ablation of Ventricular Tachycardia in Chagas Disease Patients,,University of Sao Paulo General Hospital,2021-07-21,20210721.0,10/13/2025 15:56:09,ClinicalTrials.gov,https://clinicaltrials.gov/ct2/show/NCT04984265,Not recruiting,No,18 Years,,All,14/07/2021,10,Interventional,Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ,Phase 1/Phase 2,Brazil,"Inclusion Criteria:<br><br> 1. Diagnosis of Chagas heart disease including positive serology<br><br> 2. Recurrent sustained ventricular tachycardia requiring therapy due to symptoms, ICD<br>   shocks, or requiring hospitalization.<br><br> 3. Age>18 years.<br><br> 4. Able to give written, informed consent. If the patient requires continuous<br>   sedation/anesthesia for arrhythmia control consent can be provided by the next of<br>   kin.<br><br> 5. Medically fit to undergo radiation planning and treatment sessions.<br><br> 6. Failed antiarrhythmic medications due to VT recurrence, drug intolerance, or<br>   contraindication.<br><br> 7. Failed prior catheter ablation due to arrhythmia recurrence or ineligible for<br>   endocardial or epicardial catheter ablation (LV thrombus, epicardial adhesion,<br>   megacolon, prior open chest surgery)<br><br>Exclusion Criteria:<br><br> 1. Cardiogenic shock not due to VT with no possibility of heart transplant or<br>   ventricular assist device.<br><br> 2. Inability for patient to be adequately immobilized for radiation planning and<br>   treatment.<br><br> 3. Repeat catheter ablation is felt to be a reasonable option.<br><br> 4. Previous radiation to the chest.<br><br> 5. Pregnancy or refusal to use contraception.",,Ventricular Tachycardia;Chagas Disease;Cardiac Arrhythmia,Radiation: Stereotactic Body Radiation Therapy,Safety of SBRT for the treatment of Ventricular Tachycardia;Efficacy of SBRT for the treatment of Ventricular Tachycardia,Time to VT Recurrence;VT Burden;Mortality;Cardiac Mortality,4920/19/139,Please refer to primary and secondary sponsors,,,,No,,,,,,,,,,,,No,False,          ,2021.0,18.0
NCT04984616,23 September 2024,Atorvastatin on Inflammation and Cardiac Function in Chronic Chagas Disease,Effect of Statins (Atorvastatin) on Inflammation and Cardiac Function in Patients with Chronic Chagas Disease: Pathophysiological Studies in a Multicenter Proof-of-concept,ATOCHA,Juan D. Maya,2021-06-29,20210629.0,10/13/2025 15:56:09,ClinicalTrials.gov,https://clinicaltrials.gov/ct2/show/NCT04984616,Not recruiting,No,18 Years,50 Years,All,12/10/2021,300,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator). ",Phase 2,Chile,"Inclusion Criteria:<br><br> - Adults older than 18 and younger than 50 years,<br><br> - with a weight higher than 40 kg<br><br> - Positive conventional confirmatory serology for T. cruzi infection from the NAtional<br>   Public Health institute (ISPCH), and<br><br> - A positive qPCR<br><br> - Have normal laboratory test values for the following parameters: total white blood<br>   cell count, platelet count, creatine kinase (CK), alanine aminotransferase (ALT),<br>   aspartate aminotransferase (AST), total bilirubin or creatinine, or a gamma-glutamyl<br>   transferase (GGT) > 2 times the upper limit of normal (X ULN);<br><br> - Women of reproductive age must have a negative serum pregnancy test, must not be<br>   breastfeeding, and must consistently use a highly effective contraceptive method<br>   throughout the treatment phase<br><br> - Ability to comply with all protocol-specified follow-up tests and visits and have a<br>   permanent address;<br><br> - Signed written informed consent form<br><br>Exclusion Criteria:<br><br> - Signs and symptoms of the digestive form of Chagas Disease;<br><br> - Chronic cardiac Chagas Disease stage II or higher;<br><br> - Acute or chronic health conditions such as acute infections, history of HIV<br>   infection, diabetes, liver and kidney disease;<br><br> - Hypothyroidism<br><br> - Family history of muscle disorders<br><br> - Pre-existing heart disease unrelated to Chagas disease;<br><br> - Formal contraindication to receive nifurtimox or benznidazole,<br><br> - Known history of hypersensitivity, allergy or severe adverse reactions to<br>   atorvastatin, benznidazole or nifurtimox;<br><br> - History of previous treatment for Chagas Disease;<br><br> - History of prior treatment with atorvastatin, lovastatin, rosuvastatin, simvastatin<br>   or any other statin;<br><br> - Any concomitant use of antimicrobial agents;<br><br> - History of alcohol or drug abuse;<br><br> - Any condition that precludes oral medication;<br><br> - Concomitant or intended use of CYP3A4 modifiers;<br><br> - Medical history of familial short QT syndrome or concomitant therapy with<br>   medications that may shorten the QT interval.<br><br> - Abnormal laboratory test values for the following parameters: total white blood cell<br>   count, platelet count, creatine kinase (CK), alanine aminotransferase (ALT),<br>   aspartate aminotransferase (AST), total bilirubin or creatinine, or a gamma-glutamyl<br>   transferase (GGT) > 2 times the upper limit of normal (X ULN);<br><br> - Being pregnant or breastfeeding<br><br> - Refusing to use a highly effective contraceptive method during the treatment phase.",,Chronic Chagas Disease,Drug: 40 mg Atorvastatin/day for 120 days P.O.;Drug: Atorvastatin 80;Drug: Placebo,Number of patients that present a change in the phase of the chronic cardiomyopathy,plasma levels of cytokines (pg/mL);Plasma levels of endothelial adhesion molecules (pg/mL);Proportion of patients with change in heart rate measured by electrocardiographic examination;Proportion of patients with changes in the QT interval duration (milliseconds);Proportion of patients with abnormalities in ventricular electrical conduction determined by the duration of the QRS interval (milliseconds);Proportion of patients with alterations in ventricular function as measured by changes in the ejection fraction percentage estimated by echocardiography;Plasma levels of Cardiac function biomarkers (pg/mL);Parasite load in a blood sample (number of parasites/mL);Incidence of severe adverse events,U1111-1267-3513,Please refer to primary and secondary sponsors,,,,No,,,,,,,,,,,,Yes,False,          ,2021.0,18.0
NCT04239144,15 May 2023,Sympathetic Denervation by Video-assisted Thoracoscopy in Control of Cardiac Arrhythmias in Patients With Chagas Disease,Role of Sympathetic Denervation by Video-assisted Thoracoscopy in Control of Cardiac Arrhythmias in Patients With Chagas Disease - Pilot Study Randomized Controlled Trial,,University of Sao Paulo General Hospital,2019-01-23,20190123.0,10/13/2025 15:56:09,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT04239144,Recruiting,No,18 Years,,All,09/11/2018,45,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ,,Brazil,"<br>    Inclusion Criteria:<br><br>     - Patients with Chagas Disease Cardiomyopathy having an ICD<br><br>     - At least four appropriate ICD therapies in the past six months, documented by device<br>       interrogation or medical records;<br><br>     - Use of amiodarone and beta blockers in an optimized fashion;<br><br>     - Life expectancy of more than one year<br><br>     - Conditions for following the plan of clinical follow-up of the study.<br><br>    Exclusion criteria:<br><br>     - Presence of an absolute contraindication to receive any of the possible treatments of<br>       the study;<br><br>     - Pregnant Woman;<br><br>     - Less than 18 years-old;<br><br>     - Renal insufficiency with creatinine >2.5 mg/dL (221 umol/L);<br><br>     - Mobile thrombus in the left ventricle;<br><br>     - Left Ventricle Ejection fraction < 10%;<br><br>     - Unstable angina;<br><br>     - Severe aortic stenosis<br><br>     - Primary severe mitral insufficiency;<br><br>     - New York Heart Association (NYHA) functional class IV;<br><br>     - Previous cardiac surgery or scheduled.<br>   ",,Chagas Cardiomyopathy;Ventricular Arrythmia,Procedure: Bilateral sympathectomy;Procedure: Catheter ablation,Time to Ventricular Tachycardia Recurrence;Burden of Ventricular Tachycardia Recurrence,Ventricular Tachycardia Recurrence Following Sympathectomy Compared to Catheter Ablation.;Mortality and Transplant Rate;Ventricular Ectopic Beats Density;Length of Hospital Stay;Rate of Complications Following Intervention;Impact on Left Ventricular Ejection Fraction;Autonomic Measures,49701215.2.0000.0068,Please refer to primary and secondary sponsors,"Biosense Webster, Inc.",,,No,,,,,,,,,,,,No,False,          ,2019.0,18.0
NCT02646943,18 January 2016,Longitudinal Study of Patients With Chronic Chagas Cardiomyopathy in Brazil (SaMi_Trop Project),Longitudinal Study of Patients With Chronic Chagas Cardiomyopathy in Brazil (SaMi_Trop Project),SaMi-Trop,University of Sao Paulo,2015-12-27,20151227.0,10/13/2025 15:56:09,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT02646943,Not recruiting,No,18 Years,,Both,01/07/2013,1959,Observational,"Observational Model: Cohort, Time Perspective: Prospective",,,"<br>    Eligibility Criteria: to be a client of the TMS TeleHealth System, have a positive history<br>    for T cruzi infection or Chagas disease, have an abnormal ECG and to consent to<br>    participating in the research program.<br><br>    Exclusion Criteria: The exclusion criteria include pregnancy or breast feeding, and any<br>    severe condition with ominous prognosis that indicates a life expectancy of less than two<br>    years.<br>   ",,Chagas Disease,,Death,Changes in the ECG pattern;Hospitalization due to cardiovascular,P50AI098461-02;2111129,Please refer to primary and secondary sponsors,National Institute of Allergy and Infectious Diseases (NIAID);Federal University of Minas Gerais;Federal University of São João del-Rei,,,No,,,,,,,,,,,,No,False,          ,2015.0,18.0
NCT02517632,16 December 2017,Physical Exercise Program in Chronic Chagas Heart Disease,Impact of a Physical Exercise Program in Cardiopulmonary RehAbilitation In Patients With Chronic Chagas Heart Disease: a Randomized Controlled Trial (PEACH Trial),PEACH,Evandro Chagas National Institute of Infectious Disease,2015-08-05,20150805.0,10/13/2025 15:56:09,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT02517632,Not recruiting,No,18 Years,,All,01/03/2015,30,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor). ,Phase 3,Brazil;Brazil;Brazil;Brazil;Brazil,"<br>    Inclusion Criteria: (1) Chagas disease diagnosis by serology; (2) chronic chagasic<br>    cardiomyopathy, with left ventricular ejection fraction <45% or compensated heart failure<br>    (3) clinical stability in the last three months, (4) adherence to the ambulatory clinical<br>    treatment and (5) age above 18 years.<br><br>    Exclusion Criteria: (1) pregnancy, (2) neuromuscular limitations, (3) tobacco use, (4)<br>    evidence of nonchagasic heart disease, (5) systemic conditions that limits exercise<br>    practice or hemodynamic stress tests (6) unavailability to attend three times a week for a<br>    minimum of six months, (7) practitioners of regular exercise and (8) claustrophobia.<br>   ;<br>    Inclusion Criteria: (1) Chagas disease diagnosis by serology; (2) chronic chagasic<br>    cardiomyopathy, with left ventricular ejection fraction <45% or compensated heart failure<br>    (3) clinical stability in the last three months, (4) adherence to the ambulatory clinical<br>    treatment and (5) age above 18 years.<br><br>    Exclusion Criteria: (1) pregnancy, (2) neuromuscular limitations, (3) tobacco use, (4)<br>    evidence of nonchagasic heart disease, (5) systemic conditions that limits exercise<br>    practice or hemodynamic stress tests (6) unavailability to attend three times a week for a<br>    minimum of six months, (7) practitioners of regular exercise and (8) claustrophobia.<br>   ;<br>    Inclusion Criteria: (1) Chagas disease diagnosis by serology; (2) chronic chagasic<br>    cardiomyopathy, with left ventricular ejection fraction <45% or compensated heart failure<br>    (3) clinical stability in the last three months, (4) adherence to the ambulatory clinical<br>    treatment and (5) age above 18 years.<br><br>    Exclusion Criteria: (1) pregnancy, (2) neuromuscular limitations, (3) tobacco use, (4)<br>    evidence of nonchagasic heart disease, (5) systemic conditions that limits exercise<br>    practice or hemodynamic stress tests (6) unavailability to attend three times a week for a<br>    minimum of six months, (7) practitioners of regular exercise and (8) claustrophobia.<br>   ;<br>    Inclusion Criteria: (1) Chagas disease diagnosis by serology; (2) chronic chagasic<br>    cardiomyopathy, with left ventricular ejection fraction <45% or compensated heart failure<br>    (3) clinical stability in the last three months, (4) adherence to the ambulatory clinical<br>    treatment and (5) age above 18 years.<br><br>    Exclusion Criteria: (1) pregnancy, (2) neuromuscular limitations, (3) tobacco use, (4)<br>    evidence of nonchagasic heart disease, (5) systemic conditions that limits exercise<br>    practice or hemodynamic stress tests (6) unavailability to attend three times a week for a<br>    minimum of six months, (7) practitioners of regular exercise and (8) claustrophobia.<br>   ",,Chagas Disease;Chagas Cardiomyopathy;Chagas Disease;Chagas Cardiomyopathy;Chagas Disease;Chagas Cardiomyopathy;Chagas Disease;Chagas Cardiomyopathy,"Behavioral: Exercise, nutritional and pharmaceutical counceling;Behavioral: Nutritional and pharmaceutical counceling;Behavioral: Exercise, nutritional and pharmaceutical counceling;Behavioral: Nutritional and pharmaceutical counceling;Behavioral: Exercise, nutritional and pharmaceutical counceling;Behavioral: Nutritional and pharmaceutical counceling;Behavioral: Exercise, nutritional and pharmaceutical counceling;Behavioral: Nutritional and pharmaceutical counceling",Functional capacity measured by peak exercise oxygen consumption;Functional capacity measured by peak exercise oxygen consumption;Functional capacity measured by peak exercise oxygen consumption,Muscle respiratory strength;Body composition (body fat percentage);Cardiac function (maily ejection fraction);Laboratorial biomarkers composite;Quality of life;24 hours Holter;Nutritional assessment;Pharmaceutical assessment;Microvascular reactivity;Body mass index,CAAE:38038914.6.0000.5262,Please refer to primary and secondary sponsors,"National Institute of Cardiology, Laranjeiras, Brazil",,,No,,,,,,,,,,,,No,False,          ,2015.0,18.0
NCT02386358,16 March 2015,Etiologic Treatment With Benznidazole in Adult Patients With Chronic Chagas Disease. A Randomized Clinical Trial,Etiologic Treatment With Benznidazole in Adult Patients With Chronic Chagas Disease. A Randomized Double Blind Clinical Trial,TRAENA,Instituto Nacional de Parasitologia Dr. Mario Fatala Chaben,2015-01-19,20150119.0,10/13/2025 15:56:09,ClinicalTrials.gov,http://clinicaltrials.gov/show/NCT02386358,Not recruiting,No,20 Years,55 Years,Both,01/03/1999,910,Interventional,"Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment",Phase 3,Argentina,"<br>    Inclusion Criteria:<br><br>     - Patients living in urban areas<br><br>     - Reactive to at least 2 for serological test performed in Fatala Chaben Institute<br>       (ELISA and IFI) ,<br><br>     - Patients who agreed to be part of this protocol through informed consent form signed<br><br>    Exclusion Criteria:<br><br>     - Patients with chronic Chagas disease who have received prior treatment with<br>       benznidazole<br><br>     - Other cardiomyopathies : idiopathic , alcoholic , peripartum myocarditis, secondary<br>       to coronary artery disease, valve disease, hypertension, restrictive, hypertrophic<br>       or congenital<br><br>     - Chronic renal disease<br><br>     - Bleeding disorders<br><br>     - History of liver disease or current liver disease ,<br><br>     - Any other severe clinical disease that decreases their life expectancy<br><br>     - History of severe allergies<br><br>     - Pregnant patients<br><br>     - Patients who have not signed the informed consent.<br>   ",,Chagas Disease,Drug: Benznidazole;Drug: Placebo,Cardiovascular Mortality;Development of heart failure;Severe arrhythmias with hemodynamic compromise or pacemaker implant or Implantable cardiac defibrillator,Electrocardiographic endpoints. New development of permanent changes in the electrocardiographic;Changes in clinical stage in chronic Chagas disease;Enlargement of the left ventricle (LV) detected by echocardiography.;New Heart Failure;Stroke;Serological negativization;Development and validation of RT-PCR;Changes of the secondary objectives during RCT development. New single endpoints;Combined clinical endpoints:,TRAENA,Please refer to primary and secondary sponsors,"National Council of Scientific and Technical Research, Argentina;Pan American Health Organization;Becas Carrillo Oñativia, Ministerio de Salud, Argentina;Drugs for Neglected Diseases Initiative (DNDi)",,,No,,,,,,,,,,,,No,False,          ,2015.0,20.0
NCT02498782,3 August 2015,Study to Evaluate Fexinidazole Dosing Regimens for the Treatment of Adult Patients With Chagas Disease,"Phase 2, Randomized, Multicenter, Placebo-controlled, Safety and Efficacy Study to Evaluate Six Oral Fexinidazole Dosing Regimens for the Treatment of Adult Patients With Chronic Indeterminate Chagas Disease.",,Drugs for Neglected Diseases,2014-08-20,20140820.0,10/13/2025 15:56:09,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT02498782,Recruiting,No,18 Years,50 Years,Both,01/07/2014,140,Interventional,"Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment",Phase 2,Bolivia,"<br>    Inclusion Criteria:<br><br>     - Confirmed diagnosis of T. cruzi infection by Serial qualitative PCR (three samples<br>       collected over a single day, at least one of which must be positive) AND<br>       Conventional serology (a minimum of two out of three positive tests must be positive<br>       [Conventional ELISA, Recombinant Elisa or IIF)<br><br>     - Women in reproductive age must have a negative serum pregnancy test at screening,<br>       must not be breastfeeding, and consistently use a highly effective contraceptive<br>       method during the entire trial.<br><br>     - Normal EKG  (PR =200 msec, QRS =120 msec, and QTc =400msec and =450 msec interval<br>       durations) at screening<br><br>    Exclusion Criteria:<br><br>     - Signs and/or symptoms of chronic cardiac and/or digestive form of CD (as per Study<br>       Manual of Operations)<br><br>     - History of cardiomyopathy, heart failure or ventricular arrhythmia<br><br>     - Any other acute or chronic health conditions that, in the opinion of the PI, may<br>       interfere with the efficacy and/or safety evaluation of the study drug (such as acute<br>       infections, history of HIV infection, diabetes, liver and renal disease requiring<br>       medical treatment)<br><br>     - Laboratory test values considered clinically significant or out of the allowable<br>       range at screening as follows:<br><br>        - Total WBC must be within the normal range, with an acceptable margin of +/- 5%<br>         (3,800 - 10,500 / mm3).<br><br>        - Platelets must be within the normal range up to 550,000 / mm3<br><br>        - Total bilirubin must be within the normal range Transaminases (ALT and AST) must<br>         be within the normal range, with an acceptable margin of 25% above the upper<br>         limit of normality (ULN), < 1.25 x ULN.<br><br>        - Creatinine must be within an acceptable margin of 10% above the ULN, <1.10 x<br>         ULN.<br><br>        - Alkaline phosphatase must be within the normal range up to Grade 1 CTCAE (< 2.5<br>         x ULN)<br><br>        - GGT must be within the normal range up to 2x ULN.<br><br>        - Potassium, Magnesium, Calcium must be within the normal range<br><br>     - History of alcohol abuse or any other drug addiction (as specified in the Study<br>       Manual of Operations).<br><br>     - Any condition that prevents the patient from taking oral medication.<br><br>     - Patients  with  contra-indication  (known  hypersensitivity)  to  other<br>       nitroimidazoles, e.g. metronidazole.<br><br>     - Any concomitant use of antimicrobial or anti-parasitic agents.<br>   ",,"Chagas Disease;Trypanosomiasis, South American;South American Trypanosomiasis;Disease, Chagas",Drug: Fexinidazole;Drug: Placebo,Parasitological cure rate (PCR);Adverse events;Serious Adverse events,Parasite Clearance (qualitative PCR);Parasite load;Serological response;Blood culture for parasite genotyping,DNDi-CH-FEXI-001,Please refer to primary and secondary sponsors,,,,No,,,,,,,,,,,,No,False,          ,2014.0,18.0
NCT01755377,29 August 2016,"New Tools for the Diagnosis, Prognosis and Treatment Follow-up in Chagas Disease",Evolution of Serologic Biomarkers and Diastolic Function and Segmentary Contractility Determined by Echocardiography After Treatment in Chagas Diseases,BIOMARCHA,Barcelona Centre for International Health Research,2012-12-19,20121219.0,10/13/2025 15:56:09,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT01755377,Not recruiting,No,18 Years,50 Years,Both,01/12/2012,63,Observational,"Observational Model: Cohort, Time Perspective: Prospective",,Spain,"<br>    Inclusion Criteria:<br><br>     - Patients from endemic areas (Latin America)<br><br>     - Older than 18 years old and younger than 50<br><br>     - With serological confirmation of Chagas Disease infection with two different<br>       techniques<br><br>     - Indeterminate or initial cardiac form<br><br>     - No previously treated for Chagas Disease<br><br>    Exclusion Criteria:<br><br>     - Co-morbidity: previous cardiac disease from other aetiology (ischemic, alcoholic or<br>       hypertensive), active inflammatory or immunology diseases for another agent. Hepatic<br>       disfunction<br><br>     - Pregnancy or lactation<br>   ",,Chagas Disease,Drug: Benznidazole,"Biomarkers for prognosis, early diagnosis and effectiveness of treatment.",Cardiac function after antiparasitic treatment,BIOMARCHA,Please refer to primary and secondary sponsors,,,,No,,,,,,,,,,,,No,False,          ,2012.0,18.0
NCT01755403,8 June 2015,Population Pharmacokinetics in Benznidazole-treated Adults With Chronic With Chagas Disease,Population Pharmacokinetics in Benznidazole-treated Adults With Chronic Chagas Disease. Benznidazole Pharmacokinetics and Adverse Reactions Relationship.,CINEBENZ,Barcelona Centre for International Health Research,2012-12-19,20121219.0,10/13/2025 15:56:09,ClinicalTrials.gov,http://clinicaltrials.gov/show/NCT01755403,Not recruiting,No,18 Years,60 Years,Both,01/12/2012,52,Interventional,"Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment",Phase 4,Spain,"<br>    Inclusion Criteria:<br><br>     - Adult patients with Chronic Chagas Disease diagnosed by 2 different and positive<br>       serological tests.<br><br>     - Patients with Chronic Chagas Disease who are going to start treatment with<br>       Benznidazole.<br><br>     - Any gender.<br><br>     - All the participants must agree to participate in the study and must sign the<br>       informed consent.<br><br>    Exclusion Criteria:<br><br>     - Patients younger than 18.<br><br>     - Patients with previous hypersensitivity to Benznidazole.<br><br>     - Immunocompromised patients as AIDS, cancer, chemotherapy, longterm corticoids need,<br>       primary immunodeficiency, or any other.<br><br>     - Hepatic dysfunction<br><br>     - Renal dysfunction: serum creatinin higher than 3 mg/dl.<br><br>     - Pregnancy or lactation.<br><br>     - Low adhesion to treatment or check-up.<br><br>     - Impossibility of follow-up.<br><br>     - Severe adverse reaction to Benznidazole.<br><br>     - Any other situation that could be risky for the patient.<br>   ",,Chagas Disease,Drug: Benznidazole,Population pharmacokinetic parameters of Benznidazole,Adverse reactions,CINEBENZ,Please refer to primary and secondary sponsors,,,,No,,,,,,,,,,,,No,False,          ,2012.0,18.0
NCT01744405,30 March 2015,Study Of Nifurtimox Transfer Into Breastmilk In Lactating Women With Chagas Disease,Study Of Nifurtimox Transfer Into Breastmilk In Lactating Women With Chagas Disease,LACTNFX,Hospital de Niños R. Gutierrez de Buenos Aires,2012-12-05,20121205.0,10/13/2025 15:56:09,ClinicalTrials.gov,http://clinicaltrials.gov/show/NCT01744405,Not recruiting,No,18 Years,40 Years,Female,01/12/2012,12,Observational,"Observational Model: Cohort, Time Perspective: Prospective",,Argentina,"<br>    Inclusion Criteria:<br><br>     - Lactating women with Chagas disease, not treated before<br><br>     - Use of contraception<br><br>    Exclusion Criteria:<br><br>     - History of allergy to nifurtimox or its excipients<br><br>     - Pregnancy<br><br>     - Significant heart involvement (due to Chagas disease)<br><br>     - Significant systemic diseases that could affect the interpretation of the results in<br>       the opinion of the principal investigator<br>   ",,Chagas Disease;Lactation,,Nifurtimox concentration in breastmilk and in plasma,Incidence of adverse drug reactions in women treated with nifurtimox during lactation,LACT-NIFURTIMOX,Please refer to primary and secondary sponsors,,,,No,,,,,,,,,,,,No,False,          ,2012.0,18.0
NCT01566617,1 February 2016,Impact of the Pharmaceutical Care on the Quality of Life in Patients With Chagas Heart Disease,Impact of The Pharmaceutical Care on the Quality of Life of Patients With Chagas Disease and Heart Failure: Randomized Clinical Trial,ChagasCare,Evandro Chagas Institute of Clinical Research,2012-03-23,20120323.0,10/13/2025 15:56:09,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT01566617,Recruiting,No,18 Years,76 Years,Both,01/10/2012,88,Interventional,"Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver)",,Brazil,"<br>    Inclusion Criteria:<br><br>     - The proposed clinical trial will be conducted in volunteers with Chagas disease<br>       complicated by heart failure.<br><br>     - Subjects will include adults, men and women, racial or ethnic minorities.<br><br>     - Diagnosed by two distinct Chagas serology tests (indirect immunofluorescence and<br>       enzyme linked immunosorbent assay<br><br>    Exclusion Criteria:<br><br>     - Patients with any of comorbidities that significantly affect the cardiac performance,<br>       such as coronary artery disease, moderate or severe heart valvular disease, left<br>       ventricular (LV) hypertrophy, congenital heart disease, or that limit their survival,<br>       such as malignant tumors and HIV, will be excluded from the study.<br><br>     - Patients will be also be excluded in case of failure to give informed consent,<br>       inability to perform 6 minute- walk test, significant cognitive impairment, or<br>       pregnancy.<br><br>     - Individuals who are participating in others intervention trials will also be<br>       excluded.<br>   ",,Chagas Heart Disease,Other: Standard care and Pharmaceutical care;Other: Standard care,Quality of life.,Incidence and types of drug-related problems;Physical functional capacity.,0034.0.009.000-11;Chagas2303,Please refer to primary and secondary sponsors,"Alejandro Marcel Hasslocher Moreno, MD MSc PhD student;Andrea Costa, MD PhD;Andrea Silvestre de Sousa, MD PhD;Luiz Henrique C. Sangenis, MD MSc PhD student;Marcelo Teixeira de Holanda, MD MSc PhD student;Mayara da Costa Chambela - MSc student;Pedro Emmanuel Alvarenga Americano do Brasil, MD PhD;Roberto Magalhães Saraiva, MD PhD;Sergio Salles Xavier, MD PhD",,,No,,,,,,,,,,,,Yes,False,          ,2012.0,18.0
NCT01678599,12 December 2020,Optimization of PCR Technique to Assess Parasitological Response for Patients With Chronic Chagas Disease,"Optimization of Sampling Procedure for PCR Technique to Assess Parasitological Response for Patients With Chronic Chagas Disease Treated With Benznidazole in Aiquile, Bolivia",PCR,Drugs for Neglected Diseases,2012-03-01,20120301.0,10/13/2025 15:56:09,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT01678599,Not recruiting,No,18 Years,60 Years,All,01/04/2011,220,Interventional,Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Diagnostic. Masking: None (Open Label). ,Phase 4,Bolivia,"<br>    Inclusion Criteria:<br><br>     - Age between > 18 - 60 years<br><br>     - Diagnosis of T. cruzi infection by Chagas serology. Two out of three serological tests<br>       must be positive [conventional ELISA, recombinant ELISA, or HAI)<br><br>     - Written informed consent form<br><br>    Exclusion Criteria:<br><br>     - Women in reproductive age who have a positive pregnancy test at screening, or who are<br>       breastfeeding Note: Women in reproductive age must accept to use a contraceptive<br>       method during the entire treatment phase of the trial<br><br>     - Current presentation of serious health condition such as: active pulmonary<br>       tuberculosis and clinical signs of liver or renal failure.<br><br>     - Chagasic cardiomyopathy stage II, III and IV (according to the NYHA classification)<br><br>     - Subjects requiring pacemaker implantation or other serious cardiac conduction defects<br><br>     - History of CD treatment with benznidazole or nifurtimox at any time in the past<br><br>     - Inability to comply with follow-up and/or not having a permanent address<br><br>     - History of alcohol abuse or any other drug addiction<br>   ",,Chagas Disease,Drug: Benznidazole,The primary endpoints are: - A positive or negative PCR at baseline (BL) among serology positive patients.;- Identification of the optimal relationship between sensitivity and feasibility at baseline.,"- Identification of the optimal relationship between sensitivity and Identification of the optimal relationship between sensitivity and feasibility at End Of Treatment (EOT);- The proportion of patients who convert from PCR (+) at baseline to PCR (-) at EOT - to be estimated using 1) the current sampling schedule (CS), the most sensitive one and the optimal one.;- The proportion of patients who convert from PCR (+) at baseline to PCR (-) at 6 and 12 months follow-up - to be estimated using 1) the current sampling schedule (CS) and the optimal one (based on EOT data).;- Relative reduction [(parasite count at baseline - parasite count at EOT, 6 and 12 months)/parasite count at baseline] of parasitemia - to be evaluated through parasite load at EOT, 6 and 12 months through quantitative PCR.",MSF/DNDi-CD-PCR-01,Please refer to primary and secondary sponsors,"Medecins Sans Frontieres, Netherlands",,,No,,,,,,,,,,,,No,False,          ,2012.0,18.0
NCT01547533,30 March 2015,Study of Benznidazole Transfer Into Breastmilk in Lactating Women With Chagas Disease,Study of Benznidazole Transfer Into Breastmilk in Lactating Women Treated for Chagas Disease,LACTBENZ,Hospital de Niños R. Gutierrez de Buenos Aires,2012-03-01,20120301.0,10/13/2025 15:56:09,ClinicalTrials.gov,http://clinicaltrials.gov/show/NCT01547533,Not recruiting,No,18 Years,40 Years,Female,01/08/2011,10,Observational,"Observational Model: Cohort, Time Perspective: Prospective",,Argentina,"<br>    Inclusion Criteria:<br><br>     - Lactating women with Chagas disease, not treated before<br><br>     - Use of contraception<br><br>    Exclusion Criteria:<br><br>     - History of allergy to benznidazole or its excipients<br><br>     - Pregnancy<br><br>     - Significant heart involvement (due to Chagas disease)<br><br>     - Significant systemic diseases that could affect the interpretation of the results in<br>       the opinion of the principal investigator<br>   ",,Chagas Disease;Lactation,,Benznidazole concentration in breastmilk and in plasma,incidence of adverse drug reactions in women treated with benznidazole during lactation,LACT-BENZNIDAZOLE,Please refer to primary and secondary sponsors,,,,No,,,,,,,,,,,,No,False,          ,2012.0,18.0
NCT01557140,24 August 2015,A Randomized Trial of Carvedilol in Chronic Chagas Cardiomyopathy,A Randomized Trial of Carvedilol After Renin-angiotensin System Inhibition in Chronic Chagas Cardiomyopathy,,Federal University of Minas Gerais,2012-02-21,20120221.0,10/13/2025 15:56:09,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT01557140,Not recruiting,No,18 Years,,Both,01/05/2003,42,Interventional,"Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment",Phase 4,Brazil,"<br>    Inclusion Criteria:<br><br>     - Criteria for inclusion were positivity for T cruzi as confirmed by 2 or more<br>       serological tests (indirect immunofluorescence, ELISA, and/or indirect<br>       hemagglutination) and having cardiomyopathy.<br><br>     - Cardiomyopathy was present when at least 3 of the following criteria were fulfilled:<br><br>        - LV enddiastolic diameter (LVDD) N55 mm<br><br>        - LVDD/body surface area > 2.7cm/m2<br><br>        - LV ejection fraction (LVEF) < 55%<br><br>        - QRS interval > 120 ms<br><br>        - echocardiographic evidence of diffuse or segmental systolic wall motion<br>         abnormalities.<br><br>    Exclusion Criteria:<br><br>     - Exclusion criteria were being pregnant<br><br>     - Using any h-blocker<br><br>     - Having additional comorbidities (eg, hypertension, diabetes mellitus, thyroid<br>       dysfunction, chronic obstructive pulmonary disease, asthma, and renal or hepatic<br>       failure).<br>   ",,Chagas Cardiomyopathy;Heart Failure;Dilated Cardiomyopathy,Drug: RASi plus carvedilol,Changes in left ventricular ejection fraction,Changes in Framingham score;Changes in quality of life (36-item Short-Form Health Survey);Changes in New York Heart Association functional class;Changes in cardiothoracic ratio;Changes in echocardiographic diastolic function indices;Changes in brain natriuretic peptide levels;Changes in chemokines;Changes in autoantibodies levels,Carvedilol in Chagas disease,Please refer to primary and secondary sponsors,,,,No,,,,,,,,,,,,No,False,          ,2012.0,18.0
NCT01489228,19 February 2015,Proof-of-Concept Study of E1224 to Treat Adult Patients With Chagas Disease,"Phase 2 Randomized, Multicenter, Placebo-controlled, Safety and Efficacy Study to Evaluate Three Oral E1224 Dosing Regimens and Benznidazole for the Treatment of Adult Patients With Chronic Indeterminate Chagas Disease",,Drugs for Neglected Diseases,2011-11-24,20111124.0,10/13/2025 15:56:09,ClinicalTrials.gov,http://clinicaltrials.gov/show/NCT01489228,Recruiting,No,18 Years,50 Years,Both,01/06/2011,230,Interventional,"Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment",Phase 2,Bolivia,"<br>    Screening Criteria:<br><br>     - Age >18 to < 50 years<br><br>     - Weight > 40 kg<br><br>     - Diagnosis of T. cruzi infection by conventional serology (a minimum of two out of<br>       three positive tests [enzyme linked immunosorbent assay (ELISA), indirect<br>       immunofluorescence (IIF), or hemagglutination inhibition (HAI)])<br><br>     - Signed, written informed consent form<br><br>     - No signs and/or symptoms of the chronic cardiac and/or digestive form of CD<br><br>     - No acute or chronic health conditions that may interfere with the efficacy and/or<br>       safety evaluation of the study drug<br><br>     - No formal contraindication to BZN and E1224<br><br>     - No known history of hypersensitivity, allergic, or serious adverse reactions to the<br>       study drugs<br><br>     - No history of CD treatment with BZN or NFX at any time in the past<br><br>     - No history of systemic treatment with itraconazole, ketoconazole, posaconazole,<br>       isavuconazole, or allopurinol in the past<br><br>    Inclusion Criteria:<br><br>     - Confirmed diagnosis of T. cruzi infection by serial qualitative PCR AND Conventional<br>       serology<br><br>     - Women in reproductive age must have a negative serum pregnancy test at screening,<br>       must not be breastfeeding, and consistently use and/or have partner consistently use<br>       an adequate contraceptive method<br><br>     - Normal ECG at screening<br><br>    Exclusion Criteria:<br><br>     - Abnormal laboratory test values at screening for the following parameters: total<br>       White Blood Cells (WBC) count, platelet count, alanine transaminase (ALT), aspartate<br>       transaminase (AST), total bilirubin, or creatinine; or gamma-glutamyl transferase<br>       (GGT)<br><br>     - History of alcohol abuse or any other drug addiction (as specified in the Study<br>       Manual of Operations)<br><br>     - Any condition that prevents the patient from taking oral medication<br><br>     - Any concomitant use of antimicrobial or antiparasitic agents<br>   ",,"Chronic Chagas Disease, Indeterminate",Drug: E1224;Drug: Benznidazole;Drug: Placebo,Serial negative qualitative Polymerase Chain Reaction (PCR) results (3 negative PCR results from 3 samples to be collected over 7 days) as a measure of parasitological cure at end of treatment,"Consistently negative serial qualitative PCR as a measure of sustained parasitological eradication;Qualitative PCR as a measure of parasite eradication;Quantitative PCR as a measure of change in parasite load over time;Incidence of serological conversion to negative and changes in titers over time as measured by conventional and non-conventional serologies;Changes in the levels of biomarkers over time: brain natriuretic peptide, troponin T, selected prothrombotic factors, lytic antibodies, apolipoprotein A1 and multiplex serodiagnostic assay;Area under the plasma concentration versus time curve (AUC), Peak Plasma Concentration (Cmax), Minimum Plasma Concentration (Cmin), Clearance, Volume of Distribution , and Plasma Terminal Half-Life (t1/2) of ravuconazole and benznidazole;Incidence and severity of adverse events (clinical and laboratory);Incidence of Serious Adverse Events and/or adverse events leading to treatment discontinuation;Early and late predictors of sustainable response to treatments;Correlation of pharmacokinetic parameters with parasitological response, changes in biomarkers and safety outcomes",DNDi-CH-E1224-001,Please refer to primary and secondary sponsors,"Eisai Co., Ltd.",,,No,,,,,,,,,,,,No,False,          ,2011.0,18.0
NCT00875173,23 November 2015,Selenium Treatment and Chagasic Cardiopathy (STCC),Selenium Treatment and Chagasic Cardiopathy (STCC): A Prospective Randomized Trial in Patients With Chagas Disease,STCC,Oswaldo Cruz Foundation,2008-10-20,20081020.0,10/13/2025 15:56:09,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT00875173,Recruiting,No,18 Years,65 Years,Both,01/10/2008,130,Interventional,"Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment",Phase 3,Brazil,"<br>    Inclusion Criteria:<br><br>     - altered ECHO (LVEF between 0,35 % and 45 %)<br><br>     - age between 20 and 65 years<br><br>    Exclusion Criteria:<br><br>     - patients > 65 years of age<br><br>     - smoke habit, patients with non-chagasic cardiopathy, live close to mineral deposit,<br>       metals industries and place with radioactive exposition, vegetarian<br><br>     - depressive psychological profile<br><br>     - pregnant or in lactating period<br><br>     - present or presented cancer or diabetes.<br><br>     - patients will be excluded if they take anti-convulsive medicines (Clozapine, Valproic<br>       Acid)<br>   ",,Chagas Disease,Drug: Selenium;Drug: Placebo (for Selenium),Ejection fraction by echocardiography,Electrocardiography,Oswaldo Cruz,Please refer to primary and secondary sponsors,"Conselho Nacional de Desenvolvimento Científico e Tecnológico;Ministry of Health, Brazil",,,No,,,,,,,,,,,,No,False,          ,2008.0,18.0
NCT00123916,12 December 2020,BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas' Disease,Benznidazole Evaluation for Interrupting Trypanosomiasis - The BENEFIT Trial,BENEFIT,Population Health Research Institute,2005-07-21,20050721.0,10/13/2025 15:56:09,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT00123916,Not recruiting,No,18 Years,75 Years,All,01/11/2004,2854,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Investigator, Outcomes Assessor). ",Phase 3,Argentina;Bolivia;Brazil;Colombia;El Salvador;Argentina;Bolivia;Brazil;Colombia;El Salvador;Canada,"<br>    Inclusion Criteria:<br><br>     - Consenting patients (between 18 and 75 years of age) with serological evidence of<br>       Chagas infection (any combination of 2 positive tests) and that have one or more of<br>       the following:<br><br>     - Abnormal electrocardiogram with at least two components (complete RBBB or LBBB; left<br>       anterior or posterior fascicular block; ventricular premature beat; first degree<br>       atrioventricular [AV] block; Mobitz type I AV block; sinus bradycardia; primary ST-T<br>       changes; abnormal Q waves; low voltage QRS; or atrial fibrillation);<br><br>     - Abnormal ECG (Mobitz type II, advanced or third degree AV block);<br><br>     - Increased cardiothoracic ratio (> 0.50);<br><br>     - Complex ventricular arrythmias on 24 hour ambulatory ECG monitoring;<br><br>     - Evidence of regional wall motion abnormality or reduced global left ventricular<br>       systolic function or increased left ventricular and diastolic diameter on 2D-Echo.<br><br>    Exclusion Criteria:<br><br>    Patients will be excluded if having:<br><br>     - NYHA heart failure class IV or decompensated heart failure<br><br>     - Evidence of concomitant coronary artery disease (CAD) or other etiology of dilated<br>       cardiomyopathy<br><br>     - Previous treatment with antitrypanosomal agents or an accepted indication for<br>       antiparasitic therapy<br><br>     - Inability to comply with follow-up visits<br><br>     - History of severe alcohol abuse within 2 years<br><br>     - Known chronic renal or hepatic insufficiency or hepatic insufficiency<br><br>     - Pregnancy or breast feeding<br><br>     - Megaesophagus with swallowing impairment<br><br>     - Other severe disease significantly curtailing life expectancy<br>   ",,Chagas Disease;Trypanosomiasis;Heart Disease,Drug: Benznidazole;Drug: Placebo,"Composite of First of cardiovascular events: Death, Resuscitated Cardiac Arrest, Sustained VentricularTachycardia, New/worsening Heart Failure, New Pacemaker/ICD, Stroke/TIA or other Embolic Events, Cardiac Transplant.","New development of any of the following echo changes, segmental wall motion abnormalities, ventricular aneurysm, reduction in LV ejection fraction >5%, increase in LVDD> 5 mm compared to baseline.;New 12 lead ECG alterations (complete bundle branch block, fascicular block, advanced atrio-ventricular block, atrial fibrillation, etc).;Progression of NYHA functional class by at least one category;New 12 lead electrocardiogram (ECG) alterations (complete bundle branch block; fascicular block, advanced atrio-ventricular block, atrial fibrillation, etc.);Progression of New York Heart Association (NYHA) functional class by at least one category;Evaluation of safety (adverse events: dermatitis, peripheral neuropathy, gastro-intestinal intolerance, leucopenia [2500 x 10^9 L]), tolerance and adherence to treatment;Determination of the efficacy of benznidazole in patients with Chronic Chagas heart disease based on a 50% reduction in both qualitative and quantitative PCR.;Safety and tolerability of benznidazole",CONEP-11394;BEN01,Please refer to primary and secondary sponsors,Canadian Institutes of Health Research (CIHR);World Health Organization;Instituto Dante Pazzanese de Cardiologia;University of Sao Paulo,,,No,,,,,,,,,,,,No,False,          ,2005.0,18.0
NCT02947581,21 November 2022,Sub Arachnoid Neurocysticercosis Treatment Outcome (SANTO),A Randomized Trial of Combined Albendazole Plus Praziquantel for Subarachnoid Cysticercosis of the Sylvian Fissure or the Basal Cisterns,SANTO,Universidad Peruana Cayetano Heredia,2016-10-24,20161024.0,10/13/2025 16:04:25,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT02947581,Not recruiting,No,18 Years,65 Years,All,14/11/2016,107,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator). ",Phase 3,Peru,"<br>    Inclusion Criteria:<br><br>     - - Male or female adult individuals (18 to 65 y.o.) with a diagnosis of basal<br>       subarachnoid cysticercosis (including locations in the Sylvian fissure or lower<br>       interhemispheric spaces) by neuroimaging and confirmed by serology.<br><br>     - Baseline laboratory results along acceptable ranges (specifically defined in the study<br>       protocol).<br><br>     - Willingness to accomplish the two-week minimum hospitalization required.<br><br>    Exclusion Criteria:<br><br>     - Previous therapy with ABZ or PZQ in the preceding 3 years (except for patients who<br>       received single-dose ABZ for intestinal parasites, or patients who received<br>       antiparasitic treatment between one and three years before enrollment but demonstrated<br>       lesion persistence or progression during the past 12 months).<br><br>     - A type of NCC which can expose the patient to increased risk during the study,<br>       specifically: a) intraventricular cysts; b) cysts in brainstem; c) concomitant<br>       intraparenchymal lesions greater than 3 cm of diameter in addition to their SANCC<br>       lesions; d) more than 20 intraparenchymal cysts in addition to their SANCC lesions; or<br>       d) untreated ocular cysticercosis. Patients with a lateral ventricle cyst, less than 2<br>       cm in diameter, without hydrocephalus or intracranial hypertension, can be included.<br>       The presence of concomitant intraparenchymal cysts of less than 3 cm in diameter will<br>       not exclude the patient unless there are more than 20 of them.<br><br>     - Active pulmonary tuberculosis evidenced by positive chest X-ray and positive sputum<br>       smears, or symptoms compatible with tuberculosis (fever+sweats or fever+cough) not<br>       otherwise explained.<br><br>     - Individuals with positive markers for active hepatitis.<br><br>     - Systemic disease that may affect therapy or short-term prognosis, including but not<br>       limited to chronic renal failure, hepatic insufficiency, cardiac failure, and<br>       steroid-dependent immune diseases.<br><br>     - Patients in unstable condition or with symptomatic intracranial hypertension (ICH).<br>       Definition of symptomatic ICH for this study is the presence of headaches, nausea, and<br>       vomiting, with papilledema at fundoscopic examination. Patients in this category can<br>       be considered for entrance into the study only after resolution of ICH by<br>       ventricular-peritoneal shunting or neuroendoscopic procedures involving CSF flow<br>       derivation. These procedures would be done as part of their standard medical care and<br>       are not part of the trial intervention.<br><br>     - Pregnancy during anti-parasitic treatment. If a patient becomes pregnant after<br>       treatment, she will continue in the study but will have radiological exams delayed<br>       until after delivery.<br><br>     - History of hypersensitivity to ABZ or PZQ<br><br>     - Chronic or drug abuse as defined in the study protocol.<br><br>     - Unwilling or unable to undergo MRI exams (like patients with ferromagnetic implants)<br><br>     - Inability or unwillingness of subject or legal representative to give written informed<br>       consent.<br>   ",,Neurocysticercosis,Drug: Albendazole and praziquantel;Drug: Albendazole and praziquantel placebo,Radiological efficacy at three months (3-month improvement).,"Radiological efficacy at six months (marked improvement or """"radiological cure"""") (evaluated only in patients with improvement at month 3).;Effect persistence at 12 months (no relapse) (evaluated only in patients with marked improvement at month 6) Effect persistence at 12 months (no relapse) (evaluated only in patients with marked improvement at month 6);Clinically asymptomatic patient;Decrease in serum levels",61449,Please refer to primary and secondary sponsors,,,,No,,,,,,,,,,,,Yes,False,          ,2016.0,18.0
NCT03807362,12 December 2020,CC-11050 Trial in Nepalese Patients With Erythema Nodosum Leprosum,"A Single Center, Open Label Pilot Study to Evaluate the Safety and Efficacy of CC-11050 in Nepalese Patients With Erythema Nodosum Leprosum",,The Leprosy Mission Nepal,2018-09-14,20180914.0,10/13/2025 15:59:22,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT03807362,Recruiting,No,18 Years,65 Years,All,07/01/2018,50,Interventional,Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ,Phase 2,Nepal,"<br>    Inclusion Criteria:<br><br>    Study participants must satisfy the following criteria to be enrolled in the study:<br><br>     1. Must be 18 -65 years old, weight > 35kg for women and >40kg for men at the time of<br>       signing the informed consent.<br><br>     2. Understand and voluntarily sign an informed consent document prior to any study<br>       related assessments/procedures are conducted.<br><br>     3. Have signs or symptoms of new or new episode ENL. In Step one, participants must be<br>       male. In Step 2, participants can be either male or female.<br><br>     4. Able to adhere to the study schedule and other protocol requirements.<br><br>    Exclusion Criteria:<br><br>    The presence of any of the following will exclude a participant from enrollment:<br><br>     1. Any significant medical condition, laboratory abnormality, or psychiatric illness that<br>       would prevent the participants from participating in the study.<br><br>     2. Patients on continuous rifampicin will be excluded, however, If rifampicin is given<br>       only once a month as part of a multi-drug regimen, a minimum of 2-week washout period<br>       is required prior to administration of CC-11050<br><br>     3. Any condition including the presence of laboratory abnormalities, which places the<br>       participant at unacceptable risk if he were to participate in the study.<br><br>     4. Any condition that confounds the ability to interpret data from the study (ie, HIV,<br>       chronic HepB, chronic HepC or TB patients under active treatment). Resolved TB<br>       patients will not be excluded from the study.<br><br>     5. Stable and well managed patients with Diabetes and hypertension will not be excluded<br>       from the study.<br><br>     6. Use of systemic corticosteroid or immunosuppressant therapy within 7 days of study<br>       medication initiation<br><br>     7. Pregnant or nursing females.<br>   ",,Erythema Nodosum Leprosum;Leprosy,Drug: CC-11050,Number of participants with moderate to severe ENL with severity changes as assessed by the ENL Severity Scale.,Number of participants with moderate to severe ENL with decreased duration of episode(s) as assessed by standard ENL episode definition.;Number of participants with moderate to severe ENL with decreased bacterial index (BI) as assessed by slit skin smear microscopy.;Number of participants with moderate to severe ENL with decreased bacterial index (BI) as assessed skin histopathology.;Number of patients with moderate to severe ENL with improved peripheral neuropathy as assessed by standardized monofilament and voluntary muscle tests.;Number of participants with moderate to severe ENL with improved quality of life as assessed by the World Health Organization Quality of Life tool.;Number of participants with moderate to severe ENL as assessed by standard blood panel and basic metabolic testing.;Number of participants with moderate to severe ENL as assessed by urinalysis.;Number of participants with moderate to severe ENL as assessed by serological indicators associated with ENL.,Nepal CC-11050,Please refer to primary and secondary sponsors,,,,No,,,,,,,,,,Undecided,,No,False,          ,2018.0,18.0
NCT02550080,16 December 2017,"Clinical Utility Of Genetic Screening For HLA-B*1301, On Susceptibility To Dapsone Hypersensitivity Syndrome","A Phase IV, Randomised, Multicentre, Double-blind, Study to Evaluate the Clinical Utility of Prospective Genetic Screening (HLA-B*1301) for Susceptibility to Dapsone Hypersensitivity Syndrome",,Shandong Provincial Institute of Dermatology and Venereology,2015-08-20,20150820.0,10/13/2025 15:59:22,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT02550080,Recruiting,No,18 Years,65 Years,All,01/07/2015,3130,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Care Provider). ",Phase 4,China;China;China;China;China,"<br>    Inclusion Criteria:<br><br>     - Diagnosed with cutaneous vasculitis, urticaria, psoriasis, acne, bullous skin<br>       diseases, sterile pustulosis, leprosy, pneumocystis pneumonia and any other patients<br>       who need dapsone administration.<br><br>     - Subjects are dapsone-naive.<br><br>     - All subjects must have a clinical need for treatment with dapsone that precedes the<br>       decision to participate in the study.<br><br>     - All subjects are willing to complete the 6-weeks period clinical trial.<br><br>     - All subjects are written informed consent.<br><br>    Exclusion Criteria:<br><br>     - Has previously received Dapsone therapy.<br><br>     - The subject or any of their healthcare providers is aware of the subjects HLA type.<br><br>     - Has been diagnosed with Glucose-6-phosphate dehydrogenase deficiency or methemoglobin<br>       reductase deficiency<br><br>     - Satisfies any contraindications or restrictions to Dapsone therapy as listed in the<br>       product labels.<br><br>     - Current severe illness, including heart, liver and renal failure, major organ<br>       allograft, malignancy requiring parenteral chemotherapy that can not be discontinued<br>       for the duration of the trial, or any other conditions which, in the opinion of the<br>       Investigator, would make the patient unsuitable for the study.<br><br>     - Any laboratory abnormality at Screening which, in the opinion of the Investigator,<br>       should preclude the subject's participation in the study [alanine aminotransferase<br>       (ALT), glutamic oxaloacetic transaminase(ALT), et al).<br><br>     - Pregnant women or women who are breastfeeding.<br><br>     - Subject is, in the opinion of the Investigator, unable to complete the 6 week<br>       Observation period and the EPT assessments as required.<br><br>     - A positive result for HLA-B*1301 in those subjects randomised to the genetic screening<br>       arm.<br>   ;<br>    Inclusion Criteria:<br><br>     - Diagnosed with cutaneous vasculitis, urticaria, psoriasis, acne, bullous skin<br>       diseases, sterile pustulosis, leprosy, pneumocystis pneumonia and any other patients<br>       who need dapsone administration.<br><br>     - Subjects are dapsone-naive.<br><br>     - All subjects must have a clinical need for treatment with dapsone that precedes the<br>       decision to participate in the study.<br><br>     - All subjects are willing to complete the 6-weeks period clinical trial.<br><br>     - All subjects are written informed consent.<br><br>    Exclusion Criteria:<br><br>     - Has previously received Dapsone therapy.<br><br>     - The subject or any of their healthcare providers is aware of the subjects HLA type.<br><br>     - Has been diagnosed with Glucose-6-phosphate dehydrogenase deficiency or methemoglobin<br>       reductase deficiency<br><br>     - Satisfies any contraindications or restrictions to Dapsone therapy as listed in the<br>       product labels.<br><br>     - Current severe illness, including heart, liver and renal failure, major organ<br>       allograft, malignancy requiring parenteral chemotherapy that can not be discontinued<br>       for the duration of the trial, or any other conditions which, in the opinion of the<br>       Investigator, would make the patient unsuitable for the study.<br><br>     - Any laboratory abnormality at Screening which, in the opinion of the Investigator,<br>       should preclude the subject's participation in the study [alanine aminotransferase<br>       (ALT), glutamic oxaloacetic transaminase(ALT), et al).<br><br>     - Pregnant women or women who are breastfeeding.<br><br>     - Subject is, in the opinion of the Investigator, unable to complete the 6 week<br>       Observation period and the EPT assessments as required.<br><br>     - A positive result for HLA-B*1301 in those subjects randomised to the genetic screening<br>       arm.<br>   ;<br>    Inclusion Criteria:<br><br>     - Diagnosed with cutaneous vasculitis, urticaria, psoriasis, acne, bullous skin<br>       diseases, sterile pustulosis, leprosy, pneumocystis pneumonia and any other patients<br>       who need dapsone administration.<br><br>     - Subjects are dapsone-naive.<br><br>     - All subjects must have a clinical need for treatment with dapsone that precedes the<br>       decision to participate in the study.<br><br>     - All subjects are willing to complete the 6-weeks period clinical trial.<br><br>     - All subjects are written informed consent.<br><br>    Exclusion Criteria:<br><br>     - Has previously received Dapsone therapy.<br><br>     - The subject or any of their healthcare providers is aware of the subjects HLA type.<br><br>     - Has been diagnosed with Glucose-6-phosphate dehydrogenase deficiency or methemoglobin<br>       reductase deficiency<br><br>     - Satisfies any contraindications or restrictions to Dapsone therapy as listed in the<br>       product labels.<br><br>     - Current severe illness, including heart, liver and renal failure, major organ<br>       allograft, malignancy requiring parenteral chemotherapy that can not be discontinued<br>       for the duration of the trial, or any other conditions which, in the opinion of the<br>       Investigator, would make the patient unsuitable for the study.<br><br>     - Any laboratory abnormality at Screening which, in the opinion of the Investigator,<br>       should preclude the subject's participation in the study [alanine aminotransferase<br>       (ALT), glutamic oxaloacetic transaminase(ALT), et al).<br><br>     - Pregnant women or women who are breastfeeding.<br><br>     - Subject is, in the opinion of the Investigator, unable to complete the 6 week<br>       Observation period and the EPT assessments as required.<br><br>     - A positive result for HLA-B*1301 in those subjects randomised to the genetic screening<br>       arm.<br>   ;<br>    Inclusion Criteria:<br><br>     - Diagnosed with cutaneous vasculitis, urticaria, psoriasis, acne, bullous skin<br>       diseases, sterile pustulosis, leprosy, pneumocystis pneumonia and any other patients<br>       who need dapsone administration.<br><br>     - Subjects are dapsone-naive.<br><br>     - All subjects must have a clinical need for treatment with dapsone that precedes the<br>       decision to participate in the study.<br><br>     - All subjects are willing to complete the 6-weeks period clinical trial.<br><br>     - All subjects are written informed consent.<br><br>    Exclusion Criteria:<br><br>     - Has previously received Dapsone therapy.<br><br>     - The subject or any of their healthcare providers is aware of the subjects HLA type.<br><br>     - Has been diagnosed with Glucose-6-phosphate dehydrogenase deficiency or methemoglobin<br>       reductase deficiency<br><br>     - Satisfies any contraindications or restrictions to Dapsone therapy as listed in the<br>       product labels.<br><br>     - Current severe illness, including heart, liver and renal failure, major organ<br>       allograft, malignancy requiring parenteral chemotherapy that can not be discontinued<br>       for the duration of the trial, or any other conditions which, in the opinion of the<br>       Investigator, would make the patient unsuitable for the study.<br><br>     - Any laboratory abnormality at Screening which, in the opinion of the Investigator,<br>       should preclude the subject's participation in the study [alanine aminotransferase<br>       (ALT), glutamic oxaloacetic transaminase(ALT), et al).<br><br>     - Pregnant women or women who are breastfeeding.<br><br>     - Subject is, in the opinion of the Investigator, unable to complete the 6 week<br>       Observation period and the EPT assessments as required.<br><br>     - A positive result for HLA-B*1301 in those subjects randomised to the genetic screening<br>       arm.<br>   ",,Allergic Cutaneous Vasculitis;Urticaria;Psoriasis;Acne;Bullous Skin Diseases;Sterile Pustulosis;Leprosy;Pneumocystis Pneumonia;Allergic Cutaneous Vasculitis;Urticaria;Psoriasis;Acne;Bullous Skin Diseases;Sterile Pustulosis;Leprosy;Pneumocystis Pneumonia;Allergic Cutaneous Vasculitis;Urticaria;Psoriasis;Acne;Bullous Skin Diseases;Sterile Pustulosis;Leprosy;Pneumocystis Pneumonia;Allergic Cutaneous Vasculitis;Urticaria;Psoriasis;Acne;Bullous Skin Diseases;Sterile Pustulosis;Leprosy;Pneumocystis Pneumonia,Drug: Dapsone;Genetic: HLA-B*1301;Drug: Dapsone;Genetic: HLA-B*1301;Drug: Dapsone;Genetic: HLA-B*1301;Drug: Dapsone;Genetic: HLA-B*1301,Incidence of clinically-suspected DHS during the 6-week observation period;Incidence of immunologically-confirmed DHS during the 6-week observation period;Incidence of clinically-suspected DHS during the 6-week observation period;Incidence of immunologically-confirmed DHS during the 6-week observation period;Incidence of clinically-suspected DHS during the 6-week observation period;Incidence of immunologically-confirmed DHS during the 6-week observation period,,SDPIDV-DDS-001,Please refer to primary and secondary sponsors,"Shandong Provincial Hospital;Jinan Central Hospital;Shandong Qianfo Hospital;Jinan Military General Hospital;Qingdao Center Medical Group;Liaocheng People's Hospital;Dongying People's Hospital,Shandong;Shandong Jining No. 1 People's Hospital;Dezhou People's Hospital,Shandong;Jinan City Dermatology Hospital Prevention and Treatment;Linyi City Dermatology Hospital Prevention and Treatment;Jining City Dermatology Hospital Prevention and Treatment;Weifang City Dermatology Hospital Prevention and Treatment;Laiwu City Dermatology Hospital Prevention and Treatment;Rizhao City Dermatology Hospital Prevention and Treatment",,,No,,,,,,,,,,,,No,False,          ,2015.0,18.0
NCT01885611,16 December 2017,Virgin Coconut Oil Oral Supplementation for Leprosy Patients,The Effects of Virgin Coconut Oil Supplementation on Oxidative Stress and Treatment Response Among Hansen's Disease Patients on Multi-Drug Therapy: A Pilot Study,,Philippine Dermatological Society,2013-06-14,20130614.0,10/13/2025 15:59:22,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT01885611,Not recruiting,No,18 Years,,All,01/06/2013,0,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Supportive Care. Masking: Single (Outcomes Assessor). ,Phase 1/Phase 2,Philippines;Philippines;Philippines;Philippines;Philippines,"<br>    Inclusion Criteria:<br><br>     - Patients aged 18 years and above, male or female<br><br>     - Patients with clinical evidence and histological confirmation of lepromatous leprosy<br>       (LL), borderline lepromatous leprosy (BL), borderline leprosy (BB), borderline<br>       tuberculoid leprosy (BT), or tuberculoid leprosy (TT) according to the Ridley and<br>       Jopling classification and Paucibacillary (PB) or Multibacillary (MB) disease based on<br>       the World Health Organization (WHO) classification<br><br>     - Patients should not have been on MDT in the past<br><br>     - Patients with normal blood test results for complete blood count (CBC), liver<br>       aminotransaminases (AST, ALT), glucose-6-phosphate dehydrogenase (G6PD) assay,<br>       creatinine, lipid profile and chest x-ray<br><br>    Exclusion Criteria:<br><br>     - HD patients with reactions needing prednisone therapy at time of diagnosis<br><br>     - Patients who are already taking VCO or any other oral or intravenous antioxidant<br>       supplements<br><br>     - Patients taking long term medications unrelated to leprosy<br><br>     - Pregnant women<br><br>     - Patients with history of smoking, co-infections such as tuberculosis, diabetes<br>       mellitus, any other systemic diseases or health problems<br><br>     - Patients not willing to return for follow-up<br>   ;<br>    Inclusion Criteria:<br><br>     - Patients aged 18 years and above, male or female<br><br>     - Patients with clinical evidence and histological confirmation of lepromatous leprosy<br>       (LL), borderline lepromatous leprosy (BL), borderline leprosy (BB), borderline<br>       tuberculoid leprosy (BT), or tuberculoid leprosy (TT) according to the Ridley and<br>       Jopling classification and Paucibacillary (PB) or Multibacillary (MB) disease based on<br>       the World Health Organization (WHO) classification<br><br>     - Patients should not have been on MDT in the past<br><br>     - Patients with normal blood test results for complete blood count (CBC), liver<br>       aminotransaminases (AST, ALT), glucose-6-phosphate dehydrogenase (G6PD) assay,<br>       creatinine, lipid profile and chest x-ray<br><br>    Exclusion Criteria:<br><br>     - HD patients with reactions needing prednisone therapy at time of diagnosis<br><br>     - Patients who are already taking VCO or any other oral or intravenous antioxidant<br>       supplements<br><br>     - Patients taking long term medications unrelated to leprosy<br><br>     - Pregnant women<br><br>     - Patients with history of smoking, co-infections such as tuberculosis, diabetes<br>       mellitus, any other systemic diseases or health problems<br><br>     - Patients not willing to return for follow-up<br>   ;<br>    Inclusion Criteria:<br><br>     - Patients aged 18 years and above, male or female<br><br>     - Patients with clinical evidence and histological confirmation of lepromatous leprosy<br>       (LL), borderline lepromatous leprosy (BL), borderline leprosy (BB), borderline<br>       tuberculoid leprosy (BT), or tuberculoid leprosy (TT) according to the Ridley and<br>       Jopling classification and Paucibacillary (PB) or Multibacillary (MB) disease based on<br>       the World Health Organization (WHO) classification<br><br>     - Patients should not have been on MDT in the past<br><br>     - Patients with normal blood test results for complete blood count (CBC), liver<br>       aminotransaminases (AST, ALT), glucose-6-phosphate dehydrogenase (G6PD) assay,<br>       creatinine, lipid profile and chest x-ray<br><br>    Exclusion Criteria:<br><br>     - HD patients with reactions needing prednisone therapy at time of diagnosis<br><br>     - Patients who are already taking VCO or any other oral or intravenous antioxidant<br>       supplements<br><br>     - Patients taking long term medications unrelated to leprosy<br><br>     - Pregnant women<br><br>     - Patients with history of smoking, co-infections such as tuberculosis, diabetes<br>       mellitus, any other systemic diseases or health problems<br><br>     - Patients not willing to return for follow-up<br>   ;<br>    Inclusion Criteria:<br><br>     - Patients aged 18 years and above, male or female<br><br>     - Patients with clinical evidence and histological confirmation of lepromatous leprosy<br>       (LL), borderline lepromatous leprosy (BL), borderline leprosy (BB), borderline<br>       tuberculoid leprosy (BT), or tuberculoid leprosy (TT) according to the Ridley and<br>       Jopling classification and Paucibacillary (PB) or Multibacillary (MB) disease based on<br>       the World Health Organization (WHO) classification<br><br>     - Patients should not have been on MDT in the past<br><br>     - Patients with normal blood test results for complete blood count (CBC), liver<br>       aminotransaminases (AST, ALT), glucose-6-phosphate dehydrogenase (G6PD) assay,<br>       creatinine, lipid profile and chest x-ray<br><br>    Exclusion Criteria:<br><br>     - HD patients with reactions needing prednisone therapy at time of diagnosis<br><br>     - Patients who are already taking VCO or any other oral or intravenous antioxidant<br>       supplements<br><br>     - Patients taking long term medications unrelated to leprosy<br><br>     - Pregnant women<br><br>     - Patients with history of smoking, co-infections such as tuberculosis, diabetes<br>       mellitus, any other systemic diseases or health problems<br><br>     - Patients not willing to return for follow-up<br>   ",,Hansen's Disease;Hansen's Disease;Hansen's Disease;Hansen's Disease,Other: Multi-Drug Therapy (Novartis ?);Dietary Supplement: Virgin Coconut Oil;Other: Multi-Drug Therapy (Novartis ?);Dietary Supplement: Virgin Coconut Oil;Other: Multi-Drug Therapy (Novartis ?);Dietary Supplement: Virgin Coconut Oil;Other: Multi-Drug Therapy (Novartis ?);Dietary Supplement: Virgin Coconut Oil,Change in Bacterial Indices;Change in Oxidative Stress Markers;Change in Bacterial Indices;Change in Oxidative Stress Markers;Change in Bacterial Indices;Change in Oxidative Stress Markers,Change in Clinical Response Score (CRS);Lepra reactions,UPMREB MED-2013-P3-053;PDS_PGH_2013_003,Please refer to primary and secondary sponsors,,,,No,,,,,,,,,,,,No,False,          ,2013.0,18.0
NCT01165840,19 October 2017,Effect of Weight and/or Obesity on Dapsone Drug Concentrations,"Population Pharmacokinetic Analysis of Dapsone in Normal, Overweight and Obese Volunteers",,Texas Tech University Health Sciences Center,2010-07-16,20100716.0,10/13/2025 15:59:22,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT01165840,Not recruiting,No,18 Years,,All,01/07/2010,37,Interventional,,Phase 4,United States;United States;United States;United States,"<br>    Inclusion Criteria:<br><br>     - Male and female subjects, age >18 years, of all racial and ethnic origins.<br><br>     - Non-English speaking Spanish speakers will be included in the study.<br><br>     - We are recruiting 12 normal or underweight (BMI <25 kg/m2), 12 overweight or obese<br>       (BMI 25-40 kg/m2), and 12 extremely obese (BMI > 40 kg/m2) for this study. This index<br>       is calculated using the volunteer's height and weight (Formula: weight (lb) / [height<br>       (in)]2 x 703). Half of each group will be male; the other half will be female.<br><br>    Exclusion Criteria:<br><br>     - Pregnant or nursing or unwilling to use a reliable contraception method during the<br>       study. The effects of dapsone on pregnancy are unknown. In addition, the metabolic<br>       changes that accompany pregnancy may alter the concentration-time profile of dapsone,<br>       so that the pregnancy and post-partum state would be a confounding variable.<br><br>     - Abnormal liver function tests: transaminases>10 times upper limit of normal, Alkaline<br>       phosphatase>5 times upper limit of normal, total bilirubin>5 times upper limit of<br>       normal.<br><br>     - History of allergies to dapsone, sulfones, or sulfonamides.<br><br>     - Dapsone, sulfones, or sulfonamides are contraindicated for any reason.<br><br>     - Volunteers unwilling to comply with study procedures.<br><br>     - Current suspected or documented infection of any kind.<br><br>     - Volunteers with colon resection, gastric bypass, lap band, or any other conditions<br>       inhibiting gastric absorption of drug.<br><br>     - Current or previous participation within 28 days of enrollment in another research<br>       study that involves the use of medication, contrast, or any other compound that may<br>       alter blood count and/or blood chemistry (liver function, kidney function or<br>       electrolyte balance), unless waved by PI.<br><br>     - Donation of 450 milliliters (ml) (one unit) of blood or more within 8 weeks (56 days)<br>       prior to study enrollment, unless waved by PI.<br><br>     - Current use of zidovudine, amprenavir, rifabutin, rifapentine, or saquinavir.<br><br>     - Creatinine clearance < 70 ml/minute (min) as estimated by the Cockcroft-gault<br>       equation.<br>   ;<br>    Inclusion Criteria:<br><br>     - Male and female subjects, age >18 years, of all racial and ethnic origins.<br><br>     - Non-English speaking Spanish speakers will be included in the study.<br><br>     - We are recruiting 12 normal or underweight (BMI <25 kg/m2), 12 overweight or obese<br>       (BMI 25-40 kg/m2), and 12 extremely obese (BMI > 40 kg/m2) for this study. This index<br>       is calculated using the volunteer's height and weight (Formula: weight (lb) / [height<br>       (in)]2 x 703). Half of each group will be male; the other half will be female.<br><br>    Exclusion Criteria:<br><br>     - Pregnant or nursing or unwilling to use a reliable contraception method during the<br>       study. The effects of dapsone on pregnancy are unknown. In addition, the metabolic<br>       changes that accompany pregnancy may alter the concentration-time profile of dapsone,<br>       so that the pregnancy and post-partum state would be a confounding variable.<br><br>     - Abnormal liver function tests: transaminases>10 times upper limit of normal, Alkaline<br>       phosphatase>5 times upper limit of normal, total bilirubin>5 times upper limit of<br>       normal.<br><br>     - History of allergies to dapsone, sulfones, or sulfonamides.<br><br>     - Dapsone, sulfones, or sulfonamides are contraindicated for any reason.<br><br>     - Volunteers unwilling to comply with study procedures.<br><br>     - Current suspected or documented infection of any kind.<br><br>     - Volunteers with colon resection, gastric bypass, lap band, or any other conditions<br>       inhibiting gastric absorption of drug.<br><br>     - Current or previous participation within 28 days of enrollment in another research<br>       study that involves the use of medication, contrast, or any other compound that may<br>       alter blood count and/or blood chemistry (liver function, kidney function or<br>       electrolyte balance), unless waved by PI.<br><br>     - Donation of 450 milliliters (ml) (one unit) of blood or more within 8 weeks (56 days)<br>       prior to study enrollment, unless waved by PI.<br><br>     - Current use of zidovudine, amprenavir, rifabutin, rifapentine, or saquinavir.<br><br>     - Creatinine clearance < 70 ml/minute (min) as estimated by the Cockcroft-gault<br>       equation.<br>   ;<br>    Inclusion Criteria:<br><br>     - Male and female subjects, age >18 years, of all racial and ethnic origins.<br><br>     - Non-English speaking Spanish speakers will be included in the study.<br><br>     - We are recruiting 12 normal or underweight (BMI <25 kg/m2), 12 overweight or obese<br>       (BMI 25-40 kg/m2), and 12 extremely obese (BMI > 40 kg/m2) for this study. This index<br>       is calculated using the volunteer's height and weight (Formula: weight (lb) / [height<br>       (in)]2 x 703). Half of each group will be male; the other half will be female.<br><br>    Exclusion Criteria:<br><br>     - Pregnant or nursing or unwilling to use a reliable contraception method during the<br>       study. The effects of dapsone on pregnancy are unknown. In addition, the metabolic<br>       changes that accompany pregnancy may alter the concentration-time profile of dapsone,<br>       so that the pregnancy and post-partum state would be a confounding variable.<br><br>     - Abnormal liver function tests: transaminases>10 times upper limit of normal, Alkaline<br>       phosphatase>5 times upper limit of normal, total bilirubin>5 times upper limit of<br>       normal.<br><br>     - History of allergies to dapsone, sulfones, or sulfonamides.<br><br>     - Dapsone, sulfones, or sulfonamides are contraindicated for any reason.<br><br>     - Volunteers unwilling to comply with study procedures.<br><br>     - Current suspected or documented infection of any kind.<br><br>     - Volunteers with colon resection, gastric bypass, lap band, or any other conditions<br>       inhibiting gastric absorption of drug.<br><br>     - Current or previous participation within 28 days of enrollment in another research<br>       study that involves the use of medication, contrast, or any other compound that may<br>       alter blood count and/or blood chemistry (liver function, kidney function or<br>       electrolyte balance), unless waved by PI.<br><br>     - Donation of 450 milliliters (ml) (one unit) of blood or more within 8 weeks (56 days)<br>       prior to study enrollment, unless waved by PI.<br><br>     - Current use of zidovudine, amprenavir, rifabutin, rifapentine, or saquinavir.<br><br>     - Creatinine clearance < 70 ml/minute (min) as estimated by the Cockcroft-gault<br>       equation.<br>   ;<br>    Inclusion Criteria:<br><br>     - Male and female subjects, age >18 years, of all racial and ethnic origins.<br><br>     - Non-English speaking Spanish speakers will be included in the study.<br><br>     - We are recruiting 12 normal or underweight (BMI <25 kg/m2), 12 overweight or obese<br>       (BMI 25-40 kg/m2), and 12 extremely obese (BMI > 40 kg/m2) for this study. This index<br>       is calculated using the volunteer's height and weight (Formula: weight (lb) / [height<br>       (in)]2 x 703). Half of each group will be male; the other half will be female.<br><br>    Exclusion Criteria:<br><br>     - Pregnant or nursing or unwilling to use a reliable contraception method during the<br>       study. The effects of dapsone on pregnancy are unknown. In addition, the metabolic<br>       changes that accompany pregnancy may alter the concentration-time profile of dapsone,<br>       so that the pregnancy and post-partum state would be a confounding variable.<br><br>     - Abnormal liver function tests: transaminases>10 times upper limit of normal, Alkaline<br>       phosphatase>5 times upper limit of normal, total bilirubin>5 times upper limit of<br>       normal.<br><br>     - History of allergies to dapsone, sulfones, or sulfonamides.<br><br>     - Dapsone, sulfones, or sulfonamides are contraindicated for any reason.<br><br>     - Volunteers unwilling to comply with study procedures.<br><br>     - Current suspected or documented infection of any kind.<br><br>     - Volunteers with colon resection, gastric bypass, lap band, or any other conditions<br>       inhibiting gastric absorption of drug.<br><br>     - Current or previous participation within 28 days of enrollment in another research<br>       study that involves the use of medication, contrast, or any other compound that may<br>       alter blood count and/or blood chemistry (liver function, kidney function or<br>       electrolyte balance), unless waved by PI.<br><br>     - Donation of 450 milliliters (ml) (one unit) of blood or more within 8 weeks (56 days)<br>       prior to study enrollment, unless waved by PI.<br><br>     - Current use of zidovudine, amprenavir, rifabutin, rifapentine, or saquinavir.<br><br>     - Creatinine clearance < 70 ml/minute (min) as estimated by the Cockcroft-gault<br>       equation.<br>   ",,Obesity;Leprosy;Tuberculosis;Obesity;Leprosy;Tuberculosis;Obesity;Leprosy;Tuberculosis;Obesity;Leprosy;Tuberculosis,Drug: Dapsone;Drug: Dapsone;Drug: Dapsone;Drug: Dapsone,Serum Clearance;Serum Clearance,,5UL1RR024982-02;AMAIRB97,Please refer to primary and secondary sponsors,National Center for Research Resources (NCRR),,,Yes,21/07/2016,https://clinicaltrials.gov/ct2/show/results/NCT01165840,,,,,,,,,,No,False,          ,2010.0,18.0
NCT00919542,30 March 2015,Ciclosporin in the Management of New Erythema Nodosum Leprosum,A Pilot (Double Blind Controlled) Study Randomizing Patients With New Acute ENL to Treatment Either With Ciclosporin or Prednisolone.,,London School of Hygiene and Tropical Medicine,2009-06-11,20090611.0,10/13/2025 15:59:22,ClinicalTrials.gov,http://clinicaltrials.gov/show/NCT00919542,Not recruiting,No,18 Years,65 Years,Female,01/07/2010,12,Interventional,"Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment",Phase 2,Ethiopia,"<br>    Inclusion Criteria:<br><br>     - Individuals with clinical evidence of new ENL<br><br>     - Aged 18-65<br><br>     - Weigh more than 30Kg<br><br>    Exclusion Criteria:<br><br>     - Unwillingness to give informed consent<br><br>     - Patients with severe active infections such as tuberculosis<br><br>     - Pregnant or breastfeeding women (see Appendix II)<br><br>     - Those with renal failure, abnormal renal function, hypertensive<br><br>     - Patients taking thalidomide currently or within the last 3 months<br><br>     - Patients not willing to return for follow-up<br><br>     - Women of reproductive age not willing to use contraception for the duration of the<br>       study ( see Appendix II)<br><br>     - HIV positive patients<br>   ",,Leprosy,Drug: Ciclosporin;Drug: prednisolone,Number of ENL recurrence episodes per patient,Mean time to ENL recurrence after initial control;Amount of additional prednisolone required by patients;Frequency of adverse events for patients in each treatment arm;Difference in score in Quality of Life assessment between start and end for patients in each treatment arm,ITCRBY24-ENLA,Please refer to primary and secondary sponsors,"Homes and Hospitals of St Giles;Alert Hospital, Ethiopia;Armauer Hansen Research Institute, Ethiopia",,,No,,,,,,,,,,,,Yes,False,          ,2009.0,18.0
NCT00919815,30 March 2015,Ciclosporin in the Management of New Type 1 Reactions in Leprosy,A Randomised Double Blind Controlled Trial Comparing Ciclosporin and Prednisolone in the Treatment of New Leprosy Type 1 Reactions,,London School of Hygiene and Tropical Medicine,2009-06-11,20090611.0,10/13/2025 15:59:22,ClinicalTrials.gov,http://clinicaltrials.gov/show/NCT00919815,Not recruiting,No,18 Years,65 Years,Both,01/08/2010,73,Interventional,"Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment",Phase 2/Phase 3,Ethiopia,"<br>    Inclusion Criteria:<br><br>     - Individuals with clinical evidence of T1R with new nerve function impairment (NFI).<br><br>     - Aged 18-65<br><br>     - Weigh more than 30Kg<br><br>    Exclusion Criteria:<br><br>     - Unwillingness to give informed consent<br><br>     - Patients with severe active infections such as tuberculosis<br><br>     - Pregnant or breastfeeding women (see Appendix II)<br><br>     - Those with renal failure, abnormal renal function, hypertensive<br><br>     - Patients taking thalidomide currently or within the last 3 months<br><br>     - Patients not willing to return for follow-up<br><br>     - Women of reproductive age not willing to use contraception for the duration of the<br>       study ( see Appendix II)<br><br>     - HIV positive patients<br>   ",,Leprosy,Drug: Ciclosporin;Drug: Prednisolone,improvement in nerve function and Clinical Severity Score,Incidence of adverse events;Number of T1R recurrence episodes per patient in each treatment arm;Severity of T1R recurrence for patients in each treatment arm;extra prednisolone needed to control reaction;6. Difference in score in Quality of Life assessment between start and end of treatment for patients in each treatment arm;Mean time to recurrence of T1R for patients in each treatment arm,ITCRBY24-T1RA,Please refer to primary and secondary sponsors,"Homes and Hospitals of St Giles;Alert Hospital, Ethiopia;Armauer Hansen Research Institute, Ethiopia",,,No,,,,,,,,,,,,Yes,False,          ,2009.0,18.0
NCT00919776,7 April 2015,Ciclosporin in the Management of Chronic or Recurrent Erythema Nodosum Leprosum,"A Pilot Double Blind Controlled Study Randomizing Patients Whose ENL is Not Controlled With Standard Prednisolone, and Comparing a Group Treated With Ciclosporin to a Group Treated With Additional Steroid Only.",,London School of Hygiene and Tropical Medicine,2009-06-11,20090611.0,10/13/2025 15:59:22,ClinicalTrials.gov,http://clinicaltrials.gov/show/NCT00919776,Not recruiting,No,18 Years,65 Years,Both,01/08/2010,20,Interventional,"Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment",Phase 2,Ethiopia,"<br>    Inclusion Criteria:<br><br>     - Individuals with clinical evidence of recurrent or chronic ENL<br><br>     - Aged 18-65<br><br>     - Weigh more than 30Kg<br><br>    Exclusion Criteria:<br><br>     - Unwillingness to give informed consent<br><br>     - Patients with severe active infections such as tuberculosis<br><br>     - Pregnant or breastfeeding women (see Appendix II)<br><br>     - Those with renal failure, abnormal renal function, hypertensive<br><br>     - Patients taking thalidomide currently or within the last 3 months<br><br>     - Patients not willing to return for follow-up<br><br>     - Women of reproductive age not willing to use contraception for the duration of the<br>       study ( see Appendix II)<br><br>     - HIV positive patients<br>   ",,Leprosy,Drug: prednisolone;Drug: ciclosporin,number of ENL recurrence episodes per patient,Mean time to ENL recurrence after initial control;Severity of ENL at recurrence;Amount of additional prednisolone required by patients;Frequency of adverse events for patients in each treatment arm;Difference in score in Quality of Life assessment between start and end for patients in each treatment arm,ITCCRBY24-ENLB,Please refer to primary and secondary sponsors,"Homes and Hospitals of St Giles;Alert Hospital, Ethiopia;Armauer Hansen Research Institute, Ethiopia",,,No,,,,,,,,,,,,Yes,False,          ,2009.0,18.0
NCT00919451,7 April 2015,Ciclosporin in the Management of Steroid Resistant Type 1 Reactions in Leprosy,A Pilot Study Assessing the Efficacy and Safety of Ciclosporin as a Second -Line Drug in Patients With Type 1 Reactions Who Have Not Responded to a 12 Week Course of Prednisolone.,,London School of Hygiene and Tropical Medicine,2009-06-11,20090611.0,10/13/2025 15:59:22,ClinicalTrials.gov,http://clinicaltrials.gov/show/NCT00919451,Not recruiting,No,18 Years,65 Years,Both,01/08/2010,16,Interventional,"Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment",Phase 2,Ethiopia,"<br>    Inclusion Criteria:<br><br>     - Individuals with clinical evidence of Type 1 Reaction who have not responded to 3<br>       months Prednisolone Treatment<br><br>     - Aged 18-65<br><br>     - Weigh more than 30Kg<br><br>    Exclusion Criteria:<br><br>     - Unwillingness to give informed consent<br><br>     - Patients with severe active infections such as tuberculosis<br><br>     - Pregnant or breastfeeding women (see Appendix II)<br><br>     - Those with renal failure, abnormal renal function, hypertensive<br><br>     - Patients taking thalidomide currently or within the last 3 months<br><br>     - Patients not willing to return for follow-up<br><br>     - Women of reproductive age not willing to use contraception for the duration of the<br>       study ( see Appendix II)<br><br>     - HIV positive<br>   ",,Leprosy,Drug: ciclosporin,improvement in nerve function,incidence of adverse effects;Skin lesion inflammation improvement;rate of improvement of reaction;Time to next reactional episode;extra prednisolone needed to control reaction,ITCRBY24-T1RB,Please refer to primary and secondary sponsors,"Homes and Hospitals of St Giles;Alert Hospital, Ethiopia;Armauer Hansen Research Institute, Ethiopia",,,No,,,,,,,,,,,,Yes,False,          ,2009.0,18.0
NCT00852345,13 April 2015,Treatment Protocol for Clofazamine in the Long Term Treatment of Leprosy,"Clofazamine in the Long Term Treatment of Leprosy, Phase III",,Kaiser Permanente,2009-02-26,20090226.0,10/13/2025 15:59:22,ClinicalTrials.gov,http://clinicaltrials.gov/show/NCT00852345,Not recruiting,No,18 Years,,Both,01/02/2009,,Expanded Access,,,United States,"<br>    Inclusion Criteria:<br><br>     - Known or suspected leprosy confirmed by skin biopsy and/or slit skin smears.<br><br>     - Multibacillary leprosy (lepromatous leprosy or borderline-lepromatous).<br><br>     - Paucibacillary leprosy (borderline, borderline tuberculoid, or indeterminate) if<br>       there is involvement of the cranial nerves or active acute neuritis.<br><br>     - Known or suspected ENL(erythema nodosum leprosum) (a specific immune reaction with<br>       painful skin nodules and fever)<br><br>     - Known or suspected dapsone-resistant leprosy or relapsed leprosy.<br><br>     - Intolerance of other antileprosy antibiotic (where clofazamine is substituted as<br>       apart of multidrug regimen)<br><br>    Exclusion Criteria:<br><br>     - Uncomplicated paucibacillary leprosy which would otherwise be treated with dapsone<br>       and rifampin only.<br><br>     - Known prior intolerance of Clofazamine<br><br>     - Any minor (even with parental consent)<br><br>     - Any fertile woman who is pregnant a specific immune reaction with painful skin rash<br>       and fever)<br>   ",,Leprosy,Drug: clofazamine,,,KPSC IRB 5347;IRB 5347,Please refer to primary and secondary sponsors,Health Resources and Services Administration (HRSA),,,No,,,,,,,,,,,,No,False,          ,2009.0,18.0
NCT00138437,19 February 2015,"Molecular and Immunological Tools for Detection of Strain Diversity, Drug Resistance and Immunological Responses",Molecular Epidemiology of Leprosy in Colombia,,Colorado State University,2005-08-26,20050826.0,10/13/2025 15:59:22,ClinicalTrials.gov,http://clinicaltrials.gov/show/NCT00138437,Not recruiting,No,18 Years,70 Years,Both,01/04/2006,1554,Observational,"Observational Model: Cohort, Time Perspective: Cross-Sectional",,Colombia,"<br>    Inclusion Criteria:<br><br>     - All leprosy patients (Group1), their household contacts (Group 2) and healthy persons<br>       with no known contacts with leprosy patients (Group 3), between the ages of 18 and 70<br>       years willing to participate in this study.<br><br>    Exclusion Criteria:<br><br>     - Patients unwilling to participate or unable to give informed consent will be excluded<br>       from the study.<br><br>     - Pregnant women will be excluded.<br><br>    Exclusion criteria for objective A.5 are one or more of the following conditions:<br><br>     - Chronic illnesses such as cancer<br><br>     - Diabetes<br><br>     - Hepatitis<br><br>     - HIV<br><br>     - Tuberculosis<br><br>     - Undergoing corticosteroid therapy<br><br>     - Current or previous history of immunosuppressive therapy as assessed from medical<br>       records and interviews with a physician.<br>   ",,Leprosy,,Strain typing: identification of genotypes,,09-817H,Please refer to primary and secondary sponsors,National Institute of Allergy and Infectious Diseases (NIAID),,,No,,,,,,,,,,,,Yes,False,          ,2005.0,18.0
NCT03664063,12 December 2020,PK PD Study of IDA and Azithromycin for NTDs ( ComboNTDs ),"A Pharmacokinetic and Pharmacodynamic Evaluation of Co-Administration of IDA (Ivermectin, Diethylcarbamazine and Albendazole) & Azithromycin for Integrated Treatment of Neglected Tropical Diseases",,Lihir Medical Centre,2018-09-03,20180903.0,10/13/2025 15:59:53,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT03664063,Not recruiting,No,18 Years,65 Years,All,01/09/2018,42,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ,Phase 2,Papua New Guinea,<br>    Inclusion Criteria:<br><br>     - Adult aged 18-65<br><br>     - Able to give informed consent<br><br>    Exclusion Criteria:<br><br>     - Known chronic illness<br><br>     - Hb <7 at baseline<br><br>     - Liver function or Creatinine * 1.5 Upper Limit of Normal<br><br>     - Urinary tract infection at baseline<br><br>     - Pregnancy (female participants only)<br><br>     - Routine medications which interact with study drugs<br><br>     - Lactose/Gluten intolerance<br><br>     - Permanent disability impeding study participation<br>   ,,Lymphatic Filariasis;Yaws;Trauma,Drug: Azithromycin;Drug: Albendazole;Drug: Ivermectin;Drug: Diethylcarbamazine,"Drug levels of Azithromycin, Ivermectin, Diethylcarbamazine, Albendazole",Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,ComboNTDs-PK,Please refer to primary and secondary sponsors,,,,No,,,,,,,,,,,,No,False,          ,2018.0,18.0
NCT02974049,2 May 2022,Lymphatic Filariasis (LF) in Ivory Coast,Alternative Chemotherapies for Lymphatic Filariasis (LF) Treatment and Elimination in Africa [Cote d'Ivoire],,University Hospitals Cleveland Medical Center,2016-11-22,20161122.0,10/13/2025 15:59:53,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT02974049,Not recruiting,No,18 Years,70 Years,All,01/01/2015,189,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label). ,,Côte D'Ivoire,"<br>    Inclusion Criteria:<br><br>     - Women and men 18-70 years<br><br>     - =50 MF/mL based on Nuclepore filtration<br><br>     - Willing to give informed consent<br><br>    Exclusion Criteria:<br><br>     - Prior treatment for LF within last 5 years<br><br>     - Pregnancy (perform pregnancy test)<br><br>     - Hemoglobin <7 g/dL<br><br>     - Permanent disability, serious medical illness that prevents or impedes study<br>       participation and/or comprehension<br><br>     - AST/ALT and creatinine >1.5 upper limit of normal<br><br>     - Proteinuria or hematuria >3+<br><br>     - Skin snip positivity for O. volvulus MF<br>   ",,Lymphatic Filariasis,Drug: Albendazole;Drug: Ivermectin;Drug: Diethylcarbamazine,Total clearance of Microfilariae,Total clearance of MF at 24 months;Percent MF reduction;Reduction in W. bancrofti antigen level;Alere Filariasis Test Strip negative;reduction in viable worm nests;Diversity of parasites;type and level of parasite-specific host immune response,08-14-13,Please refer to primary and secondary sponsors,Washington University School of Medicine,,,No,,,,,,,,,,,,No,False,          ,2016.0,18.0
NCT01975441,12 December 2020,"Eval 3-Drug Therapy Diethylcarbamize, Albendazole and Ivermectin That Could Accelerate LF Elimination Outside of Africa","Evaluate Triple-Drug Therapy With Diethylcarbamize (DEC), Albendazole (ALB) and Ivermectin (IVM) That Could Accelerate LF Elimination Outside of Africa",,University Hospitals Cleveland Medical Center,2013-10-28,20131028.0,10/13/2025 15:59:53,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT01975441,Not recruiting,No,18 Years,65 Years,All,01/05/2014,182,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor). ,Phase 2,Papua New Guinea,"<br>    Inclusion Criteria:<br><br>     - Men and women 18-65 years<br><br>     - >50 mf/ml in finger stick blood samples<br><br>     - Willing to give informed consent<br><br>    Exclusion Criteria:<br><br>     - Prior treatment for LF within last 5 years<br><br>     - Pregnant (do pregnancy test)<br><br>     - Hemoglobin < 7 g/dl<br><br>     - permanent disability, serious medical illness that prevents or impedes study<br>       participation and/or comprehension<br><br>     - AST/ALT and creatinine > 1.5 upper limit of normal.<br><br>     - Urine dipstick with glucose = 2+ and/or protein = 2+<br>   ",,Lymphatic Filariasis,Drug: Diethylcarbamazine;Drug: Albendazole;Drug: Ivermectin,Percentage of subjects with total clearance of in Wuchereria bancrofti (Wb) microfilaria (mf),Percentage of subjects with total clearance of Mf at 24 months.;Percent reduction in W. bancrofti antigen levels compared to baseline measured at 24 and 36 months;Percent of subjects who become circulating antigen negative at 24 months and 36 months after the beginning of the study,CWRU 3 vs 2 LF ELIM PNG,Please refer to primary and secondary sponsors,,,,No,,,,,,,,,,,,Yes,False,          ,2013.0,18.0
NCT01213576,19 October 2017,Efficacy of Higher Albendazole and Ivermectin Doses on Wuchereria Bancrofti Microfilarial Clearance in Malawi,"Efficacy of Higher Albendazole and Ivermectin Doses on Wuchereria Bancrofti Microfilarial Clearance in Malawi, Open Label Study",FED,London School of Hygiene and Tropical Medicine,2010-09-30,20100930.0,10/13/2025 15:59:53,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT01213576,Not recruiting,No,18 Years,55 Years,All,01/01/2009,70,Interventional,,,Malawi;Malawi;Malawi;Malawi,<br>    Inclusion Criteria:<br><br>     - understand and sign informed consent<br><br>     - willing to undergo night blood sampling every 6 months for 2 years<br><br>     - Age 18 to 55 years<br><br>     - Haemoglobin of equal or above 9g/dl<br><br>     - Microfilarial level of equal or above 80mg/dl<br><br>    Exclusion Criteria:<br><br>     - Non- consenting<br><br>     - Pregnancy or lactation<br><br>     - Treatment with albendazole or ivermectin within the previous 6 months<br><br>     - Known allergy to the study drugs<br>   ;<br>    Inclusion Criteria:<br><br>     - understand and sign informed consent<br><br>     - willing to undergo night blood sampling every 6 months for 2 years<br><br>     - Age 18 to 55 years<br><br>     - Haemoglobin of equal or above 9g/dl<br><br>     - Microfilarial level of equal or above 80mg/dl<br><br>    Exclusion Criteria:<br><br>     - Non- consenting<br><br>     - Pregnancy or lactation<br><br>     - Treatment with albendazole or ivermectin within the previous 6 months<br><br>     - Known allergy to the study drugs<br>   ;<br>    Inclusion Criteria:<br><br>     - understand and sign informed consent<br><br>     - willing to undergo night blood sampling every 6 months for 2 years<br><br>     - Age 18 to 55 years<br><br>     - Haemoglobin of equal or above 9g/dl<br><br>     - Microfilarial level of equal or above 80mg/dl<br><br>    Exclusion Criteria:<br><br>     - Non- consenting<br><br>     - Pregnancy or lactation<br><br>     - Treatment with albendazole or ivermectin within the previous 6 months<br><br>     - Known allergy to the study drugs<br>   ;<br>    Inclusion Criteria:<br><br>     - understand and sign informed consent<br><br>     - willing to undergo night blood sampling every 6 months for 2 years<br><br>     - Age 18 to 55 years<br><br>     - Haemoglobin of equal or above 9g/dl<br><br>     - Microfilarial level of equal or above 80mg/dl<br><br>    Exclusion Criteria:<br><br>     - Non- consenting<br><br>     - Pregnancy or lactation<br><br>     - Treatment with albendazole or ivermectin within the previous 6 months<br><br>     - Known allergy to the study drugs<br>   ,,Lymphatic Filariasis;Lymphatic Filariasis;Lymphatic Filariasis;Lymphatic Filariasis,Drug: Albendazole 400mg and ivermectin 200mcg/kg;Drug: Albendazole and ivermectin;Drug: Albendazole 400mg and ivermectin 200mcg/kg;Drug: albendazole 800mg and ivermectin 400mcg/kg bi-annually;Drug: Albendazole 400mg and ivermectin 200mcg/kg;Drug: Albendazole and ivermectin;Drug: Albendazole 400mg and ivermectin 200mcg/kg;Drug: albendazole 800mg and ivermectin 400mcg/kg bi-annually;Drug: Albendazole 400mg and ivermectin 200mcg/kg;Drug: Albendazole and ivermectin;Drug: Albendazole 400mg and ivermectin 200mcg/kg;Drug: albendazole 800mg and ivermectin 400mcg/kg bi-annually;Drug: Albendazole 400mg and ivermectin 200mcg/kg;Drug: Albendazole and ivermectin;Drug: Albendazole 400mg and ivermectin 200mcg/kg;Drug: albendazole 800mg and ivermectin 400mcg/kg bi-annually,Number of Participants Achieving Microfilarial Clearance;Number of Participants Achieving Microfilarial Clearance,Number of Participants With Microfilarial Clearance at 24 Months of Follow up,FED-311207,Please refer to primary and secondary sponsors,Emory University,,,Yes,27/02/2015,https://clinicaltrials.gov/ct2/show/results/NCT01213576,,,,,,,,,,No,False,          ,2010.0,18.0
NCT00511004,19 October 2017,Effect of Albendazole Dose on Treatment of Lymphatic Filariasis,"Effect of Albendazole Dose and Interval on Brugia Malayi Microfilarial Clearance in India: A Randomized, Open Label Study",,National Institute of Allergy and Infectious Diseases (NIAID),2007-08-02,20070802.0,10/13/2025 15:59:53,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT00511004,Not recruiting,No,18 Years,55 Years,All,01/07/2007,40,Interventional,,Phase 2,India;United States;India;United States;India;United States;India;United States,"<br>    - INCLUSION CRITERIA:<br><br>    Inclusion Criteria for Screening:<br><br>     - Age 18 years to 55 years inclusive<br><br>     - Both genders<br><br>     - Not pregnant or breastfeeding by history<br><br>     - If selected, subjects must be willing to spend 3 days on the Filariasis Chemotherapy<br>       Unit at the T.D. Medical College Hospital, Alleppey, Kerala, India<br><br>     - If selected, subjects must be willing to undergo nighttime blood draws once every 6<br>       months and Doppler ultrasound twice yearly for 2 years<br><br>     - If selected, agree to have blood stored for future studies<br><br>     - Ability to understand and give informed consent<br><br>    Inclusion Criteria for Treatment:<br><br>     - Age 18 to 55 years inclusive<br><br>     - Men and non-pregnant or non-breast feeding women<br><br>     - Microfilarial levels greater than 50mf/mL<br><br>     - Willingness to spend 3 days on the Filariasis Chemotherapy Unit at the T.D. Medical<br>       College Hospital, Alleppey, Kerala, India every 6 months for 2 years<br><br>     - Willingness to undergo nighttime blood draws once every 6 months for 2 years<br><br>     - Ability to understand and give informed consent<br><br>     - Hemaglobin (Hgb) levels for inclusion greater than 9 g/dL<br><br>     - Creatinine (Cr) less than or equal to 1.2 mg/dL<br><br>     - Alanine aminotransferase (ALT) less than 30 U/L<br><br>     - Willingness to have blood stored for future studies<br><br>    EXCLUSION CRITERIA:<br><br>    Exclusion Criteria for Screening:<br><br>     - Age less than 18 years or greater than 55 years<br><br>     - Pregnant or breast feeding by history<br><br>    Exclusion Criteria for Treatment:<br><br>     - Non-volunteers<br><br>     - Age less than 18 years or greater than 55 years<br><br>     - Pregnant or breast feeding<br><br>     - Hgb levels less than or equal to 9 g/dL<br><br>     - Cr greater than 1.3 mg/dL<br><br>     - ALT greater than 30 U/L<br><br>     - Alcohol consumption of more than 2 beers or other alcohol-containing drinks/day within<br>       a week of each drug administration<br><br>     - Temperature greater than 37.5 degrees Celsius<br><br>     - Serious medical illness<br><br>     - History of benzimidazole allergy<br><br>     - History of DEC allergy<br><br>     - Use of albendazole or DEC within past 6 months<br><br>     - Unwillingness to comply with required study visits<br>   ;<br>    - INCLUSION CRITERIA:<br><br>    Inclusion Criteria for Screening:<br><br>     - Age 18 years to 55 years inclusive<br><br>     - Both genders<br><br>     - Not pregnant or breastfeeding by history<br><br>     - If selected, subjects must be willing to spend 3 days on the Filariasis Chemotherapy<br>       Unit at the T.D. Medical College Hospital, Alleppey, Kerala, India<br><br>     - If selected, subjects must be willing to undergo nighttime blood draws once every 6<br>       months and Doppler ultrasound twice yearly for 2 years<br><br>     - If selected, agree to have blood stored for future studies<br><br>     - Ability to understand and give informed consent<br><br>    Inclusion Criteria for Treatment:<br><br>     - Age 18 to 55 years inclusive<br><br>     - Men and non-pregnant or non-breast feeding women<br><br>     - Microfilarial levels greater than 50mf/mL<br><br>     - Willingness to spend 3 days on the Filariasis Chemotherapy Unit at the T.D. Medical<br>       College Hospital, Alleppey, Kerala, India every 6 months for 2 years<br><br>     - Willingness to undergo nighttime blood draws once every 6 months for 2 years<br><br>     - Ability to understand and give informed consent<br><br>     - Hemaglobin (Hgb) levels for inclusion greater than 9 g/dL<br><br>     - Creatinine (Cr) less than or equal to 1.2 mg/dL<br><br>     - Alanine aminotransferase (ALT) less than 30 U/L<br><br>     - Willingness to have blood stored for future studies<br><br>    EXCLUSION CRITERIA:<br><br>    Exclusion Criteria for Screening:<br><br>     - Age less than 18 years or greater than 55 years<br><br>     - Pregnant or breast feeding by history<br><br>    Exclusion Criteria for Treatment:<br><br>     - Non-volunteers<br><br>     - Age less than 18 years or greater than 55 years<br><br>     - Pregnant or breast feeding<br><br>     - Hgb levels less than or equal to 9 g/dL<br><br>     - Cr greater than 1.3 mg/dL<br><br>     - ALT greater than 30 U/L<br><br>     - Alcohol consumption of more than 2 beers or other alcohol-containing drinks/day within<br>       a week of each drug administration<br><br>     - Temperature greater than 37.5 degrees Celsius<br><br>     - Serious medical illness<br><br>     - History of benzimidazole allergy<br><br>     - History of DEC allergy<br><br>     - Use of albendazole or DEC within past 6 months<br><br>     - Unwillingness to comply with required study visits<br>   ;<br>    - INCLUSION CRITERIA:<br><br>    Inclusion Criteria for Screening:<br><br>     - Age 18 years to 55 years inclusive<br><br>     - Both genders<br><br>     - Not pregnant or breastfeeding by history<br><br>     - If selected, subjects must be willing to spend 3 days on the Filariasis Chemotherapy<br>       Unit at the T.D. Medical College Hospital, Alleppey, Kerala, India<br><br>     - If selected, subjects must be willing to undergo nighttime blood draws once every 6<br>       months and Doppler ultrasound twice yearly for 2 years<br><br>     - If selected, agree to have blood stored for future studies<br><br>     - Ability to understand and give informed consent<br><br>    Inclusion Criteria for Treatment:<br><br>     - Age 18 to 55 years inclusive<br><br>     - Men and non-pregnant or non-breast feeding women<br><br>     - Microfilarial levels greater than 50mf/mL<br><br>     - Willingness to spend 3 days on the Filariasis Chemotherapy Unit at the T.D. Medical<br>       College Hospital, Alleppey, Kerala, India every 6 months for 2 years<br><br>     - Willingness to undergo nighttime blood draws once every 6 months for 2 years<br><br>     - Ability to understand and give informed consent<br><br>     - Hemaglobin (Hgb) levels for inclusion greater than 9 g/dL<br><br>     - Creatinine (Cr) less than or equal to 1.2 mg/dL<br><br>     - Alanine aminotransferase (ALT) less than 30 U/L<br><br>     - Willingness to have blood stored for future studies<br><br>    EXCLUSION CRITERIA:<br><br>    Exclusion Criteria for Screening:<br><br>     - Age less than 18 years or greater than 55 years<br><br>     - Pregnant or breast feeding by history<br><br>    Exclusion Criteria for Treatment:<br><br>     - Non-volunteers<br><br>     - Age less than 18 years or greater than 55 years<br><br>     - Pregnant or breast feeding<br><br>     - Hgb levels less than or equal to 9 g/dL<br><br>     - Cr greater than 1.3 mg/dL<br><br>     - ALT greater than 30 U/L<br><br>     - Alcohol consumption of more than 2 beers or other alcohol-containing drinks/day within<br>       a week of each drug administration<br><br>     - Temperature greater than 37.5 degrees Celsius<br><br>     - Serious medical illness<br><br>     - History of benzimidazole allergy<br><br>     - History of DEC allergy<br><br>     - Use of albendazole or DEC within past 6 months<br><br>     - Unwillingness to comply with required study visits<br>   ;<br>    - INCLUSION CRITERIA:<br><br>    Inclusion Criteria for Screening:<br><br>     - Age 18 years to 55 years inclusive<br><br>     - Both genders<br><br>     - Not pregnant or breastfeeding by history<br><br>     - If selected, subjects must be willing to spend 3 days on the Filariasis Chemotherapy<br>       Unit at the T.D. Medical College Hospital, Alleppey, Kerala, India<br><br>     - If selected, subjects must be willing to undergo nighttime blood draws once every 6<br>       months and Doppler ultrasound twice yearly for 2 years<br><br>     - If selected, agree to have blood stored for future studies<br><br>     - Ability to understand and give informed consent<br><br>    Inclusion Criteria for Treatment:<br><br>     - Age 18 to 55 years inclusive<br><br>     - Men and non-pregnant or non-breast feeding women<br><br>     - Microfilarial levels greater than 50mf/mL<br><br>     - Willingness to spend 3 days on the Filariasis Chemotherapy Unit at the T.D. Medical<br>       College Hospital, Alleppey, Kerala, India every 6 months for 2 years<br><br>     - Willingness to undergo nighttime blood draws once every 6 months for 2 years<br><br>     - Ability to understand and give informed consent<br><br>     - Hemaglobin (Hgb) levels for inclusion greater than 9 g/dL<br><br>     - Creatinine (Cr) less than or equal to 1.2 mg/dL<br><br>     - Alanine aminotransferase (ALT) less than 30 U/L<br><br>     - Willingness to have blood stored for future studies<br><br>    EXCLUSION CRITERIA:<br><br>    Exclusion Criteria for Screening:<br><br>     - Age less than 18 years or greater than 55 years<br><br>     - Pregnant or breast feeding by history<br><br>    Exclusion Criteria for Treatment:<br><br>     - Non-volunteers<br><br>     - Age less than 18 years or greater than 55 years<br><br>     - Pregnant or breast feeding<br><br>     - Hgb levels less than or equal to 9 g/dL<br><br>     - Cr greater than 1.3 mg/dL<br><br>     - ALT greater than 30 U/L<br><br>     - Alcohol consumption of more than 2 beers or other alcohol-containing drinks/day within<br>       a week of each drug administration<br><br>     - Temperature greater than 37.5 degrees Celsius<br><br>     - Serious medical illness<br><br>     - History of benzimidazole allergy<br><br>     - History of DEC allergy<br><br>     - Use of albendazole or DEC within past 6 months<br><br>     - Unwillingness to comply with required study visits<br>   ",,Lymphatic Filariasis;Lymphatic Filariasis;Lymphatic Filariasis;Lymphatic Filariasis,Drug: Albendazole;Drug: Diethylcarbamazine;Drug: Albendazole;Drug: Diethylcarbamazine;Drug: Albendazole;Drug: Diethylcarbamazine;Drug: Albendazole;Drug: Diethylcarbamazine,Microfilarial Counts at 1 Year;Microfilarial Counts at 1 Year,Adult Worm Burdens at 2 Years;Microfilarial Levels at 2 Years;Brugia Specific Immunoglobulin G4 (IgG4) Antibodies,07-I-N197;999907197,Please refer to primary and secondary sponsors,,,,Yes,31/08/2015,https://clinicaltrials.gov/ct2/show/results/NCT00511004,,,,,,,,,,No,False,          ,2007.0,18.0
NCT00375583,16 December 2017,Effect of Albendazole Dose on Clearance of Filarial Worms,"Effect of Albendazole Dose and Interval on Wuchereria Bancrofti Microfilarial Clearance in India: A Randomized, Open Label Study",,National Institute of Allergy and Infectious Diseases (NIAID),2006-09-12,20060912.0,10/13/2025 15:59:53,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT00375583,Not recruiting,No,18 Years,55 Years,All,09/09/2006,1000,Interventional,Primary purpose: Treatment. ,Phase 2,India;United States;India;United States;India;United States;India;United States;India;United States,"<br>    - INCLUSION CRITERIA (SCREENING):<br><br>    Age 18 years to 55 years inclusive.<br><br>    Both genders.<br><br>    Not pregnant or breastfeeding by history.<br><br>    If selected, subject must be willing to spend 3 days on the Clinical Trials Unit of the<br>    Government General Hospital, Chennai India.<br><br>    If selected, subject must be willing to undergo nighttime blood draws every 6 months for 2<br>    years.<br><br>    If selected, agree to have blood stored for future studies.<br><br>    Ability to understand and sign the informed consent.<br><br>    EXCLUSION CRITERIA (SCREENING):<br><br>    Non-volunteers.<br><br>    Age less than 18 years or greater than 55 years.<br><br>    Pregnant or breastfeeding by history.<br><br>    INCLUSION (TREATMENT):<br><br>    Age 18 years to 55 years.<br><br>    Men and non-pregnant or non-breastfeeding women.<br><br>    Microfilarial levels greater than 50 mf/ml.<br><br>    Willingness to spend 3 days on the Clinical Trials Unit of the Government General Hospital,<br>    Chennai India.<br><br>    Willingness to undergo nighttime blood draws every 6 months for 2 years.<br><br>    Ability to understand and sign the informed consent.<br><br>    Hb levels for inclusion greater than 9 g/dL.<br><br>    Normal Cr, ALT.<br><br>    Willingness to have blood stored for future studies.<br><br>    EXCLUSION (TREATMENT):<br><br>    Non-volunteers.<br><br>    Age less than 18 years or greater than 55 years.<br><br>    Pregnancy or breast-feeding.<br><br>    Hgb less than or equal to 9 g/dL.<br><br>    Cr greater than 1.2/100 ml.<br><br>    ALT greater than 30 U.<br><br>    Alcohol consumption of more than 2 beers or other alcohol-containing drink/day within a<br>    week of each drug administration.<br><br>    Temperature greater than 37.5 degrees C.<br><br>    Serious medical illness.<br><br>    History of benzimidazole allergy.<br><br>    History of DEC allergy.<br><br>    Use of albendazole or DEC within past 6 months.<br><br>    Unwillingness to comply with required study visits.<br>   ;<br>    - INCLUSION CRITERIA (SCREENING):<br><br>    Age 18 years to 55 years inclusive.<br><br>    Both genders.<br><br>    Not pregnant or breastfeeding by history.<br><br>    If selected, subject must be willing to spend 3 days on the Clinical Trials Unit of the<br>    Government General Hospital, Chennai India.<br><br>    If selected, subject must be willing to undergo nighttime blood draws every 6 months for 2<br>    years.<br><br>    If selected, agree to have blood stored for future studies.<br><br>    Ability to understand and sign the informed consent.<br><br>    EXCLUSION CRITERIA (SCREENING):<br><br>    Non-volunteers.<br><br>    Age less than 18 years or greater than 55 years.<br><br>    Pregnant or breastfeeding by history.<br><br>    INCLUSION (TREATMENT):<br><br>    Age 18 years to 55 years.<br><br>    Men and non-pregnant or non-breastfeeding women.<br><br>    Microfilarial levels greater than 50 mf/ml.<br><br>    Willingness to spend 3 days on the Clinical Trials Unit of the Government General Hospital,<br>    Chennai India.<br><br>    Willingness to undergo nighttime blood draws every 6 months for 2 years.<br><br>    Ability to understand and sign the informed consent.<br><br>    Hb levels for inclusion greater than 9 g/dL.<br><br>    Normal Cr, ALT.<br><br>    Willingness to have blood stored for future studies.<br><br>    EXCLUSION (TREATMENT):<br><br>    Non-volunteers.<br><br>    Age less than 18 years or greater than 55 years.<br><br>    Pregnancy or breast-feeding.<br><br>    Hgb less than or equal to 9 g/dL.<br><br>    Cr greater than 1.2/100 ml.<br><br>    ALT greater than 30 U.<br><br>    Alcohol consumption of more than 2 beers or other alcohol-containing drink/day within a<br>    week of each drug administration.<br><br>    Temperature greater than 37.5 degrees C.<br><br>    Serious medical illness.<br><br>    History of benzimidazole allergy.<br><br>    History of DEC allergy.<br><br>    Use of albendazole or DEC within past 6 months.<br><br>    Unwillingness to comply with required study visits.<br>   ;<br>    - INCLUSION CRITERIA (SCREENING):<br><br>    Age 18 years to 55 years inclusive.<br><br>    Both genders.<br><br>    Not pregnant or breastfeeding by history.<br><br>    If selected, subject must be willing to spend 3 days on the Clinical Trials Unit of the<br>    Government General Hospital, Chennai India.<br><br>    If selected, subject must be willing to undergo nighttime blood draws every 6 months for 2<br>    years.<br><br>    If selected, agree to have blood stored for future studies.<br><br>    Ability to understand and sign the informed consent.<br><br>    EXCLUSION CRITERIA (SCREENING):<br><br>    Non-volunteers.<br><br>    Age less than 18 years or greater than 55 years.<br><br>    Pregnant or breastfeeding by history.<br><br>    INCLUSION (TREATMENT):<br><br>    Age 18 years to 55 years.<br><br>    Men and non-pregnant or non-breastfeeding women.<br><br>    Microfilarial levels greater than 50 mf/ml.<br><br>    Willingness to spend 3 days on the Clinical Trials Unit of the Government General Hospital,<br>    Chennai India.<br><br>    Willingness to undergo nighttime blood draws every 6 months for 2 years.<br><br>    Ability to understand and sign the informed consent.<br><br>    Hb levels for inclusion greater than 9 g/dL.<br><br>    Normal Cr, ALT.<br><br>    Willingness to have blood stored for future studies.<br><br>    EXCLUSION (TREATMENT):<br><br>    Non-volunteers.<br><br>    Age less than 18 years or greater than 55 years.<br><br>    Pregnancy or breast-feeding.<br><br>    Hgb less than or equal to 9 g/dL.<br><br>    Cr greater than 1.2/100 ml.<br><br>    ALT greater than 30 U.<br><br>    Alcohol consumption of more than 2 beers or other alcohol-containing drink/day within a<br>    week of each drug administration.<br><br>    Temperature greater than 37.5 degrees C.<br><br>    Serious medical illness.<br><br>    History of benzimidazole allergy.<br><br>    History of DEC allergy.<br><br>    Use of albendazole or DEC within past 6 months.<br><br>    Unwillingness to comply with required study visits.<br>   ;<br>    - INCLUSION CRITERIA (SCREENING):<br><br>    Age 18 years to 55 years inclusive.<br><br>    Both genders.<br><br>    Not pregnant or breastfeeding by history.<br><br>    If selected, subject must be willing to spend 3 days on the Clinical Trials Unit of the<br>    Government General Hospital, Chennai India.<br><br>    If selected, subject must be willing to undergo nighttime blood draws every 6 months for 2<br>    years.<br><br>    If selected, agree to have blood stored for future studies.<br><br>    Ability to understand and sign the informed consent.<br><br>    EXCLUSION CRITERIA (SCREENING):<br><br>    Non-volunteers.<br><br>    Age less than 18 years or greater than 55 years.<br><br>    Pregnant or breastfeeding by history.<br><br>    INCLUSION (TREATMENT):<br><br>    Age 18 years to 55 years.<br><br>    Men and non-pregnant or non-breastfeeding women.<br><br>    Microfilarial levels greater than 50 mf/ml.<br><br>    Willingness to spend 3 days on the Clinical Trials Unit of the Government General Hospital,<br>    Chennai India.<br><br>    Willingness to undergo nighttime blood draws every 6 months for 2 years.<br><br>    Ability to understand and sign the informed consent.<br><br>    Hb levels for inclusion greater than 9 g/dL.<br><br>    Normal Cr, ALT.<br><br>    Willingness to have blood stored for future studies.<br><br>    EXCLUSION (TREATMENT):<br><br>    Non-volunteers.<br><br>    Age less than 18 years or greater than 55 years.<br><br>    Pregnancy or breast-feeding.<br><br>    Hgb less than or equal to 9 g/dL.<br><br>    Cr greater than 1.2/100 ml.<br><br>    ALT greater than 30 U.<br><br>    Alcohol consumption of more than 2 beers or other alcohol-containing drink/day within a<br>    week of each drug administration.<br><br>    Temperature greater than 37.5 degrees C.<br><br>    Serious medical illness.<br><br>    History of benzimidazole allergy.<br><br>    History of DEC allergy.<br><br>    Use of albendazole or DEC within past 6 months.<br><br>    Unwillingness to comply with required study visits.<br>   ",,Lymphatic Filariasis;Wuchereria Bancrofti Infection;Lymphatic Filariasis;Wuchereria Bancrofti Infection;Lymphatic Filariasis;Wuchereria Bancrofti Infection;Lymphatic Filariasis;Wuchereria Bancrofti Infection,Drug: DEC/Albendazole;Drug: DEC/Albendazole;Drug: DEC/Albendazole;Drug: DEC/Albendazole,Microfilarial levels.;Microfilarial levels.;Microfilarial levels.,Adult worm burden.,06-I-N244;999906244,Please refer to primary and secondary sponsors,"Tuberculosis Research Centre, India",,,No,,,,,,,,,,,,No,False,          ,2006.0,18.0
NCT06070116,10 June 2024,Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis,Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis,,Washington University School of Medicine,2023-09-14,20230914.0,10/13/2025 16:01:06,ClinicalTrials.gov,https://clinicaltrials.gov/ct2/show/NCT06070116,Recruiting,No,18 Years,75 Years,All,05/04/2024,300,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ,Phase 2,Liberia,"Inclusion Criteria:<br><br> - Adult men and women, 18 years to 75 years old<br><br> - Participants must have at least 1 palpable subcutaneous nodule (onchocercoma)<br><br> - Participants with mean skin Mf counts = 1 Mf/mg at the time of enrollment (prior to<br>   pretreatment)<br><br>Exclusion Criteria:<br><br> - History of treatment with IVM or Mox less than six months prior to pretreatment with<br>   IVM.<br><br> - Treatment with IVM or Mox outside of the study after the pre-treatment clearing dose<br>   before treatment with one of the four study treatments.<br><br> - Pregnant or breastfeeding mothers.<br><br> - Severe ocular disease at baseline (assessed just prior to the first study treatment,<br>   approximately 6-12 months after IVM pretreatment). Briefly, these conditions include<br>   severe uveitis, severe glaucoma, severe keratitis, and/or cataracts that interfere<br>   with visualization of the posterior segment of the eye. Details regarding ocular<br>   exclusion criteria are provided below. Individuals who are excluded with significant<br>   ocular disease will be referred for appropriate All ocular disease exclusion<br>   criteria apply to either eye. That is to say, participants will be excluded if any<br>   of the ocular exclusion criteria listed below are met for either eye. These<br>   exclusions are needed to reduce the risk of study treatments worsening severe<br>   pre-existing ocular disease. They also are needed to ensure that study staff will be<br>   able to adequately evaluate the posterior segment before and after treatment.<br><br>    1. Any cataract that prevents clear visualization of fundus or imaging by OCT.<br><br>    2. Severe retinal nerve fiber layer thinning of the optic nerve in the superior<br>     and inferior quadrant analysis by OCT with a corresponding visual field defect<br>     in the superior and inferior hemifield, and/or visual field loss within 5<br>     degrees of fixation in at least one hemifield. Note: If OCT is not available,<br>     the following exclusion criteria will apply: vertical cup/disc ratio by<br>     fundoscopy greater than or equal to 0.80 with a corresponding visual field<br>     defect in the superior and inferior hemifield, and/or visual field loss within<br>     5 degrees of fixation in at least one hemifield.<br><br>    3. Intraocular pressure (IOP) greater than or equal to 25 by Goldmann tonometry.<br><br>    4. Retinal detachment or retinal break.<br><br>    5. Acute ocular infection (i.e., viral conjunctivitis, corneal ulcer,<br>     endophthalmitis).<br><br>    6. Optic atrophy with a reproducible visual field defect detected by confrontation<br>     visual field testing.<br><br>    7. Exam consistent with Herpes simplex virus eye infection.<br><br>    8. Homonymous hemianopsia, quadrantopsia, bitemporal hemianopsia, or central<br>     scotoma related to cerebral vascular disease by Automated Visual field testing<br>     and confrontation visual field testing.<br><br>    9. Acute angle closure glaucoma.<br><br>   10. Gonioscopy grade 0 (slit) limiting ability to safely dilate participant.<br><br>   11. Severe tremor, blepharospasm, or other voluntary or involuntary motor condition<br>     that limits careful slit lamp examinations, OCT, gonioscopy, IOP measurement,<br>     fundus photography, and automated perimetry.<br><br>   12. Cognitive impairment that limits participant's ability to understand and<br>     perform a Visual Acuity Test with a Tumbling E chart, confrontation visual<br>     field, slit lamp exam, or any other ocular exam component.<br><br>   13. Optic nerve edema.<br><br>   14. Active retinopathy or retinitis not attributable to onchocercal disease.<br><br>   15. A history of uveitis not associated with onchocerciasis.<br><br>   16. Any pre-existing chorioretinal scar or retinal degeneration and other<br>     significant retinal pathologies (foveomacular schisis, dystrophies, arterial<br>     macroaneurysms etc) involving the macula.<br><br>   17. Severe ocular pain that the participant rates as 9 or 10 out of 10.<br><br>   18. Best corrected or pinhole visual acuity worse than 6/60 (20/200).<br><br>   19. Age-related macular degeneration (AMD).<br><br>   20. >5 motile Mf in the anterior chamber in either eye at the time of secondary<br>     screening (6 months after pre-treatment with IVM).*<br><br>   21. The presence of one or more Mf in the posterior segment of the eye (detected by<br>     any opthalmological test performed) at the time of treatment (at least six<br>     months after pre-treatment with IVM). *Note regarding exclusion criteria t and<br>     u: The cut-off of 5 Mf in either anterior chamber was suggested by external<br>     reviewers of our proposal to the Gates Foundation. These were experts in<br>     onchocerciasis selected by the Foundation. The reviews were anonymous, so we do<br>     not know their names. They also suggested that we exclude persons with any Mf<br>     in the posterior segment of the eye, and we have added that exclusion criterion<br>     to the protocol.<br><br> - Significant comorbidities such as renal insufficiency (creatinine > 2 times the<br>   upper limit of normal), liver disease (jaundice or either AST or ALT greater than<br>   2.5 times the upper limit of normal), or any other acute or chronic illness<br>   identified by study clinicians and investigators that interferes with the<br>   participant's ability to go to school or work or perform routine household chores.<br><br> - Prior allergic or hypersensitivity reactions or intolerance to IVM, Mox, ALB, or<br>   DEC.<br><br> - Evidence of severe or systemic comorbidities (aside from features of<br>   onchocerciasis), as judged by a study physician. Persons with baseline medical<br>   conditions that correspond to adverse event severity scores of grade 3 or higher<br>   will also be excluded.<br><br> - Evidence of urinary tract infection as indicated by 3+ nitrites by dipstick<br>   (individuals with 1+ or 2+ nitrites will not be excluded) or underlying chronic<br>   kidney disease as indicated by 3+ protein or 3+ blood by dipstick. Persons with<br>   urinary tract infections can be enrolled after their infections are treated and<br>   cured.<br><br> - Hgb <7 gm/dL; any such individuals will be referred to a local health center for<br>   evaluation and treatment).",,"Onchocercal Subcutaneous Nodule;Onchocerciasis;Onchocerciasis, Ocular;Onchocerca Infection;Tropical Disease",Drug: Ivermectin w/ Albendazole;Drug: Ivermectin + Diethylcarbamazine + Albendazole;Drug: Moxidectin + Albendazole;Drug: Moxidectin + Diethylcarbamazine + Albendazole,Rates and types of severe or serious adverse events within 6 months following Ivermectin treatments;Rates and types of severe or serious adverse events within 6 months following Moxidectin treatments;Proportion of all adult female worms that are fertile 24 months after first treatment,"Rates of adverse events grade 3 or higher by Ivermectin treatment group, that occur within 7 days of treatment;Rates of adverse events grade 3 or higher by Moxidectin treatment group, that occur within 7 days of treatment;Rates of adverse events grade 3 or higher in participants with ocular MF in Ivermectin treatment groups.;Rates of adverse events grade 3 or higher in participants with ocular MF in Moxidectin treatment groups.;Rates of ocular adverse events (any grade) by Ivermectin treatment group;Rates of ocular adverse events (any grade) by Moxidectin treatment groups;Percentage of adult female worms in nodules that are alive;Percentage of nodules with microfilaria in tissue;Percentage of nodules that do not contain living adult worms;Percentage of participants without microfiladermia after the first study treatment.;Percentage of participants with recurrence of microfilariae in the skin across treatment groups;Microfilariae density in the skin across treatment groups;Percentage of nodules with fully or partially calcified worms",202307136,Please refer to primary and secondary sponsors,National Public Health Institute of Liberia,,,No,,,,,,,,,,,,Yes,False,          ,2023.0,18.0
NCT04049630,27 September 2021,Clinical Trial Evaluating the Safety and Efficacy of Levamisole in Loa Loa Microfilaremic Patients,"Randomized Clinical Trial, Double-blind, Dose-escalating of Drug Intensities, Evaluating the Safety and Efficacy of Levamisole in Loa Loa Microfilaremic Patients",EOLoa,"Programme National de Lutte contre l'Onchocercose, Republic of the Congo",2019-07-26,20190726.0,10/13/2025 16:01:06,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT04049630,Not recruiting,No,18 Years,65 Years,All,16/01/2021,255,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). ",Phase 2,Congo,"<br>    Inclusion Criteria:<br><br>     - Written consent written, signed (or with thumbprint) and dated<br><br>     - Aged 18 to 65 inclusive<br><br>     - Individual microfilarial density = 1mf/mL<br><br>     - Body weight = 40 kg in women and = 45 kg in men; and less than 85 kg<br><br>     - In good health condition, as determined by the medical questionnaire and the general<br>       clinical examination: absence of acute or chronic infection<br><br>    Exclusion Criteria:<br><br>     - Participation in any study other than purely observational, in the 4 weeks preceding<br>       this study (determined by the theoretical date of administration of LEV or placebo).<br><br>     - Any vaccination in the 4 weeks preceding this study.<br><br>     - Acute infection requiring a treatment in the 10 days preceding this study, determined<br>       by the anamnesis during the medical interview (example: pulmonary infection, ENT,<br>       digestive, cutaneous, with implementation of an antibiotic treatment or not)<br><br>     - Warfarin treatment<br><br>     - Treatment with clozapine, phenythiazines, sulfasalazine, carbamazepine, synthetic<br>       antithyroid, ticlopidine, cimetidine, and gold salts: whether it is a long-term<br>       treatment, or a treatment given in a single dose 10 days before the start of treatment<br>       for the clinical trial (precaution of use compared to the risk of agranulocytosis of<br>       immuno-allergic or toxic origin)<br><br>     - Known immunosuppressive pathology<br><br>     - Past or current history of neurological (including epilepsy) or neuropsychiatric<br>       disease<br><br>     - History of agranulocytosis<br><br>     - Consumption of alcohol, taking cocaine or other drugs of abuse in the 72 hours<br>       preceding the administration of the treatment of the test determined by the anamnesis<br>       during the medical interview<br><br>     - Any condition, in the opinion of the investigator, which exposes the subject to an<br>       undue risk<br><br>     - Known intolerance to levamisole<br><br>     - Subjects who gave blood in the 8 weeks before entry into the study, with a standard<br>       volume (> 500 mL)<br><br>     - During the clinical examination: symptoms, physical signs or biological constants<br>       suggestive of systemic disorders, including renal, hepatic, cardiovascular, pulmonary,<br>       cutaneous, immunodeficiency, psychiatric disorders and other abnormalities likely to<br>       interfere with the interpretation results of the test. The doctor may then give a<br>       favorable or unfavorable opinion for the inclusion of the participant<br><br>     - Taking IVM and / or LEV during the last six months; and / or mebendazole or<br>       albendazole in the last month<br><br>     - Pregnant and lactating women (based on self-declaration)<br>   ",,"Onchocerciasis, Ocular;Loiasis","Drug: LEV 1 mg/kg;Drug: LEV 1,5 mg/kg;Drug: LEV 2,5 mg/kg;Drug: Placebo",Safety and tolerability of levamisole;Incidence of adverse events with levamisole,Efficacy of levamisole;Proportion of individuals without microfilariae of Loa loa,EOLoa/LEV,Please refer to primary and secondary sponsors,,,,No,,,,,,,,,,,,Yes,False,          ,2019.0,18.0
NCT02078024,12 December 2020,"Efficacy of Ivermectin and Albendazole Against Onchocerciasis in the Volta Region, Ghana","Comparison of Ivermectin Alone With Albendazole (ALB) Plus Ivermectin (IVM) in Their Efficacy Against Onchocerciasis in the Volta Region, Ghana.",,University Hospitals Cleveland Medical Center,2014-02-28,20140228.0,10/13/2025 16:01:06,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT02078024,Not recruiting,No,18 Years,60 Years,All,01/06/2014,375,Interventional,Allocation: Randomized. Intervention model: Factorial Assignment. Primary purpose: Diagnostic. Masking: None (Open Label). ,Phase 3,Ghana,"<br>    Inclusion Criteria:<br><br>     1. Men and women 18-60 years residing along the Kpassa in the Nkwanta North District of<br>       the Volta Region in Ghana<br><br>     2. Two or more assessable onchocercal nodules<br><br>     3. Skin microfilaria density =5mf/mg.<br><br>    Exclusion Criteria:<br><br>     1. Prior treatment with the antifilarial and/or anti-nematodal drugs diethylcarbamazine,<br>       suramin, ivermectin, albendazole, levamisole or >1week of treatment with doxycycline,<br>       within 12 months before planned test article administration.<br><br>     2. Pregnant or breastfeeding women.<br><br>     3. Low probability of residency in the area (based on subject's assessment) over the next<br>       36 months.<br><br>     4. Permanent disability, serious medical illnesses such as a stroke, advanced heart<br>       disease, uncontrolled diabetes, emphysema, etc. that prevents or impedes study<br>       participation and/or comprehension<br><br>     5. Weight of <40kg suggesting malnourishment<br><br>     6. Hemoglobin levels <7 gm/dL<br><br>     7. aspartate aminotransferase, alanine aminotransferase, creatinine > 1.5 upper limit of<br>       normal.<br><br>     8. Significant glycosuria or proteinuria (2+ or 3+ protein or glucose).<br><br>     9. Known or suspected allergy to albendazole or ivermectin or other compounds related to<br>       these classes of medication.<br>   ",,Onchocerciasis,Drug: IVM plus ALB;Drug: IVM,parasitologic efficacy,additional measures of parasitologic efficacy;compare the percentage living versus dead female worms;compare the number of nodules with intact microfilaria;assess different treatment regimens on Soil Transmitted Helminth infections;determine if IVM plus ALB enhances immunological reactions;determine if the host immune response facilitates killing or sterilizing adult worms and microfilariae,CWRU-OCR-1;WU-10-205,Please refer to primary and secondary sponsors,,,,No,,,,,,,,,,,,Yes,False,          ,2014.0,18.0
NCT05999825,30 October 2023,Sm-p80 Schistosomiasis Challenge Study,"Safety and Preliminary Efficacy of Sm-p80 + GLA-SE (SchistoShield®) Vaccine Against Controlled Human Schistosome Infection in Healthy, Schistosoma-naïve Adults",,Leiden University Medical Center,2023-08-11,20230811.0,10/13/2025 16:02:07,ClinicalTrials.gov,https://clinicaltrials.gov/ct2/show/NCT05999825,Not recruiting,No,18 Years,45 Years,All,01/09/2024,48,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Triple (Participant, Investigator, Outcomes Assessor). ",Phase 2,,"<br>    Inclusion Criteria:<br><br>     1. Subject is aged = 18 and = 45 years and in good health.<br><br>     2. Subject has adequate understanding of the procedures of the study and agrees to abide<br>       strictly thereby.<br><br>     3. Subject is able to communicate well with the investigator, is available to attend all<br>       study visits.<br><br>     4. Subject will not travel to Schistosoma-endemic countries up until treatment at week<br>       24.<br><br>     5. Subject agrees to refrain from blood and plasma donation to Sanquin or for other<br>       purposes throughout the study period.<br><br>     6. For female subjects: subject agrees to use adequate contraception and not to<br>       breastfeed for the duration of study.<br><br>     7. Subject has signed informed consent.<br><br>    Exclusion Criteria:<br><br>     1. Any history, or evidence at screening, of clinically significant symptoms, physical<br>       signs or abnormal laboratory values suggestive of systemic conditions, such as<br>       cardiovascular, pulmonary, renal, hepatic, neurological, dermatological, endocrine,<br>       malignant, haematological, infectious, immune-deficient, (severe) psychiatric and<br>       other disorders, which could compromise the health of the participant during the study<br>       or interfere with the interpretation of the study results. These include, but are not<br>       limited to, any of the following:<br><br>        - body weight <50 kg or Body Mass Index (BMI) <18.0 or >35.0 kg/m2 at screening;<br><br>        - positive HIV, HBV or HCV screening tests;<br><br>        - the use of immune modifying drugs within three months prior to study onset<br>         (inhaled and topical corticosteroids and oral anti-histamines exempted) or<br>         expected use of such during the study period;<br><br>        - history of malignancy of any organ system (other than localized basal cell<br>         carcinoma of the skin), treated or untreated, within the past 5 years;<br><br>        - any history of treatment for severe psychiatric disease by a psychiatrist in the<br>         past year;<br><br>        - history of drug or alcohol abuse interfering with normal social function in the<br>         period of one year prior to study onset.<br><br>     2. The chronic use of any drug known to interact with praziquantel, artesunate or<br>       lumefantrine metabolism (e.g. phenytoïn, carbamazepine, phenobarbital, primidon,<br>       dexamethason, rifampicine, cimetidine, flecaïnide, metoprolol, imipramine,<br>       amitriptyline, clomipramine, class IA and III anti-arrythmics, antipsychotics,<br>       antidepressants, macrolides, fluorchinolones, imidazole- and triazole antimycotics,<br>       antihistamines). Because lumefantrine may cause extension of QT-time, chronic use of<br>       drugs with effect on QT interval will result in exclusion from study participation.<br><br>     3. Any planned vaccination within 28 days before the start of the trial until the end of<br>       the immunisation phase (week 12), with the exception of SARS-CoV-2 vaccines or<br>       influenza vaccines.<br><br>     4. For female subjects: positive serum pregnancy test on the day before first<br>       immunisation.<br><br>     5. Any history of schistosomiasis or treatment for schistosomiasis.<br><br>     6. Positive serology for schistosomiasis or elevated serum CAA at screening.<br><br>     7. Known hypersensitivity to or contra-indications (including co-medication) for use of<br>       praziquantel, artesunate or lumefantrine.<br><br>     8. Being an employee or student of the department of Parasitology or Infectious diseases<br>       of the LUMC.<br>   ",,Schistosoma Mansoni;Schistosomiasis,Biological: Sm-p80 + GLA-SE Vaccine;Other: Placebo;Biological: Schistosoma mansoni infection,Vaccine efficacy,Safety of (repeated) immunisation;Immunogenicity,Sm-p80,Please refer to primary and secondary sponsors,Texas Tech University Health Sciences Center;MRC/UVRI and LSHTM Uganda Research Unit,,,No,,,,,,,,,,,,Yes,False,          ,2023.0,18.0
NCT05085470,6 February 2023,Repeated Controlled Human Schistosoma Mansoni Infection,Safety and Protective Efficacy of Repeated Controlled Human Schistosoma Mansoni Infection,,Leiden University Medical Center,2021-08-06,20210806.0,10/13/2025 16:02:07,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT05085470,Not recruiting,No,18 Years,45 Years,All,29/10/2021,24,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Other. Masking: Triple (Participant, Care Provider, Investigator). ",,Netherlands,"<br>    Inclusion Criteria:<br><br>     1. Subject is aged = 18 and = 45 years and in good health.<br><br>     2. Subject has adequate understanding of the procedures of the study and agrees to abide<br>       strictly thereby.<br><br>     3. Subject is able to communicate well with the investigator, is available to attend all<br>       study visits.<br><br>     4. Subject will remain within Europe (excluding Corsica) during the study period.<br><br>     5. Subject agrees to refrain from blood and plasma donation to Sanquin or for other<br>       purposes throughout the study period.<br><br>     6. For female subjects: subject agrees to use adequate contraception and not to<br>       breastfeed for the duration of study.<br><br>     7. Subject has signed informed consent.<br><br>    Exclusion Criteria:<br><br>     1. Any history, or evidence at screening, of clinically significant symptoms, physical<br>       signs or abnormal laboratory values suggestive of systemic conditions, such as<br>       cardiovascular, pulmonary, renal, hepatic, neurological, dermatological, endocrine,<br>       malignant, haematological, infectious, immune-deficient, (severe) psychiatric and<br>       other disorders, which could compromise the health of the volunteer during the study<br>       or interfere with the interpretation of the study results. These include, but are not<br>       limited to, any of the following:<br><br>        - body weight <50 kg or Body Mass Index (BMI) <18.0 or >35.0 kg/m2 at screening;<br><br>        - positive HIV, hepatitis B virus or hepatitis C virus screening tests;<br><br>        - the use of immune modifying drugs within three months prior to study onset<br>         (inhaled and topical corticosteroids and oral anti-histamines exempted) or<br>         expected use of such during the study period;<br><br>        - history of malignancy of any organ system (other than localized basal cell<br>         carcinoma of the skin), treated or untreated, within the past 5 years;<br><br>        - any history of treatment for severe psychiatric disease by a psychiatrist in the<br>         past year;<br><br>        - history of drug or alcohol abuse interfering with normal social function in the<br>         period of one year prior to study onset.<br><br>     2. The chronic use of any drug known to interact with praziquantel, artesunate or<br>       lumefantrine metabolism (e.g. phenytoin, carbamazepine, phenobarbital, primidone,<br>       dexamethasone, rifampicin, cimetidine, flecainide, metoprolol, imipramine,<br>       amitriptyline, clomipramine, class IA and III anti-arrythmics, antipsychotics,<br>       antidepressants, macrolides, fluoroquinolones, imidazole- and triazole antimycotics,<br>       antihistamines). Because lumefantrine may cause extension of QT-time, chronic use of<br>       drugs with effect on QT interval will result in exclusion from study participation.<br><br>     3. For female subjects: positive urine pregnancy test at screening.<br><br>     4. Any history of schistosomiasis or treatment for schistosomiasis.<br><br>     5. Positive serology for schistosomiasis or elevated serum CAA at screening.<br><br>     6. Known hypersensitivity to or contra-indications (including co-medication) for use of<br>       praziquantel, artesunate or lumefantrine.<br><br>     7. Being an employee or student of the department of Parasitology or Infectious diseases<br>       of the LUMC.<br>   ",,Schistosomiasis;Schistosoma Mansoni,Biological: Schistosoma mansoni infection;Biological: Placebo mock infection,Protective efficacy;Safety of (repeated) exposure to male Sm cercariae based on self-reported adverse events,Time to CAA positivity;Peak serum CAA levels;Eosinophils;Antibody responses;Cellular responses;Attack rate,ReCoHSI,Please refer to primary and secondary sponsors,,,,No,,,,,,,,,,,,Yes,False,          ,2021.0,18.0
NCT04269915,29 April 2024,Single-sex Female Controlled Human Schistosomiasis Mansoni Infection,Establishing a Female-only Controlled Human Schistosoma Mansoni Infection Model: a Safety and Dose Finding Study (CoHSI2),,Leiden University Medical Center,2020-02-10,20200210.0,10/13/2025 16:02:07,ClinicalTrials.gov,https://clinicaltrials.gov/ct2/show/NCT04269915,Not recruiting,Yes,18 Years,45 Years,All,12/08/2020,13,Interventional,Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Other. Masking: None (Open Label). ,,Netherlands,"<br>    Inclusion Criteria:<br><br>     - Subject is aged = 18 and = 45 years and in good health.<br><br>     - Subject has adequate understanding of the procedures of the study and agrees to abide<br>       strictly thereby.<br><br>     - Subject is able to communicate well with the investigator, is available to attend all<br>       study visits.<br><br>     - Subject will remain within Europe (excluding Corsica) during the study period and is<br>       reachable by mobile telephone from week 3 to week 8 of the study period.<br><br>     - Subject agrees to refrain from blood donation to """"Sanquin"""" (blood bank) or for other<br>       purposes throughout the study period.<br><br>     - For female subjects: subject agrees to use adequate contraception and not to<br>       breastfeed for the duration of study.<br><br>     - Subject has signed informed consent.<br><br>    Exclusion Criteria:<br><br>     - Any history, or evidence at screening, of clinically significant symptoms, physical<br>       signs or abnormal laboratory values suggestive of systemic conditions, such as<br>       cardiovascular, pulmonary, renal, hepatic, neurological, dermatological, endocrine,<br>       malignant, haematological, infectious, immune-deficient, psychiatric and other<br>       disorders, which could compromise the health of the volunteer during the study or<br>       interfere with the interpretation of the study results. These include, but are not<br>       limited to, any of the following:<br><br>        - body weight <50 kg or Body Mass Index (BMI) <18.0 or >30.0 kg/m2 at screening;<br><br>        - positive human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis<br>         C virus (HCV) screening tests;<br><br>        - the use of immune modifying drugs within three months prior to study onset<br>         (inhaled and topical corticosteroids and oral anti-histamines exempted) or<br>         expected use of such during the study period;<br><br>        - history of malignancy of any organ system (other than localized basal cell<br>         carcinoma of the skin), treated or untreated, within the past 5 years;<br><br>        - any history of treatment for severe psychiatric disease by a psychiatrist in the<br>         past year;<br><br>        - history of drug or alcohol abuse interfering with normal social function in the<br>         period of one year prior to study onset.<br><br>        - The chronic use of any drug known to interact with praziquantel, artesunate or<br>         lumefantrine metabolism (e.g. phenytoin, carbamazepine, phenobarbital, primidon,<br>         dexamethasone, rifampicin, cimetidine, flecainide, metoprolol, imipramine,<br>         amitriptyline, clomipramine, class I-A and III anti-arrythmics, antipsychotics,<br>         antidepressants, macrolides, fluoroquinolones, imidazole- and triazole<br>         antimycotics, antihistamines) Because lumefantrine may cause extension of<br>         QT-time, chronic use of drugs with effect on QT interval are excluded from the<br>         study.<br><br>     - For female subjects: positive urine pregnancy test at screening.<br><br>     - Any history of schistosomiasis or treatment for schistosomiasis.<br><br>     - Positive serology for schistosomiasis or elevated serum CAA at screening.<br><br>     - Known hypersensitivity to or contra-indications (including co-medication) for use of<br>       praziquantel, artesunate or lumefantrine.<br><br>     - Being an employee or student of the department of parasitology or infectious diseases<br>       of the Leiden University Medical Center.<br>   ",,Schistosomiasis;Schistosomiasis Mansoni,Biological: female Schistosoma mansoni cercariae,"Number and severity of adverse events, possibly, probably or definitely related to controlled human Schistosoma mansoni infection with female cercariae.;Number of female cercariae at which 100% volunteers show detectable Schistosoma mansoni circulating anodic antigen.",Average number of weeks until positive serum circulating anodic antigen (CAA) test;Comparison of peak serum circulating anodic antigen (CAA) concentration in different dose groups;Humoral (antibody) response profile by protein and glycan array between infected and uninfected individuals;Ex vivo lymphocyte profiles using flow cytometry between infected and uninfected individuals;Changes over time in commensal gut bacteria by looking at the relative abundance of microbiota using 16S rRNA gene amplicon sequencing after controlled human Schistosoma mansoni infection with female cercariae,CoHSI2,Please refer to primary and secondary sponsors,,,,No,,,,,,,,,,,,Yes,True ,parent    ,2020.0,18.0
NCT04264130,12 December 2020,Effect of Artemisinin-based Combination Therapies on Schistosomiasis on Malaria Co-infection,Evaluation of the Effect of Artemisinin-based Combination Therapies on Urinary Schistosoma Haematobium When Administered for the Treatment of Malaria Co-infection,SACT,Centre de Recherche Médicale de Lambaréné,2020-02-06,20200206.0,10/13/2025 16:02:07,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT04264130,Not recruiting,No,,,All,31/07/2018,54,Interventional,Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ,Phase 2,Gabon,<br>    Inclusion Criteria:<br><br>     - Malaria infection diagnosed by Rapid Diagnostic Tests (RDTs) or thick blood smear<br><br>     - Urinary schistosomiasis diagnosed by presence of Schistosoma haematobium eggs in the<br>       urine before malaria treatment<br><br>     - Written informed consent<br><br>    Exclusion Criteria:<br><br>     - Patients treated with PZQ during the previous 6 weeks<br><br>     - Known intolerance /allergy to any study drug<br><br>     - Pregnancy<br>   ,,Schistosomiasis Haematobia,Drug: Artesunate-Pyronaridine;Drug: Artemether-Lumefantrine;Drug: Artefenomel-Ferroquine,Egg Reduction Rate (ERR);Egg Reduction Rate (ERR),Cure Rate (CR);Cure Rate (CR),CEI-006/2018,Please refer to primary and secondary sponsors,,,,No,,,,,,,,,,No,,No,False,          ,2020.0,18.0
NCT03458338,12 December 2020,Prevalence of Chronic Kidney Disease (CKD) and Risk Factors in Sub-Saharan Africa,CKD Prevalence and the Role of Cardiovascular Risk Factors and Infectious Diseases in a Region of Sub-Saharan Africa,RenalOne,"University Hospital, Basel, Switzerland",2018-03-01,20180301.0,10/13/2025 16:02:07,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT03458338,Not recruiting,No,18 Years,100 Years,All,08/12/2010,1006,Observational,,,Switzerland,<br>    Inclusion Criteria:<br><br>     - =18 years<br><br>    Exclusion Criteria:<br><br>     - pregnant<br><br>     - not able or willing to provide an informed signed consent<br>   ,,Chronic Kidney Diseases;Diabetes Mellitus;Hypertension;Tuberculosis;Schistosomiasis;HIV Infections,Diagnostic Test: estimated glomerular filtration rate and albuminuria,Point prevalence of chronic kidney disease measured by lab values,Risk factors for chronic kidney disease measured by lab values and questionnaire,RenalOne,Please refer to primary and secondary sponsors,Swiss Tropical & Public Health Institute;Ifakara Health Institute,,,No,,,,,,,,,,No,,No,False,          ,2018.0,18.0
NCT03158298,25 April 2022,Seropositivity and Adverse Birth Events in Migrants From Bilharzia-endemic Areas,Association of Schistosomiasis Seropositivity With Adverse Birth Events in Migrants From Bilharzia-endemic Areas,Bilharzia,Jena University Hospital,2017-05-16,20170516.0,10/13/2025 16:02:07,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT03158298,Not recruiting,No,18 Years,,Female,01/06/2017,82,Observational,,,Germany,<br>    Inclusion Criteria:<br><br>     - Pregnancy<br><br>     - Immigration from a country/geographic area with declared endemic schistosomiasis<br>       according to World Health Organization criteria<br><br>     - Signed informed consent<br><br>    Exclusion Criteria:<br><br>     - Placenta pathology of any cause<br><br>     - Any medical condition affecting fetal growth<br>   ,,Schistosomiasis,Other: Specimen collection,Schistosoma Serology,Birth Weight;Preterm Birth;Intrauterine Growth Restriction;Stillbirth,ZKS0094,Please refer to primary and secondary sponsors,"Technische Universität München;Charite University, Berlin, Germany;University Hospital in Halle",,,Yes,14/04/2022,https://clinicaltrials.gov/ct2/show/results/NCT03158298,,,,,,,,,,Yes,False,          ,2017.0,18.0
NCT03110757,8 February 2021,"A Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel)(R) With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Exposed Adults","A Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel(R) With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Exposed Adults",,National Institute of Allergy and Infectious Diseases (NIAID),2017-03-21,20170321.0,10/13/2025 16:02:07,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT03110757,Not recruiting,No,18 Years,50 Years,All,20/05/2018,60,Interventional,"Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Prevention. Masking: Double (Participant, Investigator). ",Phase 1,Brazil,"<br>    Inclusion Criteria:<br><br>     1. Provide written informed consent prior to any study procedures.<br><br>     2. Able to understand and comply with planned study procedures and be available for all<br>       study visits.<br><br>     3. Male or non-pregnant female aged 18 to 50, inclusive at the time of enrollment.<br><br>     4. Are in good health, as determined by vital signs (oral temperature, pulse, and blood<br>       pressure), medical history, and brief physical examination at screening.<br><br>       -Existing medical diagnoses or conditions (except those in the Subject Exclusion<br>       Criteria) must be deemed as stable chronic medical conditions. A stable chronic<br>       medical condition is defined as no change in prescription medication, dose, or<br>       frequency of medication in the last 3 months (90 days) and health outcomes of the<br>       specific disease are considered to be within acceptable limits in the last 6 months<br>       (180 days). Any change due to change of health care provider, or that is done for<br>       financial reasons, as long as in the same class of medication, will not be considered<br>       a violation of this inclusion criterion. Any change in prescription medication due to<br>       improvement of a disease outcome, as determined by the site principal investigator or<br>       appropriate sub-investigator, will not be considered a violation of this inclusion<br>       criterion. Subjects may be on chronic or as needed medications if, in the opinion of<br>       the site principal investigator or appropriate sub-investigator, they pose no<br>       additional risk to subject safety or assessment of reactogenicity and immunogenicity.<br>       Topical, nasal, and inhaled medications (with the exception of corticosteroids as<br>       outlined in the Subjects Exclusion Criteria), vitamins, and contraceptives are<br>       permitted.<br><br>     5. Vital signs (oral temperature, pulse, and blood pressure) are all within normal<br>       protocol-defined ranges.<br><br>       -The normal protocol-defined ranges for vital signs include (a) oral temperature less<br>       than 38.0 degrees celsius, (b) pulse 50 to 100 bpm, inclusive, (c) systolic blood<br>       pressure 85 to 150 mmHg, inclusive, and (d) diastolic blood pressure 55 to 90 mmHg,<br>       inclusive. Pulse rate <50 is acceptable for 2nd and 3rd vaccinations if the subject is<br>       otherwise healthy with documented sinus bradycardia at baseline.<br><br>     6. Laboratory tests (alanine aminotransferase, creatinine, white blood cell count,<br>       hemoglobin, and platelets) are all within protocol-defined reference ranges.<br><br>       -The protocol-defined ranges for laboratory tests include (a) alanine aminotransferase<br>       (ALT) of less than 1.25-times the upper reference limit, (b) creatinine less than 1.25<br>       times the upper reference limit (c) white blood cells (WBC) between 3.3 x10^3/uL and<br>       10.4 x10^3/uL, inclusive, (d) hemoglobin 11.4 g/dL or greater for females or 12.1 g/dL<br>       or greater for males, (e) platelets greater than 130 x10^3/uL. Laboratory test results<br>       for 2nd and 3rd vaccinations may be at Grade 1 if considered unrelated to study<br>       product.<br><br>     7. Urinalysis with no greater than trace protein and negative for glucose.<br><br>     8. Female subjects of childbearing potential must agree to practice highly effective<br>       contraception for a minimum of 30 days prior to study product exposure and for 30 days<br>       after last vaccination.<br><br>        - Female subjects who are surgically sterile via tubal sterilization, bilateral<br>         oophorectomy or hysterectomy or who have been postmenopausal for greater than 1<br>         year are not considered to be of childbearing potential.<br><br>        - Highly effective methods of contraception are defined as having low failure rates<br>         (i.e. less than 1% per year) when used consistently and correctly and may<br>         include, but are not limited to, abstinence from intercourse with a male partner,<br>         monogamous relationship with a vasectomized partner, male condoms or diaphragm<br>         with spermicide, intrauterine devices, and licensed hormonal methods.<br><br>     9. Female subjects of childbearing potential must have a negative urine or serum<br>       pregnancy test within 24 hours prior to study vaccination.<br><br>     10. Able to correctly answer all questions on the informed consent comprehension<br>       questionnaire.<br><br>    Exclusion Criteria:<br><br>     1. Has the intention to become pregnant within 5 months after enrollment in this study.<br><br>     2. Female subjects who are breastfeeding or plan to breastfeed at any given time from the<br>       first study vaccination until 30 days after their last study vaccination.<br><br>     3. Has an acute illness, including a documented oral temperature of 38.0 degrees celsius<br>       or greater, within 72 hours prior to vaccination.<br><br>     4. Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic,<br>       rheumatologic, autoimmune, diabetes, or renal disease by history, physical<br>       examination, and/or laboratory studies.<br><br>     5. Is immunosuppressed as a result of an underlying illness or treatment.<br><br>       -Causes for immunosuppression may include, but are not limited to, poorly-controlled<br>       diabetes mellitus, cirrhosis, renal insufficiency, active neoplastic disease or a<br>       history of any hematologic malignancy, connective tissue disease, organ transplant.<br><br>     6. Using or intends to continue using oral or parenteral steroids, high-dose inhaled<br>       steroids (>800 µg/day of beclomethasone dipropionate or equivalent) or other<br>       immunosuppressive or cytotoxic drugs.<br><br>     7. Positive hepatitis B surface antigen (HBsAg)<br><br>     8. Positive confirmatory test for HIV infection<br><br>     9. Positive confirmatory test for hepatitis C virus (HCV) infection<br><br>     10. Volunteer has had a history of alcohol or illicit drug abuse during the past 24<br>       months.<br><br>     11. Received immunoglobulin or other blood products (with exception of Rho D<br>       immunoglobulin) within 90 days prior to study vaccination.<br><br>     12. History of a severe allergic reaction or anaphylaxis to known components of the study<br>       vaccines.<br><br>     13. Has an acute or chronic medical condition that, in the opinion of the investigator,<br>       would render participation in this study unsafe or would interfere with the evaluation<br>       of responses.<br><br>       -This includes, but is not limited to: known liver disease, renal disease,<br>       neurological disorders, visual field defects, cardiac disorders, pulmonary disorders,<br>       diabetes mellitus, and transplant recipients.<br><br>     14. History of splenectomy<br><br>     15. Is participating or plans to participate in another clinical trial with an<br>       interventional agent during the duration of the study.<br><br>       -This may include other licensed or unlicensed vaccines, drugs, biologics, devices,<br>       blood products, or medications.<br><br>     16. Received any licensed live vacc",,Schistosomiasis,Biological: GLA-AF;Biological: Hepatitis B Virus Vaccine (Recombinant);Biological: Sm-TSP-2/Alhydrogel,The occurrence of new-onset chronic medical conditions (including AESI);The occurrence of solicited injection site reactogenicity;The occurrence of solicited injection site reactogenicity;The occurrence of solicited injection site reactogenicity;The occurrence of solicited systemic reactogenicity;The occurrence of solicited systemic reactogenicity;The occurrence of solicited systemic reactogenicity;The occurrence of study vaccine-related SAEs;The occurrence of vaccine-related clinical safety laboratory adverse events;The occurrence of vaccine-related clinical safety laboratory adverse events;The occurrence of vaccine-related clinical safety laboratory adverse events;The occurrence of vaccine-related clinical safety laboratory adverse events;The occurrence of vaccine-related clinical safety laboratory adverse events,The anti-Sm-TSP-2 IgG antibody response using an indirect ELISA;The anti-Sm-TSP-2 IgG antibody response using an indirect ELISA;The anti-Sm-TSP-2 IgG antibody response using an indirect ELISA;The anti-Sm-TSP-2 IgG antibody response using an indirect ELISA;The anti-Sm-TSP-2 IgG antibody response using an indirect ELISA;The anti-Sm-TSP-2 IgG level using an indirect ELISA,HHSN272201300015I;14-0100,Please refer to primary and secondary sponsors,,,,No,,,,,,,,,,,,Yes,False,          ,2017.0,18.0
NCT02878564,7 November 2016,Effect of Schistosomiasis Mansoni on HIV Susceptibility and Female Genital Immunology,Effect of Schistosomiasis Mansoni and Its Treatment on HIV Susceptibility and Female Genital Immunology,,University of Toronto,2016-08-15,20160815.0,10/13/2025 16:02:07,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT02878564,Not recruiting,No,18 Years,45 Years,Female,01/03/2016,34,Interventional,"Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science",Phase 4,Uganda,"<br>    Inclusion Criteria:<br><br>     - Positive (score above """"trace"""") on a urine CCA rapid test<br><br>     - Willing to be treated with praziquantel<br><br>     - Willing to give informed consent, and answer short questionnaires on economic status,<br>       and sexual risk behavior.<br><br>     - Willing to comply with the requirements of the protocol<br><br>     - HIV and classical STI (see below) negative<br><br>    Exclusion Criteria:<br><br>     - HIV infected<br><br>     - Malaria infected<br><br>     - Pregnant.<br><br>     - Irregular menstrual cycle, or actively menstruating at the time of genital sampling.<br><br>     - Tested positive for classical STIs (syphilis, gonorrhea, chlamydia, Trichomonas<br>       vaginalis) or having genital ulcers<br><br>     - Prior hysterectomy<br><br>     - Deemed by physician to be unlikely to complete study protocol.<br>   ",,Schistosomiasis Mansoni;HIV,Drug: Praziquantel,Change in the percentage of endocervical CD4+ T cells susceptible to HIV pseudovirus entry after treatment of schistosomiasis.;Change in the number of endocervical CD4+ T cells susceptible to HIV pseudovirus entry after treatment of schistosomiasis.,Change in the percentage of blood CD4+ T cells susceptible to HIV pseudovirus entry after treatment of schistosomiasis.;Change in the phenotype of endocervical and blood CD4+ T cells after treatment of schistosomiasis.;Change in genital proinflammatory cytokine levels after treatment of schistosomiasis.;Change in the cervico-vaginal microbiome after treatment of schistosomiasis.;Change in the cervico-vaginal proteome after treatment of schistosomiasis.;Change in the percentage of endocervical CD4+ T cells susceptible to HIV pseudovirus entry after treatment of schistosomiasis.;Change in the number of endocervical CD4+ T cells susceptible to HIV pseudovirus entry after treatment of schistosomiasis.,UT-Schisto,Please refer to primary and secondary sponsors,"UVRI-IAVI HIV Vaccine Program, Uganda",,,No,,,,,,,,,,,,No,False,          ,2016.0,18.0
NCT02755324,12 December 2020,Single-sex Controlled Human Schistosomiasis Infection: Safety and Dose Finding,Establishing a Single-sex Controlled Human Schistosomiasis Infection Model: Safety and Dose Finding,,Leiden University,2016-04-25,20160425.0,10/13/2025 16:02:07,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT02755324,Not recruiting,No,18 Years,45 Years,All,27/10/2016,17,Interventional,Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Other. Masking: None (Open Label). ,,Netherlands,"<br>    Inclusion Criteria:<br><br>     1. Subject is aged = 18 and = 45 years and in good health.<br><br>     2. Subject has adequate understanding of the procedures of the study and agrees to abide<br>       strictly thereby.<br><br>     3. Subject is able to communicate well with the investigator, is available to attend all<br>       study visits.<br><br>     4. Subject will remain within Europe (excluding Corsica) during the study period and is<br>       reachable by mobile telephone from week 3 to week 12 of the study period.<br><br>     5. Subject agrees to refrain from blood donation throughout the study period.<br><br>     6. For female subjects: subject agrees to use adequate contraception and not to<br>       breastfeed for the duration of study.<br><br>     7. Subject has signed informed consent.<br><br>    Exclusion Criteria:<br><br>     1. Any history, or evidence at screening, of clinically significant symptoms, physical<br>       signs or abnormal laboratory values suggestive of systemic conditions, such as<br>       cardiovascular, pulmonary, renal, hepatic, neurological, dermatological, endocrine,<br>       malignant, haematological, infectious, immune-deficient, psychiatric and other<br>       disorders, which could compromise the health of the volunteer during the study or<br>       interfere with the interpretation of the study results. These include, but are not<br>       limited to, any of the following:<br><br>        - body weight <50 kg or Body Mass Index (BMI) <18.0 or >30.0 kg/m2 at screening;<br><br>        - positive HIV, hepatitis B or hepatitis C screening tests;<br><br>        - the use of immune modifying drugs within three months prior to study onset<br>         (inhaled and topical corticosteroids and oral anti-histamines exempted) or<br>         expected use of such during the study period;<br><br>        - history of malignancy of any organ system (other than localized basal cell<br>         carcinoma of the skin), treated or untreated, within the past 5 years;<br><br>        - any history of treatment for severe psychiatric disease by a psychiatrist in the<br>         past year;<br><br>        - history of drug or alcohol abuse interfering with normal social function in the<br>         period of one year prior to study onset.<br><br>        - Any clinically significant abnormalities (including extended QT interval) on<br>         electrocardiogram<br><br>     2. The chronic use of any drug known to interact with praziquantel, or artesunate or<br>       lumefantrine metabolism (e.g. phenytoin, carbamazepine, phenobarbital, primidon,<br>       dexamethasone, rifampicin, cimetidine, flecainide, metoprolol, imipramine,<br>       amitriptyline, clomipramine, class I and III anti-arrythmics, antipsychotics,<br>       antidepressants, macrolides, fluoroquinolones, imidazole- and triazole antimycotics,<br>       antihistamines) Because lumefantrine may cause extension of QT-time, chronic use of<br>       drugs with effect on QT interval are excluded from the study.<br><br>     3. For female subjects: positive urine pregnancy test at screening.<br><br>     4. Any history of schistosomiasis or treatment for schistosomiasis.<br><br>     5. Positive serology for schistosomiasis or elevated serum or urine circulating anodic<br>       antigen or positive Schistosoma serology at baseline.<br><br>     6. Known hypersensitivity to or contra-indications (including co-medication) for use of<br>       praziquantel or, artesunate or lumefantrine.<br><br>     7. Being an employee or student of the department of parasitology or infectious diseases<br>       of the Leiden University Medical Center.<br>   ",,Schistosomiasis;Schistosoma Mansoni,Biological: male Schistosoma mansoni cercariae,"Number of grade 3 and 4 adverse events, possibly, probably or definitely related to controlled human Schistosoma mansoni infection with male cercariae.;The number of male cercariae at which 100% volunteers show detectable Schistosoma mansoni circulating anodic antigen (CAA).",Average number of weeks until positive serum circulating anodic antigen test;Comparison of the height of the peak serum circulating anodic antigen concentration in low dose compared with high dose group;Comparison of the humoral (antibody) response profile by protein and glycan array between infected and uninfected individuals;Differences in in ex vivo lymphocyte profiles between infected and uninfected individuals,CoHSI1,Please refer to primary and secondary sponsors,,,,No,,,,,,,,,,Undecided,,Yes,False,parent    ,2016.0,18.0
ISRCTN48837681,24 October 2022,Study and implementation of urogenital schistosomiasis elimination in Zanzibar (Unguja and Pemba islands),Study and implementation of urogenital schistosomiasis elimination in Zanzibar (Unguja and Pemba islands) using an integrated multidisciplinary approach                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            ,,Natural History Museum (UK),2012-09-05,20120905.0,10/13/2025 16:02:07,ISRCTN,https://www.isrctn.com/ISRCTN48837681,Not Recruiting,No,,,Both,01/11/2011,72000,Interventional,Randomised intervention trial with three study arms (Treatment),Not Applicable,Switzerland;Tanzania;United Kingdom;England,"Inclusion criteria: <br>        1. Schoolchildren, either male or female, aged 9-12 years, attending the selected schools (in each study year)<br>        2. First-year students, either male or female, attending the selected schools (in years 1 and 5)<br>        3. Adults aged 20-55 years from the selected communities (shehias), only one adult per household, pregnant women are eligible (in years 1 and 5)<br>        4. Submitted written informed consent sheet signed by parent or legal guardian in case of participating children or signed by the participant in case of participating adults<br>        5. Oral assent from participant given<br>        6. One urine sample provided (from 9-12-year old children in each study year; from first-year students and adults in years 1 and 5)<br>        7. One blood sample obtained (from first-year students in years 1 and 5)<br>      ","Exclusion criteria: <br>        1. Children not attending the selected schools<br>        2. Children not aged 9-12 years (in years 2, 3, and 4)<br>        3. Children not aged 9-12 years or being first-year students (in years 1 and 5)<br>        4. Adults not resident in the selected shehias<br>        5. Adults aged <20 or >55 years (in years 1 and 5)<br>        6. Written informed consent not submitted or not signed by parent or legal guardian in case of participating children or not signed by the participant in case of participating adults<br>        7. No oral assent given<br>        8. No urine sample provided (for 9-12-year old children in each study year; for first-year students and adults in years 1 and 5)<br>        9. No blood sample obtained (from first-year students in years 1 and 5)<br>      ",Schistosoma haematobium infections <br>Infections and Infestations <br>Schistosomiasis due to Schistosoma haematobium [urinary schistosomiasis],"<br>        The study will be implemented in 45 shehias in both Unguja and Pemba. Among the 45 shehias on each island 15 were randomly assigned to one of the following three intervention arms:<br>        1. Treatment per the National Plan of the Zanzibar Ministry of Health (twice yearly preventive chemotherapy with praziquantel, including social mobilization and education)<br>        2. Treatment per the National Plan plus snail control<br>        3. Treatment per the National Plan plus intensive behaviour change interventions<br>",<br>        Current primary outcome measure as of 25/03/2019:<br>        S. haematobium infection prevalence and intensity based on urine filtration results in 9- to 12-year-old children after five years of follow-up (i.e. at the 5-year endline survey in 2017)<br><br>        Previous primary outcome measure:<br>        Elimination of urogenital schistosomiasis in Unguja and reduction of the S. haematobium prevalence <10% in Pemba after 5 years of interventions<br>      ,"<br>        1. Prevalence and intensity of S. haematobium infections in 9-12-year-old schoolchildren and antibody levels against S. haematobium in first-year students, hence judging current infection status and history of exposure, and prevalence and intensity of S. haematobium infections in adults and first-year students<br>        2. Impact of niclosamide on snail populations, schistosome transmission and reinfection of the Zanzibari population<br>        3. Changes in the behaviour of the human population associated with parasite transmission<br>        4. Sensitivity and specificity of novel diagnostic methods<br>      ",Nil known;Nil known;N/A,"University of Georgia Research Foundation Inc. (USA), World Health Organization (Switzerland), The Schistosomiasis Control Initiative (UK), Bayer S.A.S. (France)",,,01/01/1900,Yes,,,,31/12/2017,,        2012 Protocol article in https://www.ncbi.nlm.nih.gov/pubmed/23110494 protocol        2013 Results article in https://www.ncbi.nlm.nih.gov/pubmed/24147165 results        2015 Results article in https://www.ncbi.nlm.nih.gov/pubmed/25973845 results        2015 Results article in https://www.ncbi.nlm.nih.gov/pubmed/26329827 results        2016 Results article in https://www.ncbi.nlm.nih.gov/pubmed/26727915 results        2016 Results article in https://www.ncbi.nlm.nih.gov/pubmed/27399310 results        2016 Results article in https://www.ncbi.nlm.nih.gov/pubmed/27428066 results        2016 Results article in https://www.ncbi.nlm.nih.gov/pubmed/27498244 results        2016 Results article in https://www.ncbi.nlm.nih.gov/pubmed/27986092 results        2018 Results article in https://www.ncbi.nlm.nih.gov/pubmed/30352631 results        2019 Results article in https://www.ncbi.nlm.nih.gov/pubmed/31255591 results (added 02/07/2019)        2019 Results article in https://www.ncbi.nlm.nih.gov/pubmed/31059495 results (added 03/01/2020)        2020 Results article in https://pubmed.ncbi.nlm.nih.gov/32887642/ qPCR results (added 07/09/2020)        Results article in https://pubmed.ncbi.nlm.nih.gov/36215334/ Population genetic analysis of Schistosoma haematobium (added 11/10/2022)      ,,,,Available on request,    The trialists intend to publish our study results in the peer-reviewed (whenever possible open-access) literature before the end of 2018.    Updated 26/03/2019: The investigators intend to publish the study results in the peer-reviewed open access literature before the end of 2019.,No,False,          ,2012.0,11.4
NCT01288872,12 December 2020,Praziquantel-Pharmacokinetic Study,Praziquantel Pharmacokinetics in Pregnancy and During Lactation,,National Institute of Allergy and Infectious Diseases (NIAID),2011-01-28,20110128.0,10/13/2025 16:02:07,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT01288872,Not recruiting,No,18 Years,99 Years,Female,01/01/2012,47,Interventional,Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ,Phase 1,Philippines,"<br>    Inclusion Criteria:<br><br>    Screening:<br><br>     - Woman must be age 18 or over.<br><br>     - Present to a study midwife or health center.<br><br>     - Live in a study village.<br><br>    Inclusion criteria for the study are as follows:<br><br>     - Infected with Schistosomiasis (S.) japonicum.<br><br>     - Age 18 or older.<br><br>     - Participant is otherwise healthy as determined by history, physical exam, ultrasound<br>       (if pregnant) and laboratory assessment, with the exception of laboratory values cited<br>       in Exclusion Criteria.<br><br>     - Early pregnancy cohort: pregnant, between 12-16 weeks gestation.<br><br>     - Late pregnancy cohort: pregnant, between 30-36 weeks gestation<br><br>     - Lactating nonpregnant: 5-7 months postpartum inclusive (up to 7 months and 31 days)<br>       with negative pregnancy test.<br><br>     - Ability to provide informed consent to participate.<br><br>    Exclusion Criteria:<br><br>     - Presence of significant disease/illness that is either acute or chronic. This will be<br>       defined by history, physical examination, ultrasound (if pregnant) and laboratory<br>       assessment. In particular:<br><br>        1. History of seizures or other neurologic disorder, chronic medical problem<br>         determined by history or physical examination, e.g., active hepatitis, renal<br>         disease, tuberculosis, heart disease.<br><br>        2. Grade 3 or higher laboratory abnormality of blood urea nitrogen (BUN),<br>         creatinine, bilirubin, white blood cell count, or platelet count will warrant<br>         exclusion. Grade 2 or higher abnormality of alanine aminotransferase (ALT) or<br>         aspartate aminotransferase (AST) will warrant exclusion. For hemoglobin, women<br>         with severe anemia defined as hemoglobin less than 7.0 g/dL will be excluded.<br><br>        3. If pregnant, with myoma on ultrasound that are sub-mucosal OR women with myoma<br>         that are in any location and greater than 5 cm in size.<br><br>        4. If pregnant, with congenital anomalies of the reproductive tract that would be<br>         expected to cause decreased fetal weight or greatly increase the risk of<br>         pre-maturity such as duplicate uterus, uterine septum.<br><br>        5. For less clear cases, we will define significant illness as one that<br>         significantly alters a woman's ability to perform activities of daily living,<br>         causes symptoms at least two days per week, or necessitates regular use of<br>         medication. In the case of acute medical conditions, such as urinary tract<br>         infection, pneumonia, or febrile illness, enrollment may be postponed until the<br>         illness is successfully treated (not currently on any medication for the<br>         illness).<br><br>     - For lactating postpartum subjects: milk supply suspected to be marginal so that 24<br>       hour interruption of nursing likely to lead to inability to restart breast feeding,<br>       evidence of breast infection, or history of breast surgery.<br><br>     - Presence of cysts in the eye suggestive of neurocysticercosis.<br><br>     - Regular use of a medication for a chronic medical condition.<br><br>     - History of severe allergic reaction (anaphylaxis, facial swelling, or difficulty<br>       breathing) or seizure with praziquantel administration.<br><br>     - If pregnant, fetus has congenital anomaly determined by ultrasound or is determined to<br>       be nonviable e.g., blighted ovum.<br><br>     - Twin or higher order pregnancy.<br><br>     - Woman has been enrolled into this study or its companion study (""""S. japonicum and<br>       pregnancy outcomes: A Randomized, Double Blind, Placebo Controlled Trial (RCT). DMID<br>       Protocol Number: 06-0039"""") for a previous pregnancy.<br><br>     - Inability to comprehend study procedures and provide informed consent due to limited<br>       cognitive abilities or other reason, or refuses to provide informed consent.<br><br>     - Subjects receiving during the previous month any of the following drugs which may<br>       interact with praziquantel (PZQ) bioavailability, metabolism and/or elimination:<br>       carbamazepine, chloroquine, cimetidine, dexamethasone, erythromycin, fosphenytoin,<br>       itraconazole, ketoconazole, phenobarbital, phenytoin, rifampin, or any protease<br>       inhibitor or non-nucleoside reverse transcriptase inhibitor.<br><br>     - Subjects ingesting grapefruit juice during the previous week.<br>   ",,Schistosomiasis,Drug: Praziquantel,"Comparison of PZQ and 4-hydroxy PZQ PK parameters in pregnant and nonpregnant lactating subjects, central tendency and distribution (Cmax, Tmax, t ½, AUC, CL/F and Vd/F).;Early Pregnancy Cohort only: Assessed for the presence of pre-eclampsia.;Pregnant women only: newborn congenital anomalies. The number of infants with congenital anomalies;Early Pregnancy Cohort only: number of subjects experiencing a spontaneous abortion and number of stillbirths reported after drug administration; and live birth rate among pregnant subjects.;Toxicity to maternal bone marrow, kidney, and liver will be assessed by measurement of complete blood count, blood urea nitrogen (BUN) and creatinine, and liver function tests (AST, ALT, and bilirubin).;Subjects will be observed in hospital for adverse events/serious adverse events (AE/SAEs).",,5U01AI066050-07;08-0049,Please refer to primary and secondary sponsors,,,,No,,,,,,,,,,,,Yes,False,          ,2011.0,18.0
NCT00486863,19 October 2017,S. Japonicum and Pregnancy Outcomes,"S. Japonicum and Pregnancy Outcomes: A Randomized, Double Blind, Placebo Controlled Trial (RCT)",,National Institute of Allergy and Infectious Diseases (NIAID),2007-06-14,20070614.0,10/13/2025 16:02:07,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT00486863,Not recruiting,No,18 Years,99 Years,Female,01/08/2007,370,Interventional,,Phase 2,Philippines;United States;Philippines;United States;Philippines;United States;Philippines;United States,"<br>    Inclusion Criteria:<br><br>    For screening:<br><br>     - Female, age 18 or over.<br><br>     - Present to a study midwife with suspected pregnancy.<br><br>     - Live in a study village.<br><br>    For the main study:<br><br>     - Infected with S. japonicum.<br><br>     - Pregnancy as determined by urine pregnancy test.<br><br>     - Age 18 or older.<br><br>     - Participant is otherwise healthy as determined by history, physical exam, ultrasound<br>       and laboratory assessment.<br><br>     - Pregnancy between 12-16 weeks gestation.<br><br>     - Ability to provide informed consent to participate.<br><br>    Exclusion Criteria:<br><br>     - Presence of significant disease/illness that is either acute or chronic. This will be<br>       defined by history, physical examination, ultrasound and laboratory assessment. In<br>       particular:<br><br>        1. History of seizures or other neurologic disorder, chronic medical problem<br>         determined by history or physical examination, e.g. active hepatitis,<br>         tuberculosis, heart disease.<br><br>        2. Grade 3 or higher laboratory abnormality of blood urea nitrogen (BUN),<br>         Creatinine, bilirubin, white blood cell count, or platelet count will warrant<br>         exclusion. Grade 2 or higher abnormality of alanine aminotransferase (ALT) or<br>         aspartate aminotransferase (AST) will warrant exclusion. For hemoglobin, women<br>         with severe anemia defined as hemoglobin less than 7.0 g/dl will be excluded.<br><br>        3. Women with myoma on ultrasound that are sub-mucosal or women with myoma that is<br>         in any location and greater than 5 cm in size.<br><br>        4. Women with congenital anomalies of the reproductive tract that would be expected<br>         to cause decreased fetal weight or greatly increase the risk of prematurity such<br>         as duplicate uterus, uterine septum.<br><br>        5. For less clear cases, the researchers will define significant illness as one that<br>         significantly alters a woman's ability to perform activities of daily living,<br>         causes symptoms at least two days per week, or necessitates regular use of<br>         medication. In the case of acute medical conditions such as urinary tract<br>         infection, pneumonia, febrile illness, enrollment may be postponed until the<br>         illness is successfully treated (not currently on any medication for the illness)<br>         or the illness self resolves if this occurs before 16 weeks gestation.<br><br>     - Presence of cysts in the eye suggestive of neurocysticercosis.<br><br>     - Regular use of a medication for a chronic medical condition.<br><br>     - History of severe allergic reaction (anaphylaxis, facial swelling, or difficulty<br>       breathing) or seizure with praziquantel administration.<br><br>     - Fetus has congenital anomaly determined by 12-16 week ultrasound or is determined to<br>       be nonviable (e.g. blighted ovum).<br><br>     - Twin or higher order pregnancy.<br><br>     - Woman has been enrolled into this study for a previous pregnancy.<br><br>     - Inability to comprehend study procedures and provide informed consent due to limited<br>       cognitive abilities or other, or refuses to provide informed consent.<br>   ;<br>    Inclusion Criteria:<br><br>    For screening:<br><br>     - Female, age 18 or over.<br><br>     - Present to a study midwife with suspected pregnancy.<br><br>     - Live in a study village.<br><br>    For the main study:<br><br>     - Infected with S. japonicum.<br><br>     - Pregnancy as determined by urine pregnancy test.<br><br>     - Age 18 or older.<br><br>     - Participant is otherwise healthy as determined by history, physical exam, ultrasound<br>       and laboratory assessment.<br><br>     - Pregnancy between 12-16 weeks gestation.<br><br>     - Ability to provide informed consent to participate.<br><br>    Exclusion Criteria:<br><br>     - Presence of significant disease/illness that is either acute or chronic. This will be<br>       defined by history, physical examination, ultrasound and laboratory assessment. In<br>       particular:<br><br>        1. History of seizures or other neurologic disorder, chronic medical problem<br>         determined by history or physical examination, e.g. active hepatitis,<br>         tuberculosis, heart disease.<br><br>        2. Grade 3 or higher laboratory abnormality of blood urea nitrogen (BUN),<br>         Creatinine, bilirubin, white blood cell count, or platelet count will warrant<br>         exclusion. Grade 2 or higher abnormality of alanine aminotransferase (ALT) or<br>         aspartate aminotransferase (AST) will warrant exclusion. For hemoglobin, women<br>         with severe anemia defined as hemoglobin less than 7.0 g/dl will be excluded.<br><br>        3. Women with myoma on ultrasound that are sub-mucosal or women with myoma that is<br>         in any location and greater than 5 cm in size.<br><br>        4. Women with congenital anomalies of the reproductive tract that would be expected<br>         to cause decreased fetal weight or greatly increase the risk of prematurity such<br>         as duplicate uterus, uterine septum.<br><br>        5. For less clear cases, the researchers will define significant illness as one that<br>         significantly alters a woman's ability to perform activities of daily living,<br>         causes symptoms at least two days per week, or necessitates regular use of<br>         medication. In the case of acute medical conditions such as urinary tract<br>         infection, pneumonia, febrile illness, enrollment may be postponed until the<br>         illness is successfully treated (not currently on any medication for the illness)<br>         or the illness self resolves if this occurs before 16 weeks gestation.<br><br>     - Presence of cysts in the eye suggestive of neurocysticercosis.<br><br>     - Regular use of a medication for a chronic medical condition.<br><br>     - History of severe allergic reaction (anaphylaxis, facial swelling, or difficulty<br>       breathing) or seizure with praziquantel administration.<br><br>     - Fetus has congenital anomaly determined by 12-16 week ultrasound or is determined to<br>       be nonviable (e.g. blighted ovum).<br><br>     - Twin or higher order pregnancy.<br><br>     - Woman has been enrolled into this study for a previous pregnancy.<br><br>     - Inability to comprehend study procedures and provide informed consent due to limited<br>       cognitive abilities or other, or refuses to provide informed consent.<br>   ;<br>    Inclusion Criteria:<br><br>    For screening:<br><br>     - Female, age 18 or over.<br><br>     - Present to a study midwife with suspected pregnancy.<br><br>     - Live in a study village.<br><br>    For the main study:<br><br>     - Infected with S. japonicum.<br><br>     - Pregnancy as determined by urine pregnancy test.<br><br>     - Age 18 or older.<br><br>     - Participant is otherwise healthy as determined by history, physical exam, ultrasound<br>       and laboratory assessment.<br><br>     - Pregnancy between 12-16 weeks gestation.<br><br>     - Ability to provide informed consent to participate.<br><br>    Exclusion Criteria:<br><br>     - Presence of significant disease/illness that is either acute or chronic. This will be<br>       defined by history, physical examination, ultrasound and laboratory assessment. In<br>       particular:<br><br>        1. History of seizures or other neurologic disorder, chronic medical problem<br>         determined by history or physical examination, e.g. active hepatitis,<br>         tuberculosis, heart disease.<br><br>        2. Grade 3 or higher laboratory abnormality of blood urea nitrogen (BUN),<br>         Creatinine, bilirubin, white blood cell count, or platelet count will warrant<br>         exclusion. Grade 2 or higher abnormality of alanine aminotransferase (ALT) or<br>         aspartate aminotransferase (AST) will warrant exclusion. For hemoglobin, women<br>         with severe anemia defined as hemoglobin less than 7.0 g/dl will be excluded.<br><br>        3. Women with myoma on ultrasound that are sub-mucosal or women with myoma that is<br>         in any location and greater than 5 cm in size.<br><br>        4. Women with congenital anomalies of the reproductive tract that would be expected<br>         to cause decreased fetal weight or greatly increase the risk of prematurity such<br>         as duplicate uterus, uterine septum.<br><br>        5. For less clear cases, the researchers will define significant illness as one that<br>         significantly alters a woman's ability to perform activities of daily living,<br>         causes symptoms at least two days per week, or necessitates regular use of<br>         medication. In the case of acute medical conditions such as urinary tract<br>         infection, pneumonia, febrile illness, enrollment may be postponed until the<br>         illness is successfully treated (not currently on any medication for the illness)<br>         or the illness self resolves if this occurs before 16 weeks gestation.<br><br>     - Presence of cysts in the eye suggestive of neurocysticercosis.<br><br>     - Regular use of a medication for a chronic medical condition.<br><br>     - History of severe allergic reaction (anaphylaxis, facial swelling, or difficulty<br>       breathing) or seizure with praziquantel administration.<br><br>     - Fetus has congenital anomaly determined by 12-16 week ultrasound or is determined to<br>       be nonviable (e.g. blighted ovum).<br><br>     - Twin or higher order pregnancy.<br><br>     - Woman has been enrolled into this study for a previous pregnancy.<br><br>     - Inability to comprehend study procedures and provide informed consent due to limited<br>       cognitive abilities or other, or refuses to provide informed consent.<br>   ;<br>    Inclusion Criteria:<br><br>    For screening:<br><br>     - Female, age 18 or over.<br><br>     - Present to a study midwife with suspected pregnancy.<br><br>     - Live in a study village.<br><br>    For the main study:<br><br>     - Infected with S. japonicum.<br><br>     - Pregnancy as determined by urine pregnancy test.<br><br>     - Age 18 or older.<br><br>     - Participant is otherwise healthy as determined by history, physical exam, ultrasound<br>       and laboratory assessment.<br><br>     - Pregnancy between 12-16 weeks gestation.<br><br>     - Ability to provide informed consent to participate.<br><br>    Exclusion Criteria:<br><br>     - Presence of significant disease/illness that is either acute or chronic. This will be<br>       defined by history, physical examination, ultrasound and laboratory assessment. In<br>       particular:<br><br>        1. History of seizures or other neurologic disorder, chronic medical problem<br>         determined by history or physical examination, e.g. active hepatitis,<br>         tuberculosis, heart disease.<br><br>        2. Grade 3 or higher laboratory abnormality of blood urea nitrogen (BUN),<br>         Creatinine, bilirubin, white blood cell count, or platelet count will warrant<br>         exclusion. Grade 2 or higher abnormality of alanine aminotransferase (ALT) or<br>         aspartate aminotransferase (AST) will warrant exclusion. For hemoglobin, women<br>         with severe anemia defined as hemoglobin less than 7.0 g/dl will be excluded.<br><br>        3. Women with myoma on ultrasound that are sub-mucosal or women with myoma that is<br>         in any location and greater than 5 cm in size.<br><br>        4. Women with congenital anomalies of the reproductive tract that would be expected<br>         to cause decreased fetal weight or greatly increase the risk of prematurity such<br>         as duplicate uterus, uterine septum.<br><br>        5. For less clear cases, the researchers will define significant illness as one that<br>         significantly alters a woman's ability to perform activities of daily living,<br>         causes symptoms at least two days per week, or necessitates regular use of<br>         medication. In the case of acute medical conditions such as urinary tract<br>         infection, pneumonia, febrile illness, enrollment may be postponed until the<br>         illness is successfully treated (not currently on any medication for the illness)<br>         or the illness self resolves if this occurs before 16 weeks gestation.<br><br>     - Presence of cysts in the eye suggestive of neurocysticercosis.<br><br>     - Regular use of a medication for a chronic medical condition.<br><br>     - History of severe allergic reaction (anaphylaxis, facial swelling, or difficulty<br>       breathing) or seizure with praziquantel administration.<br><br>     - Fetus has congenital anomaly determined by 12-16 week ultrasound or is determined to<br>       be nonviable (e.g. blighted ovum).<br><br>     - Twin or higher order pregnancy.<br><br>     - Woman has been enrolled into this study for a previous pregnancy.<br><br>     - Inability to comprehend study procedures and provide informed consent due to limited<br>       cognitive abilities or other, or refuses to provide informed consent.<br>   ",,Schistosomiasis;Schistosomiasis;Schistosomiasis;Schistosomiasis,Drug: Praziquantel;Other: Placebo;Drug: Praziquantel;Other: Placebo;Drug: Praziquantel;Other: Placebo;Drug: Praziquantel;Other: Placebo,Mean Newborn Birth Weight;Mean Newborn Birth Weight,"Number of Participants Whose Pregnancy Resulted in a Live Birth;Mean Change in Maternal Hemoglobin From 14 to 32 Weeks Gestation;Median Change in Maternal Transferrin Receptor:Ferritin Ratio From 14 to 32 Weeks Gestation;Median Maternal Hepcidin at 32 Weeks Gestation;Mean Change in Maternal Weight From 14 to 32 Weeks Gestation;Mean Change in Maternal Thigh Skinfold Thickness From 14 to 32 Weeks Gestation;Newborn Median Serum Transferrin Receptor:Ferritin Ratio;Number of Subjects With Reduction in S. Japonicum Egg Counts From Screening to 22 Weeks Gestation of Greater Than 90 Percent;Number of Participants Reporting Serious Adverse Events Within 24 Hours of Dosing;Number of Participants Experiencing Fetal Loss by Abortion;Number of Participants Reporting Abnormalities in Hematology Assessments Within 24 Hours of Dosing;Number of Participants Reporting Abnormalities in Clinical Chemistry Assessments Within 24 Hours of Dosing;Number of Participants Whose Infant Was Born With Congenital Anomalies;Number of Participants With Pre-eclampsia;Maternal Serum Cytokine Levels of TNF-alpha, TNF-alpha Receptors I and II, IL-1, and IL-6;Placental Blood Cytokine Levels;Cytokeratin 18 Neo-epitope Staining as a Measure of Apoptosis;Praziquantel Pharmacokinetic Concentrations;4-hydroxy Praziquantel Pharmacokinetic Concentrations",06-0039,Please refer to primary and secondary sponsors,,,,Yes,07/02/2014,https://clinicaltrials.gov/ct2/show/results/NCT00486863,,,,,,,,,,Yes,False,          ,2007.0,18.0
NCT03926728,16 May 2022,Safety and Immunogenicity of a Chlamydia Vaccine CTH522,"A Phase I, Double-blind, Parallel, Randomised and Placebo-controlled Trial Investigating the Safety and Immunogenicity of a Chlamydia Vaccine, CTH522, in Healthy Adults",CHLM-02,Statens Serum Institut,2019-04-15,20190415.0,10/13/2025 16:04:53,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT03926728,Not recruiting,No,18 Years,45 Years,All,17/02/2020,65.0,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). ",Phase 1,United Kingdom,"<br>    Inclusion Criteria:<br><br>    IC1: Healthy males and females between 18-45 years old on the day of the first vaccination<br>    IC2: Has been properly informed about the trial and signed the consent form IC3: Is willing<br>    and likely to comply with trial procedures IC4: Is prepared to grant authorised persons<br>    access to his/her trial-related medical record IC5: Is willing to use acceptable<br>    contraceptive measures during the trial (two weeks before and two weeks after the trial).<br>    Heterosexually active female capable of becoming pregnant must agree to use hormonal<br>    contraception, intrauterine device, intrauterine hormonereleasing system, or to complete<br>    abstinence from at least two weeks before the first vaccination until at least two weeks<br>    after the last. Complete abstinence (defined as refraining from heterosexual intercourse)<br>    must be in line with the preferred and usual lifestyle of the subject. Periodic abstinence<br>    (e.g. calendar, ovulation, symptothermal, post-ovulation methods), withdrawal and<br>    progestogen-only oral hormonal contraception where inhibition of ovulation is not the<br>    primary mode of action are not acceptable methods of contraception<br><br>    Exclusion criteria:<br><br>    EX1: Is positive for C. trachomatis via urine PCR or has a known history of C. trachomatis<br>    EX2: Is positive for gonorrhoea via urine PCR test, or HIV, hepatitis B/C, syphilis via<br>    blood tests EX3: Has a significant active disease such as cardiac, liver, immunological,<br>    neurological, psychiatric or clinically significant abnormality of haematological or<br>    biochemical parameters EX4: Has BMI = 35 kg/m2 EX5: Is currently participating in another<br>    clinical trial with an investigational or noninvestigational drug or device, or was treated<br>    with an investigational drug within 28 days before the first vaccination EX6: Has received,<br>    or plans to receive, any immunisation within 14 days of the start of the trial or during<br>    the trial immunisations EX7: Is currently receiving treatment with systemic<br>    immunosuppressive agents. Topical steroids are allowed unless applied to the IM or ID<br>    injection site EX8: Has a condition which in the opinion of the investigator is not<br>    suitable for participation in the trial EX9: Is known or confirmed to have an allergy to<br>    any of the vaccine constituents EX10: Is unable to refrain from the use of contact lenses.<br>    Contact lenses should be avoided two days before TO administration and for seven days later<br>    (longer if any ongoing local eye AE) EX11: Has any evident ocular disease upon<br>    ophthalmoscopic exam at screening or any medical history of ocular disease that, in the<br>    opinion of the investigator, may impact the subject's participation in the trial EX12: Is<br>    pregnant (positive pregnancy test) or breastfeeding or not willing to use contraception<br>    during the trial EX13: Has confirmed a history of pelvic inflammatory disease or<br>    significant gynaecological diseases<br>   ",,Trachoma,Biological: CTH522-CAF01 IM;Biological: CTH522-CAF09b IM;Biological: CTH522 ID;Biological: CTH522 TO;Biological: Placebo (Saline),Local injection reactions;Local ocular reactions;Systemic reactions,Secondary - immunogenicity,CHLM-02,Please refer to primary and secondary sponsors,Imperial College London,,,No,,,,,,,,,,,,Yes,False,          ,2019.0,18.0
NCT01975051,19 February 2015,"A Study to Explore Association of Treatment Regimens for Visceral Leishmaniasis, Host Immunological, Genetical and Nutrition Factors With Post-kala-azar Dermal Leishmaniasis (PKDL)","A Study to Explore Association of Treatment Regimens for Visceral Leishmaniasis, Host Immunological, Genetical and Nutrition Factors With Post-kala-azar Dermal Leishmaniasis (PKDL)",,"International Centre for Diarrhoeal Disease Research, Bangladesh",2013-10-23,20131023.0,10/13/2025 16:05:22,ClinicalTrials.gov,http://clinicaltrials.gov/show/NCT01975051,Not recruiting,No,18 Years,60 Years,Both,01/01/2013,36,Interventional,"Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment",Phase 4,Bangladesh,<br>    Inclusion Criteria:<br><br>     - History of Visceral Leishmaniasis<br><br>     - Presence of hypopigmented rash<br><br>     - Rk39 strip test positive<br><br>     - Written informed consent from the participant<br><br>    Exclusion Criteria:<br><br>     - Any medical condition that may affect the safety of the patient during study<br>       procedure<br><br>     - Any condition which comprises the ability to comply the study procedure<br><br>     - Presence of splenomegaly<br><br>     - Posotive skin smear for mycobacterium leprae<br><br>     - Positive skin smear for fungus<br><br>     - Pregnancy test positive<br>   ,,Post-kala-azar Dermal Leishmaniasis,Drug: Mitefosine,"Explore the association of treatment regimens for visceral leishmaniasis, host immunological, genetical and nutrition factors with Post-kala-azar Dermal Leishmaniasis (PKDL)",,PR-12057,Please refer to primary and secondary sponsors,University of Nagasaki.,,,No,,,,,,,,,,,,No,False,          ,2013.0,18.0
NCT01360762,12 December 2020,Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients With Pentamidine: a Cohort Study,Secondary Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients Using Pentamidine as a Prophylactic Agent: a Prospective Cohort Study,,"Institute of Tropical Medicine, Belgium",2011-05-24,20110524.0,10/13/2025 16:05:22,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT01360762,Not recruiting,No,18 Years,,All,01/11/2011,74,Interventional,Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Prevention. Masking: None (Open Label). ,Phase 3,Ethiopia,"<br>    Inclusion Criteria:<br><br>     - Patients diagnosed with Visceral Leishmaniosis (VL) during the recruitment period that<br>       are EITHER treated for VL relapse and have a documented negative test of cure (TOC),<br>       OR are treated for primary VL and have a documented CD4 <200 or WHO stage 4 disease<br>       during the recruitment period and have a documented negative TOC<br><br>     - Patients treated for VL in the past with documented CD4 <200 or WHO stage 4 disease<br>       during the recruitment period AND documented negative TOC after the latest VL<br>       treatment and currently asymptomatic OR currently negative diagnostic test<br>       (microscopy)<br><br>     - Patients agreeing to start or continue antiretroviral treatment (first or second line)<br><br>     - Patients willing to provide written informed consent<br><br>    Exclusion Criteria:<br><br>     - Patients with known hypersensitivity to pentamidine<br><br>     - Patients with known renal failure<br><br>     - Patients with diabetes mellitus (type I or II)<br><br>     - Patients unlikely to attend follow-up visits/comply with study requirements<br><br>     - Pregnant and lactating women<br><br>     - Any other condition that could increase the risk of toxicity of pentamidine to such an<br>       extent outweighing the expected benefit (eg severe cardiac dysfunction).<br>   ",,Visceral Leishmaniosis;HIV-infection/Aids,Drug: Pentamidine,Probability of Relapse-free Survival;Number of Participants With Serious Adverse Events (SAEs),Number of Participants With Adverse Events;Number of Treatment Discontinuations and Interruptions;Number of Required Additional Interventions,ITMC0109,Please refer to primary and secondary sponsors,"Addis Ababa University;University of Gondar;Tigray Regional Health Bureau, Tigray Region;Amhara Regional Health Bureau, Amhara Region;Medecins Sans Frontieres, Netherlands;Leishmania East Africa Platform (LEAP);Drugs for Neglected Diseases",,,Yes,15/02/2019,https://clinicaltrials.gov/ct2/show/results/NCT01360762,,,,,,,,,,Yes,False,          ,2011.0,18.0
NCT00497601,19 February 2015,A Phase II Study To Assess Safety and Efficacy Of Short-Course Regimens Of Amphotericin B Emulsion In Kala-Azar,"A Prospective, Single Center, Open-Label, Dose-Escalation Phase II Study To Assess Safety and Efficacy Of Short-Course Regimens Of Amphotericin B Emulsion In Treatment Naïve Or Resistant Cases Of Visceral Leishmaniasis (Kala-Azar).",,Banaras Hindu University,2007-07-05,20070705.0,10/13/2025 16:05:22,ClinicalTrials.gov,http://clinicaltrials.gov/show/NCT00497601,Not recruiting,No,18 Years,65 Years,Both,01/02/2007,60,Interventional,"Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment",Phase 2,India,"<br>    Inclusion Criteria:<br><br>     1. Male or female subjects between 18 years and 65 years of age (both inclusive).<br><br>     2. Subject/subject's legally acceptable representative is willing and able to give<br>       written informed consent to participate in the study.<br><br>     3. Treatment naive subjects having symptoms and/or signs of visceral leishmaniasis with<br>       parasitological confirmation of Kala-azar (by splenic or bone marrow aspirate smear<br>       examination).<br><br>    If subjects are previously treated with other antileishmanial drugs except amphotericin B<br>    containing preparations, they will be enrolled in the study only after clinical and<br>    parasitological evidence that the disease is unresponsive to adequate treatment with other<br>    drugs, and after an appropriate wash out period<br><br>    Exclusion Criteria:<br><br>     1. Subjects with past history of treatment with Amphotericin B for Kala-azar.<br><br>     2. Subjects positive for HIV infection.<br><br>     3. Concomitant life threatening or serious disease.<br><br>     4. Concurrent malaria (malarial parasite test to be negative prior to study treatment<br>       administration), tuberculosis or bacterial pneumonia.<br><br>     5. Haemoglobin < 6 gm/dl, total leukocyte count < 1,500/cmm, platelet count < 50,000/cmm<br><br>     6. Abnormal liver and renal functions (BUN and serum creatinine > 1.5 times upper limit<br>       of normal (ULN), AST/ALT > 2.5 times ULN, and bilirubin > 1.5 times ULN).<br><br>     7. Pregnant or nursing women.<br><br>     8. Known hypersensitivity to Amphotericin B or inactive ingredients of study drug<br>       formulation.<br><br>     9. Subjects receiving any of the medications prohibited by the study protocol.<br><br>     10. Evidence of significant haematological, cardiac, hepatic, renal, respiratory,<br>       neurological or metabolic disease or any condition which, in the opinion of the<br>       investigator, might interfere with the evaluation of the study objectives.<br><br>     11. Simultaneous participation in another trial or received any investigational product <<br>       30 days prior to enrolment.<br>   ",,Visceral Leishmaniasis,Drug: Amphotericin B fat emulsion in visceral leishmaniasis;Drug: Amphotericin B fat emulsion;Drug: Amphotericin B in fat emulsion,"Clinical and parasitological cure at end of treatment and final cure (no relapse) at six months, no hematological, hepatic or renal toxicity",,BSV-AMBE II-KA-706,Please refer to primary and secondary sponsors,,,,No,,,,,,,,,,,,No,False,          ,2007.0,18.0
NCT03664063,12 December 2020,PK PD Study of IDA and Azithromycin for NTDs ( ComboNTDs ),"A Pharmacokinetic and Pharmacodynamic Evaluation of Co-Administration of IDA (Ivermectin, Diethylcarbamazine and Albendazole) & Azithromycin for Integrated Treatment of Neglected Tropical Diseases",,Lihir Medical Centre,2018-09-03,20180903.0,10/13/2025 16:05:54,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT03664063,Not recruiting,No,18 Years,65 Years,All,01/09/2018,42,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ,Phase 2,Papua New Guinea,<br>    Inclusion Criteria:<br><br>     - Adult aged 18-65<br><br>     - Able to give informed consent<br><br>    Exclusion Criteria:<br><br>     - Known chronic illness<br><br>     - Hb <7 at baseline<br><br>     - Liver function or Creatinine * 1.5 Upper Limit of Normal<br><br>     - Urinary tract infection at baseline<br><br>     - Pregnancy (female participants only)<br><br>     - Routine medications which interact with study drugs<br><br>     - Lactose/Gluten intolerance<br><br>     - Permanent disability impeding study participation<br>   ,,Lymphatic Filariasis;Yaws;Trauma,Drug: Azithromycin;Drug: Albendazole;Drug: Ivermectin;Drug: Diethylcarbamazine,"Drug levels of Azithromycin, Ivermectin, Diethylcarbamazine, Albendazole",Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,ComboNTDs-PK,Please refer to primary and secondary sponsors,,,,No,,,,,,,,,,,,No,False,          ,2018.0,18.0
